metoprolol has been researched along with Cardiac Failure in 551 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF)." | 9.51 | Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. ( Ding, Y; Li, J; Wei, Z; Zhu, L, 2022) |
| " The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier." | 9.30 | The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. ( Charpidou, A; Georgakopoulos, P; Karavidas, A; Kouvela, M; Kyriakidis, M; Mamalis, N; Perpinia, A; Zimeras, S, 2019) |
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 9.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded "seamless" phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF)." | 9.27 | A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. ( Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB, 2018) |
| "To prospectively evaluate the impact of metoprolol achieved heart rate (HR) on cardiac-motor function and quality of life (QoL) in chronic heart failure (CHF) patients." | 9.24 | A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. ( Cheng, X; Liu, J; Liu, X; Meng, Y, 2017) |
| "In a 2 × 2 factorial, randomized, placebo-controlled, double-blind trial, we assigned 130 adult women with early breast cancer and no serious co-morbidity to the angiotensin receptor blocker candesartan cilexetil, the β-blocker metoprolol succinate, or matching placebos in parallel with adjuvant anticancer therapy." | 9.22 | Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. ( Bratland, Å; Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2016) |
| "Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany." | 9.20 | Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. ( Agewall, S; Atar, D; Cebola, R; Frankenstein, L; Fröhlich, H; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Täger, T; Zhao, J, 2015) |
| "To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional *4 allele (1846G>A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605)." | 9.19 | An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. ( Balmforth, AJ; Batty, JA; de Boer, RA; Hall, AS; Hjalmarson, Å; Kjekshus, J; van der Harst, P; van Veldhuisen, DJ; Waagstein, F; White, HL; Wikstrand, J, 2014) |
| "Patients with Killip class II or less anterior ST-segment-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention within 6 hours of symptoms onset were randomized to receive intravenous metoprolol (n=131) or not (control, n=139) before reperfusion." | 9.17 | Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri ( Acebal, C; Albarrán, A; Arias, M; Bastante, T; Cabrera, JA; Casado, I; Cuellas, C; de la Torre-Hernández, JM; Escalera, N; Fernández-Campos, MJ; Fernández-Friera, L; Fernández-Jiménez, R; Fernández-Ortiz, A; Fernández-Vázquez, F; Fuster, V; García-Álvarez, A; García-Prieto, J; García-Rubira, JC; García-Ruiz, JM; Goicolea, J; Hernández-Antolín, R; Ibanez, B; Iglesias-Vázquez, JA; Iñiguez, A; Jiménez-Borreguero, J; López-Romero, P; Macaya, C; Mateos, A; Pérez de Prado, A; Pizarro, G; Pocock, S; Rodriguez, MD; Ruiz-Mateos, B; Sánchez-Brunete, V; Sanz, G; Sanz-Rosa, D; Valenciano, J, 2013) |
| "To determine advantages of therapy of functional class (FC) I-II chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction in patients with hypertensive disease (HD) with metoprolol succinate or quinapril and to assess their effect on regulatory-adaptive status." | 9.16 | [Advantages of quinapril therapy in patients with arterial hypertension and functional class III chronic heart failure with preserved left ventricular ejection fraction]. ( Kanorskiĭ, SG; Pokrovskiĭ, VM; Tregubov, VG, 2012) |
| "Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear." | 9.15 | Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study. ( Christiansen, B; Dominguez, H; Falskov, B; Hermann, TS; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2011) |
| "The aim of this study was to assess the effect ofmetoprolol on cardiac function in children with heart failure." | 9.14 | Influence of metoprolol on systolic and diastolic function in children with heart failure. ( Abaskhanian, ZA; Ghader, FR, 2009) |
| "To determine whether metoprolol succinate (a beta(1)-selective beta-blocker) remains beta(1)-selective compared with carvedilol (a nonselective beta-blocker) during upward titration of doses in patients with American College of Cardiology (ACC) stage C heart failure." | 9.14 | Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. ( Gilbert, EM; Lombardi, WL; Macgregor, J; Munger, M; Stoddard, GP; Zebrack, JS, 2009) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 9.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 9.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "Sixteen men with mild, stable heart failure (NYHA class II to III; left ventricular ejection fraction <40%) underwent serial blood sampling for plasma natriuretic peptide levels and received infusions of atrial natriuretic peptide (ANP) and BNP before and 6 weeks after the introduction and uptitration of metoprolol or 6 weeks unchanged therapy in a randomized, parallel-group design." | 9.12 | Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. ( Davis, ME; Frampton, CM; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, 2006) |
| "The purpose of this study was to compare the effects of immediate-release (IR) metoprolol and extended-release (XL) metoprolol on measures of heart rate variability in chronic systolic heart failure patients." | 9.12 | Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. ( Aquilante, CL; Binkley, PF; Hatton, PS; Johnson, JA; Pauly, DF; Schofield, RS; Terra, SG, 2006) |
| "We aimed to compare the effects of carvedilol and metoprolol succinate on left atrial (LA) function in patients with chronic heart failure." | 9.12 | Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. ( Acikel, M; Arslan, S; Atesal, S; Bozkurt, E; Erol, MK; Gundogdu, F; Senocak, H, 2007) |
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 9.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 9.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months." | 9.12 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Erhardt, L; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, P; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "To investigate whether metoprolol controlled release/extended release (CR/XL) once daily would improve diastolic and systolic left ventricular function in patients with chronic heart failure and decreased ejection fraction." | 9.11 | Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. ( Frøland, G; Gullestad, L; Hole, T; Offstad, J; Skjaerpe, T, 2004) |
| "Metoprolol CR/XL was easily instituted, safe and well tolerated in elderly patients with systolic heart failure." | 9.11 | Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. ( Deedwania, PC; Ghali, JK; Gottlieb, S; Waagstein, F; Wikstrand, JC, 2004) |
| "Cardiovascular risk and risk reduction were analyzed in five subgroups defined by quintiles (Q) of pretreatment resting HR in the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 9.11 | What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). ( Bermann, G; Deedwania, P; Egstrup, K; Elkayam, U; Gottlieb, S; Gullestad, L; Hjalmarson, A; Kjekshus, J; Rashkow, A; Wedel, H; Wikstrand, J, 2005) |
| "The objective of the current study was to examine the efficacy and tolerability of the beta-blocker metoprolol succinate controlled release/extended release (CR/XL) in patients with diabetes in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 9.11 | Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. ( Deedwania, PC; Ghali, JK; Giles, TD; Herlitz, J; Hildebrandt, P; Kjekshus, J; Klibaner, M; Spinar, J; Stanbrook, H; Vitovec, J; Wikstrand, J, 2005) |
| "Data from electronic dosing monitors and published pharmacokinetic parameters were used to derive medication adherence measures for immediate-release metoprolol and examine their association with health care utilization of outpatients aged 50 years or older with heart failure." | 9.11 | Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. ( Brater, DC; Li, J; Morris, AB; Murray, MD; Tu, W; Wu, J; Young, J, 2005) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 9.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 9.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure." | 9.11 | Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. ( Anzai, T; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A, 2005) |
| "We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg)." | 9.10 | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). ( Fagerberg, B; Goldstein, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2002) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 9.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "To evaluate neurohumoral factors as markers for left-ventricular (LV) antiremodelling from metoprolol treatment in patients with chronic LV systolic heart failure." | 9.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 9.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 9.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily)." | 9.10 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2003) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 9.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "A subgroup analysis was performed in black patients who participated in the Metoprolol CR/XL Randomized Intervention trial in Congestive Heart Failure trial." | 9.10 | Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). ( Deedwania, P; Goldstein, S; Gottlieb, S; Wikstrand, J, 2003) |
| " Thirty-three patients with CHF, with exercise limited by dyspnea and left ventricular ejection fraction of 26 +/- 4%, were randomized to receive metoprolol or carvedilol for 6 months." | 9.10 | Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). ( Blanchet, M; Ducharme, A; Fortier, A; Juneau, M; Larivée, L; Marquis, J; Nigam, A; Racine, N; Rouleau, JL; Tardif, JC; White, M, 2003) |
| "This was a prespecified subgroup analysis of a double-blind, randomized trial: the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF)." | 9.10 | Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. ( Czuriga, I; Ghali, JK; Herlitz, J; Hjalmarson, A; Jánosi, A; Klibaner, M; Wikstrand, J, 2003) |
| "The effects of spironolactone or metoprolol added to a conventional treatment protocol on QT dispersion, which is accepted as a sudden cardiac death predictor, were evaluated in heart failure patients." | 9.10 | Effects of spironolactone and metoprolol on QT dispersion in heart failure. ( Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Ozbay, Y, 2003) |
| "We describe the effect of controlled-release/extended-release (CR/XL) metoprolol succinate once daily on mortality and hospitalizations among patients with a history of hypertension complicated by chronic systolic heart failure." | 9.10 | Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. ( Denny, M; Fenster, P; Herlitz, J; Heywood, T; Masszi, G; Rasmussen, S; Thorgeirsson, G; Wachtell, K; Wikstrand, J, 2002) |
| "We looked at evidence of clinical deterioration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) by analyzing events and symptoms during the first 90 days." | 9.10 | Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Deedwania, P; Fisher, ML; Gottlieb, SS; Gullestad, L; Kjekshus, J; Vitovec, J; Wikstrand, J, 2002) |
| "MERIT-HF (Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure) was a randomized, placebo-controlled study, the purpose of which was to evaluate the effect of metoprolol controlled-release/extended-release (CR/XL) in 3991 patients with New York Heart Association class II to IV heart failure and LVEF < or =0." | 9.10 | Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, PC; Ghali, JK; Gottlieb, SS; Piña, IL; Wikstrand, JC, 2002) |
| "In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure." | 9.10 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; J Remme, W; Komajda, M; Metra, M; Poole-Wilson, PA; Swedberg, K; Torp-Pedersen, C, 2002) |
| "Forty-eight patients with congestive heart failure were investigated: 30 patients with dilated cardiomyopathy participating in a placebo-controlled trial (15 on placebo, 15 on metoprolol), and 18 patients treated by metoprolol in an open protocol." | 9.09 | Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. ( Andersson, B; Lomsky, M; Strömblad, SO; Waagstein, F, 1999) |
| "Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has not been proven." | 9.09 | Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) ( , 1999) |
| "This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure." | 9.09 | Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, ON; Steinmetz, M, 1999) |
| "The study was undertaken to investigate the effect of metoprolol CR/XL on all-cause mortality in patients with heart failure in New York Heart Association (NYHA) class II-IV." | 9.09 | The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. ( Goldstein, S; Hjalmarson, A, 1999) |
| "This study was performed to compare the long-term clinical efficacy of treatment with metoprolol versus carvedilol in patients with chronic heart failure." | 9.09 | Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. ( Chan, KW; Chan, SK; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yip, G, 1999) |
| "To compare the hemodynamic effects of twice daily metoprolol tartrate (MT) and once daily metoprolol succinate (MS) in congestive heart failure patients." | 9.09 | Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, O, 2000) |
| "To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure." | 9.09 | Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. ( Aldershvile, J; Ball, S; Deedwania, P; Dietz, R; Dunselman, PH; El Allaf, D; Fagerberg, B; Goldstein, S; Gottlieb, S; Gullestad, L; Halinen, M; Herlitz, J; Hjalmarson, A; Jánosi, A; Kjekshus, J; Kuch, J; Neuhaus, KL; Rickenbacher, P; Thorgeirsson, G; Vítovec, J; Waagstein, F; Wedel, H; Wikstrand, J, 2000) |
| "Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs." | 9.09 | Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. ( Boldi, E; Dei Cas, L; Giubbini, R; Metra, M; Modena, MG; Nodari, S, 2000) |
| "The MERIT-HF study was designed to investigate the effect of once-daily dosing of metoprolol succinate CR/XL added to standard therapy in patients with chronic heart failure." | 9.09 | Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Fagerberg, B, 2000) |
| "In this randomized, placebo-controlled and double-blind substudy to the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF), 41 patients were examined with magnetic resonance imaging three times in a six-month period, assessing LV dimensions and function." | 9.09 | Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Larsson, HB; Nilsson, JC; Sondergaard, L, 2000) |
| " The objective of this study was to determine if these antioxidant effects are detectable in patients with heart failure and to compare carvedilol with the selective beta-blocker metoprolol." | 9.09 | Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. ( Arumanayagam, M; Chan, S; Sanderson, JE; Tong, S, 2001) |
| "6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction | 9.09 | Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. ( Aarsland, T; Fagertun, H; Gullestad, L; Kjekshus, J; Manhenke, C; Skårdal, R; Wikstrand, J, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 9.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 9.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "Fifteen patients with chronic heart failure were randomized to a 3-way crossover study to receive metoprolol IR 50 mg 3 times daily, CR/XL 100 mg once daily, and CR/XL 200 mg once daily for 7 days." | 9.09 | Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. ( Aberg, J; Andersson, B; Lindelöw, B; Täng, MS; Wikstrand, J, 2001) |
| "To evaluate whether xamoterol, a partial agonist, would improve exercise time more than metoprolol in patients with mild to moderate heart failure after a myocardial infarction." | 9.08 | Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. ( Erhardt, L; Melcher, A; Persson, H; Rythe'n-Alder, E, 1995) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 9.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "Metoprolol partly reverses Gi alpha-upregulation and beta-adrenoceptor downregulation in heart failure, which might contribute to the clinical improvement of patients treated with beta-blockers." | 9.08 | Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. ( Becker, H; Eschenhagen, T; Hanrath, P; Jakob, H; Schmitz, W; Scholz, H; Schumacher, C; Sigmund, M; Steinfath, M, 1996) |
| " Metoprolol treatment restores the blunted inotropic response to milrinone in patients with heart failure, indicating that postreceptor events (e." | 9.08 | Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. ( Böhm, M; Deutsch, HJ; Hartmann, D; Rosée, KL; Stäblein, A, 1997) |
| "The aim of this study is to describe the impact of early treatment with metoprolol on prognosis during 1 year of follow-up in patients with suspected acute myocardial infarction (AMI) and indirect signs of congestive heart failure (CHF)." | 9.08 | Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial). ( Herlitz, J; Hjalmarson, A; Lindqvist, J; Swedberg, K; Waagstein, F, 1997) |
| "Metoprolol is a cardioselective beta blocker that has been shown to improve left ventricular function and symptoms of congestive heart failure (CHF) and also to decrease the number of hospitalizations due to CHF." | 9.08 | Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee. ( , 1997) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 9.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 9.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "To investigate the alterations of plasma endothelin-1(ET-1) in patients with congestive heart failure(CHF) and the effects of metoprolol on it, plasma ET-1 and norepinephrine(NE) were measured in 43 patients using radioimmunoassay and high-performance liquid chromatography methods." | 9.08 | [Changes of plasma endothelin-1 in patients with congestive heart failure and the influence of metoprolol]. ( Sun, M; Xu, H; Zhou, H, 1998) |
| "This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction." | 9.07 | Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. ( Bennett, SK; Fisher, ML; Gottlieb, SS; Greenberg, NL; Hamilton, BP; Patten, RD; Plotnick, GD, 1994) |
| "In a double blind study of metoprolol in the treatment of suspected acute myocardial infarction 698 patients (study group) received metoprolol and 697 a placebo (control group)." | 9.05 | Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. ( Herlitz, J; Hjalmarson, A; Holmberg, S; Swedberg, K; Vedin, A; Waagstein, F; Waldenström, A; Wedel, H; Wilhelmsen, L; Wilhelmsson, C, 1984) |
| "Long-term treatment with appropriate doses of carvedilol or metoprolol is currently recommended for patients with heart failure with reduced ejection fraction (HFrEF) to decrease the risk of death, hospitalizations, and patients' symptoms." | 8.91 | Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. ( Afonso, L; Briasoulis, A; Palla, M, 2015) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 8.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "To review the pharmacology, pharmacokinetics, efficacy, and tolerability of extended-release (ER) metoprolol succinate and its role in the management of chronic heart failure." | 8.82 | Extended-release metoprolol succinate in chronic heart failure. ( Patterson, JH; Tangeman, HJ, 2003) |
| "Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a beta1-selective agent that improved survival and reduced hospitalization among patients with New York Heart Association class II-IV heart failure in a randomized trial." | 8.81 | Metoprolol CR/XL in the treatment of chronic heart failure. ( Gattis, WA, 2001) |
| "Both metoprolol and carvedilol improve cardiac function and prolong survival in patients with heart failure." | 8.81 | Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. ( Antonopoulos, GV; Berlin, JA; Chittams, J; Konstam, MA; Packer, M; Udelson, JE, 2001) |
| "Metoprolol CR/XL effectively decreases mortality and improves clinical status in patients with stable mild to moderate (NYHA functional class II or III) chronic heart failure due to left ventricular systolic dysfunction, and the drug is effective in patients with ischaemic or dilated cardiomyopathy." | 8.80 | Metoprolol: a review of its use in chronic heart failure. ( Markham, A; Prakash, A, 2000) |
| "Multiclinic controlled studies have shown that enalapril alone 10 to 40 mg/day orally is effective in lowering blood pressure in patients with essential hypertension." | 8.77 | Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. ( Davies, RO; Moncloa, F; Sromovsky, JA; Walker, JF, 1985) |
| "During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris." | 8.77 | Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. ( Benfield, P; Brogden, RN; Clissold, SP, 1986) |
| "Compare heart rate control between parenteral metoprolol and diltiazem and identify safety outcomes in the acute management of atrial fibrillation (AFib) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 8.31 | Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction. ( Allison-Aipa, T; Choi, M; Kapustova, K; Phan, B, 2023) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 8.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| " The purpose of this study was to verify whether metoprolol regulates AKAP5 expression and test the role of AKAP5 postinjury in mitigating cardiac infarction-associated tissue remodeling and fibrosis." | 8.12 | Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart. ( Wang, H; Wang, Q; Wang, Z; Zhang, B; Zhang, X; Zhu, F, 2022) |
| " In order to explore the demand for cardiovascular disease treatment, make up for the lack of chronic diseases affecting people's physical harm, and improve the success rate of cardiovascular disease treatment, a method to observe the efficacy and myocardial remodeling of trimetazidine combined with metoprolol in elderly patients with coronary heart disease and heart failure based on integrated traditional Chinese and Western medicine was proposed." | 8.12 | Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine. ( Lu, Y; Ni, H; Shi, H; Sun, Y; Wang, F, 2022) |
| "Atrial fibrillation (Afib) with rapid ventricular response (RVR) is acutely treated with intravenous push (IVP) metoprolol (MET) or diltiazem (DIL)." | 8.12 | Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. ( Compagner, CT; Holzhausen, JM; Reich, EK; Wysocki, CR; Zimmerman, LH, 2022) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 8.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "To explore the effect of metoprolol tartrate tablets and recombinant human natriuretic peptide B (NPPB) on sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and patients with heart failure (AMI-HF)." | 8.02 | Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure. ( Lin, Y; Liu, C; Yao, L; Zhang, L, 2021) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 8.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "To assess gender-, age-, and the dose-related influence of metoprolol on cardiac function, motor function, quality-of-life (QoL), and mental status in Chinese chronic heart failure (CHF) patients." | 7.96 | Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study. ( Cheng, X; Feng, Z; Liu, Q; Meng, Y; Zhu, M, 2020) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 7.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| "The objective of this study was to examine the effects of metoprolol versus diltiazem in the acute management of atrial fibrillation (AF) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 7.91 | Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. ( Ackerbauer, KA; DeMott, JM; Hirschy, R; O'Donnell, EP; Peksa, GD, 2019) |
| "Aim - optimization of the treatment of obesity and chronic heart failure (CHF) patients by identifying key factors for the progression of cardiac decompensation and the principles of using metoprolol succinate, taking into account pharmacogenetic aspects in the complex treatment of this comorbidity." | 7.91 | METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE. ( Gasanov, I; Rudyk, Y, 2019) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 7.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "The β-blockers carvedilol and metoprolol succinate both reduce mortality in patients with heart failure (HF), but the comparative clinical effectiveness of these drugs is unknown." | 7.80 | Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. ( Hviid, A; Melbye, M; Pasternak, B; Svanström, H, 2014) |
| "In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks." | 7.79 | Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. ( Babick, A; Dhalla, NS; Elimban, V; Zieroth, S, 2013) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 7.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| "In COMET (Carvedilol or Metoprolol European Trial), carvedilol reduced mortality compared with metoprolol in patients with chronic heart failure." | 7.76 | Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy. ( Boman, K; Cleland, JG; Jansson, JH; Nilsson, T; Poole-Wilson, P; Swedberg, K, 2010) |
| "To investigate the effect of metoprolol on the expression of G protein-coupled receptor kinases 2 (GRK2) in lymphocyte of advanced elderly patients with chronic heart failure." | 7.76 | [Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure]. ( Gao, WQ; Han, CG; Liu, YX; Wang, Q; Yang, TS; Zhao, YX; Zhu, P, 2010) |
| "Obvious elevation of PP is associated with a better response to metoprolol succinate sustained-release tablets in elderly hypertensive patients with chronic heart failure, and 3 months of treatment with the tablets can significantly improve the cardiac function and lower the levels of VEGF, hs-CRP and BNP in these patients." | 7.76 | [Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure]. ( Lin, ZP; Zhang, ZW, 2010) |
| "The aims of this study were to examine the relationships between CYP2D6 genotype and metoprolol dose, S- and R-metoprolol concentrations and clinical effects in patients with systolic heart failure." | 7.75 | CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. ( Begg, EJ; Gardiner, SJ; Jensen, BP; Lainchbury, JG; Roberts, RL; Sharp, CF; Troughton, RW, 2009) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 7.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 7.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "To investigate the effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with heart failure." | 7.74 | [Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure]. ( Han, LH; Jiang, B; Jiang, TB; Jiang, WP; Li, BY; Li, HX; Liu, ZH; Song, JP; Yang, XJ; Zou, C, 2007) |
| "To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death." | 7.74 | Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. ( Anand, IS; Ensrud, KE; Nelson, DB; Rector, TS, 2008) |
| "Using data from a large United States health-insurance claims database, we conducted a retrospective study to compare the risks of death and hospitalization and the cost of inpatient care in heart failure patients receiving carvedilol vs." | 7.73 | Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. ( Delea, TE; Edelsberg, JS; Hagiwara, M; Oster, G; Stanford, R, 2005) |
| "The role of phosphorylation of the ryanodine receptor at serine-2808 (RyRS2808) in congestive heart failure (CHF) is controversial, and effects of RyRS2808 phosphorylation on contraction are unclear." | 7.73 | Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. ( Chen, SR; Davidoff, AW; Mei, J; Obayashi, M; Stuyvers, BD; ter Keurs, HE; Xiao, B, 2006) |
| "The MERIT-HF trial demonstrated improved survival and fewer hospitalizations for worsening heart failure with extended-release (ER) metoprolol succinate in patients with heart failure." | 7.73 | Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. ( Caro, JJ; Deedwania, PC; Gottlieb, S; Hauch, O; Hillson, E; Hjalmarson, A; Kim, J; Migliaccio-Walle, K; Nova, W; O'Brien, JA; Wedel, H; Wikstrand, J, 2005) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 7.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "Metoprolol succinate was given to 60 patients with class I-III heart failure and ejection fraction <45% after myocardial infarction." | 7.72 | [Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. ( Churganova, LIu; Gavril'eva, SA; Ivanov, GG; Poltavskaia, MG; Sheianov, MV; Shumilova, KM; Syrkin, AL, 2003) |
| "Carvedilol and metoprolol are beta(1)-adrenoceptor antagonists that decrease mortality in heart failure." | 7.72 | Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure? ( Doggrell, SA, 2004) |
| "The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF), the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) have all demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization in patients with heart failure." | 7.72 | How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, P; Fagerberg, B; Ghali, J; Goldstein, S; Gottlieb, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2003) |
| "Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure." | 7.71 | Effects of metoprolol in chagasic patients with severe congestive heart failure. ( Angel, F; Arata de Bellabarba, G; Dávila, DF; Donis, JH, 2002) |
| "The purpose of this study was to estimate the cost-effectiveness of beta-blocker therapy with either metoprolol or carvedilol in addition to conventional therapy for patients with heart failure (HF) in Canada." | 7.71 | Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. ( Briggs, AH; Demers, C; Levy, AR; O'Brien, BJ, 2001) |
| "This study analyzed the effect of the beta(1)-selective beta-blocker metoprolol succinate controlled release/extended release (CR/XL) once daily on mortality, hospitalizations and tolerability in patients with severe heart failure." | 7.71 | Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. ( Fagerberg, B; Goldstein, S; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2001) |
| "This study was designed to examine the effects of denopamine, a selective beta1-adrenergic agonist, in a murine model of congestive heart failure (CHF) due to viral myocarditis." | 7.70 | Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. ( Matsumori, A; Nishio, R; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1998) |
| "To investigate the effects of beta-blocker (metoprolol) or angiotensin-converting enzyme inhibitor (captopril) treatment on neurohormonal function in a randomized prospective study on patients with heart failure due to dilated cardiomyopathy." | 7.70 | The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. ( Dahlström, U; Jansson, K; Karlberg, BE; Karlberg, KE; Karlsson, E; Nylander, E; Nyquist, O, 1999) |
| "Long-term metoprolol therapy improves cardiac performance and decreases mortality in patients with chronic congestive heart failure (CHF)." | 7.70 | Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. ( DiBona, GF; Sawin, LL, 1999) |
| "This analysis was carried out to clarify the capacity of metoprolol to prevent cardiac events in Japanese post-myocardial infarction patients during a follow-up period of 16." | 7.70 | Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group. ( Hayashi, T; Inoki, T; Ishikawa, K; Kanamasa, K; Katayama, K; Kimura, A; Kitayama, K; Miyataka, M; Takenaka, T; Yabushita, H, 2000) |
| "The hemodynamic and myocardial metabolic effects of enoximone (phosphodiesterase III inhibitor), alone or in combination with metoprolol (beta-adrenergic blocker), were studied in patients with congestive heart failure." | 7.68 | Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. ( Branzi, A; Caldarera, I; Galie, N; Grattoni, C; Magnani, B; Magnani, G; Melandri, G; Rapezzi, C, 1993) |
| " beta-receptor density and ejection fraction in congestive heart failure (CHF) before and after conventional therapy with small dose of beta-blocker (metoprolol) or captopril were compared." | 7.68 | [Changes in lymphocyte beta-receptor density in patients with heart failure before and after metoprolol or captopril administration]. ( Ma, C; Qin, S, 1992) |
| "To define the effects of 2 months of metoprolol therapy on cardiac function, aerobic performance and sympathetic nervous system activity, metoprolol (75 to 100 mg/day) was administered to 10 patients with chronic congestive heart failure (CHF)." | 7.68 | Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. ( Abrass, IB; Nemanich, JW; Stratton, JR; Veith, RC, 1990) |
| " Based on the Chinese and International guidelines and the Chinese clinical practice, we are conducting this study (NCT03413410) to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose in Chinese acute coronary syndrome (ACS) patients during hospitalisation." | 6.90 | Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study. ( Chen, Y; Dong, W; Li, D; Liu, Y; Mu, Y; Wang, J; Zhou, H; Zhou, S, 2019) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 6.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| "The study comprised 59 patients with congestive heart failure, New York Heart Association class II or III, and left ventricular ejection fraction <35%." | 6.70 | Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. ( de Groot, AC; de Milliano, PA; Lie, KI; Tijssen, JG; van Eck-Smit, BL; Van Zwieten, PA, 2002) |
| "This study indicates that treatment with metoprolol succinate for a 6-month period is safe and well tolerated and is associated with an increase in left ventricular ejection fraction and a decrease in ventricular ectopic beats." | 6.69 | Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. ( Anderson, JL; Friday, G; Gheorghiade, M; Goldstein, S; Gottlieb, S; Hall, C; Haskell, L; Jessup, M; Karlsberg, RP; Kennedy, HL, 1999) |
| " The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day." | 6.69 | MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. ( Böhm, M; Darius, H; Genth-Zotz, S; Hanrath, P; Hartmann, D; Meyer, J; Sigmund, M; Treese, N; Waagstein, F; Zotz, RJ, 2000) |
| "The bucindolol group had an increase in systolic elastance, whereas the metoprolol group had a parallel left shift in this relation." | 6.68 | Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. ( Eichhorn, EJ; Hatfield, B; Heesch, CM; Marcoux, L, 1995) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 6.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| " These include the choice of dose and dosage regimen of immediate-release metoprolol tartrate, a dosage form that has never been shown to reduce mortality in patients with heart failure." | 6.42 | Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. ( Bauman, JL; Talbert, RL, 2004) |
| "We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure." | 6.20 | Beta-blocker benefit according to severity of heart failure. ( Bouzamondo, A; Hulot, JS; Lechat, P; Sanchez, P, 2003) |
| "This survival study was designed to address whether beta-1-blockade utilizing metoprolol CR/XL (controlled release/extended release) once daily added to standard therapy reduces mortality and morbidity in patients with decreased ejection fraction and symptoms of heart failure." | 6.19 | MERIT-HF mortality and morbidity data. ( Fagerberg, B; Hjalmarson, A, 2000) |
| "To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF)." | 5.51 | Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. ( Ding, Y; Li, J; Wei, Z; Zhu, L, 2022) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 5.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| " One observation study showed no difference between metoprolol and diltiazem for successful rate control, but worsening heart failure symptoms occurred more frequently in those receiving diltiazem compared to metoprolol (19 patients [33%] vs." | 5.41 | Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. ( Balhara, KS; Ehmann, MR; Hinson, JS; Lobner, K; Niforatos, JD; Ramcharran, L; Weygandt, PL, 2023) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 5.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| "There were included 56 patients with congestive heart failure, 38 with ischemic heart disease and 18 with idiopathic dilated cardiomyopathy, 40 males and 16 females, aged between 25 and 65 years, who were compared with 19 healthy individuals, 12 males and 7 females, of the same age." | 5.35 | The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure. ( Bodisz, G; Ilea, M; Mălai, A; Pop, D; Zdrenghea, D; Zdrenghea, M, 2009) |
| " Therefore we analyzed 24-h ECG Holter recordings from a study which compared the long-term clinical efficacy of metoprolol tartrate to carvedilol in chronic heart failure patients using the same dosing regimen as in COMET." | 5.33 | Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? ( Chan, SK; Fung, JW; Leung, LY; Sanderson, JE; Yip, GW; Yu, CM, 2005) |
| " Pharmacokinetic studies have also been performed in heart failure patients and have demonstrated that ER metoprolol succinate is associated with a more pronounced and even beta1-blockade over a 24-h period than the IR formulation." | 5.32 | Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. ( Andersson, B; Kendall, MJ; Klibaner, M; Stanbrook, H; Wikstrand, J, 2003) |
| " The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier." | 5.30 | The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. ( Charpidou, A; Georgakopoulos, P; Karavidas, A; Kouvela, M; Kyriakidis, M; Mamalis, N; Perpinia, A; Zimeras, S, 2019) |
| "The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF)." | 5.30 | Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. ( Abraham, WT; Aleong, R; Anand, IS; Ayala-Paredes, F; Bristow, MR; Carroll, IA; Connolly, SJ; Davis, G; Dufton, C; Emery, LL; Healey, JS; Ilkhanoff, L; Kao, DP; Khaykin, Y; Krueger, SK; Marshall, D; Merkely, B; Miloradović, V; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Wranicz, JK; Ziegler, PD, 2019) |
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 5.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| "The Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Metoprolol Succinate for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure (GENETIC-AF) trial is a multicenter, randomized, double-blinded "seamless" phase 2B/3 trial of bucindolol hydrochloride versus metoprolol succinate, for the prevention of symptomatic AF/AFL in patients with reduced ejection fraction heart failure (HFrEF)." | 5.27 | A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. ( Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB, 2018) |
| " There were no significant differences in the secondary endpoints of recurrent angina, readmission, and tachyarrhythmias except for more first- and second-degree AV blocks with metoprolol (12." | 5.24 | Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine". ( Bisht, DS; Gokhroo, RK; Gupta, S; Kishore, K; Priti, K; Ranwa, BL, 2017) |
| "To prospectively evaluate the impact of metoprolol achieved heart rate (HR) on cardiac-motor function and quality of life (QoL) in chronic heart failure (CHF) patients." | 5.24 | A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. ( Cheng, X; Liu, J; Liu, X; Meng, Y, 2017) |
| "Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials." | 5.22 | Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. ( Esler, M; Grassi, G; Kjeldsen, SE; Kreutz, R; Mancia, G; Pathak, A, 2022) |
| "In a 2 × 2 factorial, randomized, placebo-controlled, double-blind trial, we assigned 130 adult women with early breast cancer and no serious co-morbidity to the angiotensin receptor blocker candesartan cilexetil, the β-blocker metoprolol succinate, or matching placebos in parallel with adjuvant anticancer therapy." | 5.22 | Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. ( Bratland, Å; Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2016) |
| "Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany." | 5.20 | Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. ( Agewall, S; Atar, D; Cebola, R; Frankenstein, L; Fröhlich, H; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Täger, T; Zhao, J, 2015) |
| "To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional *4 allele (1846G>A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605)." | 5.19 | An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. ( Balmforth, AJ; Batty, JA; de Boer, RA; Hall, AS; Hjalmarson, Å; Kjekshus, J; van der Harst, P; van Veldhuisen, DJ; Waagstein, F; White, HL; Wikstrand, J, 2014) |
| "The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated." | 5.17 | Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). ( Abu-Zeitone, A; Jons, C; Kutyifa, V; McNitt, S; Moss, AJ; Ruwald, AC; Ruwald, MH; Zareba, W, 2013) |
| "Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure." | 5.17 | Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure. ( Bakx, A; de Peuter, OR; Kamphuisen, PW; Kok, WE; Meijers, JC; Nieuwland, R; Schaap, MC; Somsen, GA; van den Bogaard, B; Verberne, HJ, 2013) |
| "Patients with Killip class II or less anterior ST-segment-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention within 6 hours of symptoms onset were randomized to receive intravenous metoprolol (n=131) or not (control, n=139) before reperfusion." | 5.17 | Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri ( Acebal, C; Albarrán, A; Arias, M; Bastante, T; Cabrera, JA; Casado, I; Cuellas, C; de la Torre-Hernández, JM; Escalera, N; Fernández-Campos, MJ; Fernández-Friera, L; Fernández-Jiménez, R; Fernández-Ortiz, A; Fernández-Vázquez, F; Fuster, V; García-Álvarez, A; García-Prieto, J; García-Rubira, JC; García-Ruiz, JM; Goicolea, J; Hernández-Antolín, R; Ibanez, B; Iglesias-Vázquez, JA; Iñiguez, A; Jiménez-Borreguero, J; López-Romero, P; Macaya, C; Mateos, A; Pérez de Prado, A; Pizarro, G; Pocock, S; Rodriguez, MD; Ruiz-Mateos, B; Sánchez-Brunete, V; Sanz, G; Sanz-Rosa, D; Valenciano, J, 2013) |
| "To determine advantages of therapy of functional class (FC) I-II chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction in patients with hypertensive disease (HD) with metoprolol succinate or quinapril and to assess their effect on regulatory-adaptive status." | 5.16 | [Advantages of quinapril therapy in patients with arterial hypertension and functional class III chronic heart failure with preserved left ventricular ejection fraction]. ( Kanorskiĭ, SG; Pokrovskiĭ, VM; Tregubov, VG, 2012) |
| "Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear." | 5.15 | Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study. ( Christiansen, B; Dominguez, H; Falskov, B; Hermann, TS; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2011) |
| "The aim of this study was to assess the effect ofmetoprolol on cardiac function in children with heart failure." | 5.14 | Influence of metoprolol on systolic and diastolic function in children with heart failure. ( Abaskhanian, ZA; Ghader, FR, 2009) |
| "To determine whether metoprolol succinate (a beta(1)-selective beta-blocker) remains beta(1)-selective compared with carvedilol (a nonselective beta-blocker) during upward titration of doses in patients with American College of Cardiology (ACC) stage C heart failure." | 5.14 | Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. ( Gilbert, EM; Lombardi, WL; Macgregor, J; Munger, M; Stoddard, GP; Zebrack, JS, 2009) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 5.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 5.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "to study the safety of switching from short-acting metoprolol to long-acting bisoprolol in patients with cardiac failure and postinfarction impaired left ventricular systolic function." | 5.13 | Switching beta-blocker therapy in chronic heart failure. ( Somlói, M; Toldy-Schedel, E; Tomcsányi, J; Wettstein, A, 2008) |
| "Sixteen men with mild, stable heart failure (NYHA class II to III; left ventricular ejection fraction <40%) underwent serial blood sampling for plasma natriuretic peptide levels and received infusions of atrial natriuretic peptide (ANP) and BNP before and 6 weeks after the introduction and uptitration of metoprolol or 6 weeks unchanged therapy in a randomized, parallel-group design." | 5.12 | Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. ( Davis, ME; Frampton, CM; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, 2006) |
| "First, given the wide confidence interval, it was impossible to detect an interaction between metoprolol and mortality in patients with atrial fibrillation and heart failure." | 5.12 | Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. ( Aass, H; Dunselman, PH; El Allaf, D; Gullestad, L; Halinen, M; Kjekshus, J; Ohlsson, L; van Veldhuisen, DJ; Wedel, H; Wikstrand, J, 2006) |
| "The purpose of this study was to compare the effects of immediate-release (IR) metoprolol and extended-release (XL) metoprolol on measures of heart rate variability in chronic systolic heart failure patients." | 5.12 | Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. ( Aquilante, CL; Binkley, PF; Hatton, PS; Johnson, JA; Pauly, DF; Schofield, RS; Terra, SG, 2006) |
| "We aimed to compare the effects of carvedilol and metoprolol succinate on left atrial (LA) function in patients with chronic heart failure." | 5.12 | Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. ( Acikel, M; Arslan, S; Atesal, S; Bozkurt, E; Erol, MK; Gundogdu, F; Senocak, H, 2007) |
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 5.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 5.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "The purpose of the study was to evaluate the influence of metoprolol succinate and carvedilol on the physical ability (FA) of patients with chronic heart failure (CHF) of different etiologies." | 5.12 | [The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. ( Andreev, DA; Kalashnikov, VIu; Poltavskaia, MG; Sarkisova, EA; Svet, AV; Syrkin, AL, 2007) |
| "In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months." | 5.12 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Erhardt, L; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, P; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "To investigate whether metoprolol controlled release/extended release (CR/XL) once daily would improve diastolic and systolic left ventricular function in patients with chronic heart failure and decreased ejection fraction." | 5.11 | Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. ( Frøland, G; Gullestad, L; Hole, T; Offstad, J; Skjaerpe, T, 2004) |
| "The COMET trial was a prospective, double-blind, randomised trial comparing carvedilol, a comprehensive adrenergic receptor antagonist, with metoprolol, a beta-1-selective agent in patients with heart failure and left ventricular systolic dysfunction." | 5.11 | A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Erhardt, L; Goode, K; Hanrath, P; Komajda, M; Metra, M; Poole-Wilson, PA; Remme, WJ; Swedberg, K; Torp-Pedersen, C, 2004) |
| "Metoprolol CR/XL was easily instituted, safe and well tolerated in elderly patients with systolic heart failure." | 5.11 | Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. ( Deedwania, PC; Ghali, JK; Gottlieb, S; Waagstein, F; Wikstrand, JC, 2004) |
| " To assess the effect of metoprolol succinate controlled release/extended release (CR/XL) combined with high versus low doses of ACEI and digitalis, we analyzed data from The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) in which patients with heart failure and left ventricular ejection fraction < or =40% were randomized to metoprolol CR/XL versus placebo." | 5.11 | Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. ( Deedwania, PC; Dunselman, P; Ghali, JK; Goldstein, S; Gottlieb, SS; Waagstein, F; Wikstrand, JC, 2004) |
| "Cardiovascular risk and risk reduction were analyzed in five subgroups defined by quintiles (Q) of pretreatment resting HR in the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 5.11 | What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). ( Bermann, G; Deedwania, P; Egstrup, K; Elkayam, U; Gottlieb, S; Gullestad, L; Hjalmarson, A; Kjekshus, J; Rashkow, A; Wedel, H; Wikstrand, J, 2005) |
| "The objective of the current study was to examine the efficacy and tolerability of the beta-blocker metoprolol succinate controlled release/extended release (CR/XL) in patients with diabetes in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 5.11 | Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. ( Deedwania, PC; Ghali, JK; Giles, TD; Herlitz, J; Hildebrandt, P; Kjekshus, J; Klibaner, M; Spinar, J; Stanbrook, H; Vitovec, J; Wikstrand, J, 2005) |
| "Data from electronic dosing monitors and published pharmacokinetic parameters were used to derive medication adherence measures for immediate-release metoprolol and examine their association with health care utilization of outpatients aged 50 years or older with heart failure." | 5.11 | Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. ( Brater, DC; Li, J; Morris, AB; Murray, MD; Tu, W; Wu, J; Young, J, 2005) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 5.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "VEGF promoter polymorphisms +405 and -460 were examined in 596 CHF patients enrolled in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF) study and in 187 healthy controls." | 5.11 | The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. ( De Boer, RA; Hall, AS; van der Meer, P; van der Steege, G; van Veldhuisen, DJ; Voors, AA; White, HL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 5.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "In this study, we aimed to investigate effects of metoprolol treatment on transmitral, pulmonary venous flows and spontaneous echo contrast in patients with heart failure." | 5.11 | [Effects of beta-blockers on transmitral, pulmonary venous flows, and spontaneous echo-contrast grades in heart failure]. ( Aydin, M; Cam, F; Doğan, SM; Dursun, A; Gürsürer, M; Madak, H; Onuk, T, 2005) |
| "It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure." | 5.11 | Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. ( Anzai, T; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A, 2005) |
| "We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg)." | 5.10 | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). ( Fagerberg, B; Goldstein, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2002) |
| "Patients with chronic heart failure were randomized to treatment (double blind) with metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy." | 5.10 | Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. ( Chan, SK; Fung, JW; Sanderson, JE; Yeung, LY, 2002) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 5.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "To evaluate neurohumoral factors as markers for left-ventricular (LV) antiremodelling from metoprolol treatment in patients with chronic LV systolic heart failure." | 5.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 5.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 5.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily)." | 5.10 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2003) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 5.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "A subgroup analysis was performed in black patients who participated in the Metoprolol CR/XL Randomized Intervention trial in Congestive Heart Failure trial." | 5.10 | Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). ( Deedwania, P; Goldstein, S; Gottlieb, S; Wikstrand, J, 2003) |
| " Thirty-three patients with CHF, with exercise limited by dyspnea and left ventricular ejection fraction of 26 +/- 4%, were randomized to receive metoprolol or carvedilol for 6 months." | 5.10 | Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). ( Blanchet, M; Ducharme, A; Fortier, A; Juneau, M; Larivée, L; Marquis, J; Nigam, A; Racine, N; Rouleau, JL; Tardif, JC; White, M, 2003) |
| "This was a prespecified subgroup analysis of a double-blind, randomized trial: the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF)." | 5.10 | Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. ( Czuriga, I; Ghali, JK; Herlitz, J; Hjalmarson, A; Jánosi, A; Klibaner, M; Wikstrand, J, 2003) |
| "The effects of spironolactone or metoprolol added to a conventional treatment protocol on QT dispersion, which is accepted as a sudden cardiac death predictor, were evaluated in heart failure patients." | 5.10 | Effects of spironolactone and metoprolol on QT dispersion in heart failure. ( Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Ozbay, Y, 2003) |
| "We describe the effect of controlled-release/extended-release (CR/XL) metoprolol succinate once daily on mortality and hospitalizations among patients with a history of hypertension complicated by chronic systolic heart failure." | 5.10 | Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. ( Denny, M; Fenster, P; Herlitz, J; Heywood, T; Masszi, G; Rasmussen, S; Thorgeirsson, G; Wachtell, K; Wikstrand, J, 2002) |
| "We looked at evidence of clinical deterioration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) by analyzing events and symptoms during the first 90 days." | 5.10 | Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Deedwania, P; Fisher, ML; Gottlieb, SS; Gullestad, L; Kjekshus, J; Vitovec, J; Wikstrand, J, 2002) |
| "MERIT-HF (Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure) was a randomized, placebo-controlled study, the purpose of which was to evaluate the effect of metoprolol controlled-release/extended-release (CR/XL) in 3991 patients with New York Heart Association class II to IV heart failure and LVEF < or =0." | 5.10 | Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, PC; Ghali, JK; Gottlieb, SS; Piña, IL; Wikstrand, JC, 2002) |
| "In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure." | 5.10 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; J Remme, W; Komajda, M; Metra, M; Poole-Wilson, PA; Swedberg, K; Torp-Pedersen, C, 2002) |
| "Forty-eight patients with congestive heart failure were investigated: 30 patients with dilated cardiomyopathy participating in a placebo-controlled trial (15 on placebo, 15 on metoprolol), and 18 patients treated by metoprolol in an open protocol." | 5.09 | Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. ( Andersson, B; Lomsky, M; Strömblad, SO; Waagstein, F, 1999) |
| "Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has not been proven." | 5.09 | Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) ( , 1999) |
| "This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure." | 5.09 | Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, ON; Steinmetz, M, 1999) |
| "The study was undertaken to investigate the effect of metoprolol CR/XL on all-cause mortality in patients with heart failure in New York Heart Association (NYHA) class II-IV." | 5.09 | The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. ( Goldstein, S; Hjalmarson, A, 1999) |
| "This study was performed to compare the long-term clinical efficacy of treatment with metoprolol versus carvedilol in patients with chronic heart failure." | 5.09 | Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. ( Chan, KW; Chan, SK; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yip, G, 1999) |
| "To compare the hemodynamic effects of twice daily metoprolol tartrate (MT) and once daily metoprolol succinate (MS) in congestive heart failure patients." | 5.09 | Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, O, 2000) |
| "To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure." | 5.09 | Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. ( Aldershvile, J; Ball, S; Deedwania, P; Dietz, R; Dunselman, PH; El Allaf, D; Fagerberg, B; Goldstein, S; Gottlieb, S; Gullestad, L; Halinen, M; Herlitz, J; Hjalmarson, A; Jánosi, A; Kjekshus, J; Kuch, J; Neuhaus, KL; Rickenbacher, P; Thorgeirsson, G; Vítovec, J; Waagstein, F; Wedel, H; Wikstrand, J, 2000) |
| "Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs." | 5.09 | Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. ( Boldi, E; Dei Cas, L; Giubbini, R; Metra, M; Modena, MG; Nodari, S, 2000) |
| "This article reviews the design and results of REACH-1 (Research on Endothelin Antagonism in Chronic Heart Failure) and MERIT (Metoprolol controlled and Extended release, Randomised Intervention Trial in congestive Heart Failure), two recently reported clinical trials that investigated, respectively, the role of a non-selective endothelin antagonist (bosentan) and of a beta-selective blocker for the treatment of heart failure." | 5.09 | Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. ( Cleland, JG; Mylona, P, 1999) |
| "The MERIT-HF study was designed to investigate the effect of once-daily dosing of metoprolol succinate CR/XL added to standard therapy in patients with chronic heart failure." | 5.09 | Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). ( Fagerberg, B, 2000) |
| "In this randomized, placebo-controlled and double-blind substudy to the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF), 41 patients were examined with magnetic resonance imaging three times in a six-month period, assessing LV dimensions and function." | 5.09 | Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Larsson, HB; Nilsson, JC; Sondergaard, L, 2000) |
| " The objective of this study was to determine if these antioxidant effects are detectable in patients with heart failure and to compare carvedilol with the selective beta-blocker metoprolol." | 5.09 | Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. ( Arumanayagam, M; Chan, S; Sanderson, JE; Tong, S, 2001) |
| "6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction | 5.09 | Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. ( Aarsland, T; Fagertun, H; Gullestad, L; Kjekshus, J; Manhenke, C; Skårdal, R; Wikstrand, J, 2001) |
| "International placebo-controlled survival trials (Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS-II], and Carvedilol Prospective Randomized Cumulative Survival trial [COPERNICUS]) evaluating the effects of b-blockade in patients with heart failure have all demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization." | 5.09 | Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. ( Deedwania, P; Demets, D; Fagerberg, B; Goldstein, S; Gottlieb, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 5.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "Thirty-six patients with chronic heart failure were randomized to the nonselective beta-blocker carvedilol or the selective beta-blocker metoprolol (double-blind)." | 5.09 | Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. ( Al-Hesayen, A; Allan, R; Azevedo, ER; Floras, JS; Kelly, S; Kubo, T; Mak, S; Newton, GE; Parker, JD; Schofield, A, 2001) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 5.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "Fifteen patients with chronic heart failure were randomized to a 3-way crossover study to receive metoprolol IR 50 mg 3 times daily, CR/XL 100 mg once daily, and CR/XL 200 mg once daily for 7 days." | 5.09 | Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. ( Aberg, J; Andersson, B; Lindelöw, B; Täng, MS; Wikstrand, J, 2001) |
| "To evaluate whether xamoterol, a partial agonist, would improve exercise time more than metoprolol in patients with mild to moderate heart failure after a myocardial infarction." | 5.08 | Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. ( Erhardt, L; Melcher, A; Persson, H; Rythe'n-Alder, E, 1995) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 5.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "Metoprolol partly reverses Gi alpha-upregulation and beta-adrenoceptor downregulation in heart failure, which might contribute to the clinical improvement of patients treated with beta-blockers." | 5.08 | Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. ( Becker, H; Eschenhagen, T; Hanrath, P; Jakob, H; Schmitz, W; Scholz, H; Schumacher, C; Sigmund, M; Steinfath, M, 1996) |
| " Metoprolol treatment restores the blunted inotropic response to milrinone in patients with heart failure, indicating that postreceptor events (e." | 5.08 | Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. ( Böhm, M; Deutsch, HJ; Hartmann, D; Rosée, KL; Stäblein, A, 1997) |
| "The aim of this study is to describe the impact of early treatment with metoprolol on prognosis during 1 year of follow-up in patients with suspected acute myocardial infarction (AMI) and indirect signs of congestive heart failure (CHF)." | 5.08 | Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial). ( Herlitz, J; Hjalmarson, A; Lindqvist, J; Swedberg, K; Waagstein, F, 1997) |
| "Metoprolol is a cardioselective beta blocker that has been shown to improve left ventricular function and symptoms of congestive heart failure (CHF) and also to decrease the number of hospitalizations due to CHF." | 5.08 | Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee. ( , 1997) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 5.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 5.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "To investigate the alterations of plasma endothelin-1(ET-1) in patients with congestive heart failure(CHF) and the effects of metoprolol on it, plasma ET-1 and norepinephrine(NE) were measured in 43 patients using radioimmunoassay and high-performance liquid chromatography methods." | 5.08 | [Changes of plasma endothelin-1 in patients with congestive heart failure and the influence of metoprolol]. ( Sun, M; Xu, H; Zhou, H, 1998) |
| "This clinical trial was performed to determine the safety and clinical impact of titrated metoprolol therapy in patients with heart failure, documented coronary artery disease and a low ejection fraction." | 5.07 | Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. ( Bennett, SK; Fisher, ML; Gottlieb, SS; Greenberg, NL; Hamilton, BP; Patten, RD; Plotnick, GD, 1994) |
| "The purpose of this study was to determine the incidence of ventricular tachycardia and fibrillation without hypotension or heart failure after treatment with recombinant tissue-type plasminogen activator (rt-PA), anatomic correlates of their development, the effect of immediate intravenous metoprolol on their occurrence and the outcome of patients with these arrhythmias." | 5.07 | Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial In ( Berger, PB; Frederick, MM; Podrid, PJ; Ruocco, NA; Ryan, TJ, 1993) |
| "Ten patients with congestive heart failure were given metoprolol (50 mg/day) or placebo during a double-blind, crossover, randomized study." | 5.07 | Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. ( D'Onofrio, F; Gambardella, A; Marrazzo, G; Paolisso, G; Teasuro, P; Varricchio, M; Verza, M, 1992) |
| "Beta-blockers such as metoprolol, carvedilol, and bisoprolol are indicated for the treatment of patients with reduced ejection fraction heart failure." | 5.05 | Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure. ( Ingram, A; Valente, M, 2020) |
| "1 This study was designed to compare in a randomized cross-over trial pindolol, a beta-adrenoceptor blocking agent with intrinsic sympathomimetic activity and metoprolol, a cardioselective beta-adrenoceptor blocker lacking sympathomimetic activity in hypertensives with incipient heart failure." | 5.05 | The influence of beta-adrenoceptor blockade on left ventricular function. ( Hahn, B; Strauer, BE, 1982) |
| "In a double blind study of metoprolol in the treatment of suspected acute myocardial infarction 698 patients (study group) received metoprolol and 697 a placebo (control group)." | 5.05 | Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. ( Herlitz, J; Hjalmarson, A; Holmberg, S; Swedberg, K; Vedin, A; Waagstein, F; Waldenström, A; Wedel, H; Wilhelmsen, L; Wilhelmsson, C, 1984) |
| "The Göteborg Metoprolol Trial was a double-blind, placebo-controlled, stratified trial aimed at evaluating the effect of the beta 1-selective blocker, metoprolol, in suspected acute myocardial infarction and during 2 years of follow-up." | 5.05 | Göteborg Metoprolol Trial: design, patient characteristics and conduct. ( Herlitz, J; Holmberg, S; Pennert, K; Swedberg, K; Vedin, A; Waagstein, F; Waldenström, A; Waldenström, J; Wedel, H; Wilhelmsen, L, 1984) |
| " Studies investigating any of three beta blockers (carvedilol, bisoprolol, and extended release metoprolol succinate) which are known to be effective in adult patients with heart failure were included." | 4.91 | Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies. ( Cho, MJ; Jung Kwak, M; Kim, HY; Kim, YM; Lee, HD; Lim, RK; Park, KH, 2015) |
| "Long-term treatment with appropriate doses of carvedilol or metoprolol is currently recommended for patients with heart failure with reduced ejection fraction (HFrEF) to decrease the risk of death, hospitalizations, and patients' symptoms." | 4.91 | Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. ( Afonso, L; Briasoulis, A; Palla, M, 2015) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 4.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "Results of the investigation of metoprolol CR/XL which was conducted in large randomized controlled study MERIT-HF in patients with chronic heart failure (CHF) are presented." | 4.84 | [Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups]. ( Bugrimova, MA; Iosava, IK; Pataraia, SA; Preobrazhenskiĭ, DV; Sidorenko, BA, 2008) |
| "To review the pharmacology, pharmacokinetics, efficacy, and tolerability of extended-release (ER) metoprolol succinate and its role in the management of chronic heart failure." | 4.82 | Extended-release metoprolol succinate in chronic heart failure. ( Patterson, JH; Tangeman, HJ, 2003) |
| "In the United States, carvedilol and metoprolol (tartrate or succinate) are the most commonly employed beta-adrenoreceptor antagonists for the treatment of heart failure." | 4.82 | Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. ( McBride, BF; White, CM, 2005) |
| "There is overwhelming evidence that beta blocker therapy in the form of metoprolol, bisoprolol, and carvedilol can have positive outcomes on morbidity, mortality, and quality of life in patients who have been diagnosed with mild to severe heart failure." | 4.82 | Emerging trends in the management of heart failure: Beta blocker therapy. ( Rone, T; Sauls, JL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol." | 4.82 | [Beta-adrenolytics in heart failure--are they all really equal?]. ( Filipiak, KJ; Opolski, G, 2005) |
| "Several recently completed survival trials, including Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial have examined the effects of ss-blockers on survival and the need for hospitalization." | 4.81 | Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial. ( Ghali, JK; Goldstein, S; Wikstrand, J, 2002) |
| "Metoprolol CR/XL (metoprolol succinate extended-release tablets) is a beta1-selective agent that improved survival and reduced hospitalization among patients with New York Heart Association class II-IV heart failure in a randomized trial." | 4.81 | Metoprolol CR/XL in the treatment of chronic heart failure. ( Gattis, WA, 2001) |
| "Both metoprolol and carvedilol improve cardiac function and prolong survival in patients with heart failure." | 4.81 | Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. ( Antonopoulos, GV; Berlin, JA; Chittams, J; Konstam, MA; Packer, M; Udelson, JE, 2001) |
| "All patients with New York Heart Association class II and III heart failure should receive beta-blocker therapy with bisoprolol, carvedilol, or metoprolol." | 4.81 | Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. ( Lee, S; Spencer, A, 2001) |
| "Metoprolol CR/XL effectively decreases mortality and improves clinical status in patients with stable mild to moderate (NYHA functional class II or III) chronic heart failure due to left ventricular systolic dysfunction, and the drug is effective in patients with ischaemic or dilated cardiomyopathy." | 4.80 | Metoprolol: a review of its use in chronic heart failure. ( Markham, A; Prakash, A, 2000) |
| "Multiclinic controlled studies have shown that enalapril alone 10 to 40 mg/day orally is effective in lowering blood pressure in patients with essential hypertension." | 4.77 | Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. ( Davies, RO; Moncloa, F; Sromovsky, JA; Walker, JF, 1985) |
| "During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris." | 4.77 | Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. ( Benfield, P; Brogden, RN; Clissold, SP, 1986) |
| "Compare heart rate control between parenteral metoprolol and diltiazem and identify safety outcomes in the acute management of atrial fibrillation (AFib) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 4.31 | Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction. ( Allison-Aipa, T; Choi, M; Kapustova, K; Phan, B, 2023) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 4.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| " The purpose of this study was to verify whether metoprolol regulates AKAP5 expression and test the role of AKAP5 postinjury in mitigating cardiac infarction-associated tissue remodeling and fibrosis." | 4.12 | Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart. ( Wang, H; Wang, Q; Wang, Z; Zhang, B; Zhang, X; Zhu, F, 2022) |
| " In order to explore the demand for cardiovascular disease treatment, make up for the lack of chronic diseases affecting people's physical harm, and improve the success rate of cardiovascular disease treatment, a method to observe the efficacy and myocardial remodeling of trimetazidine combined with metoprolol in elderly patients with coronary heart disease and heart failure based on integrated traditional Chinese and Western medicine was proposed." | 4.12 | Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine. ( Lu, Y; Ni, H; Shi, H; Sun, Y; Wang, F, 2022) |
| "Atrial fibrillation (Afib) with rapid ventricular response (RVR) is acutely treated with intravenous push (IVP) metoprolol (MET) or diltiazem (DIL)." | 4.12 | Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. ( Compagner, CT; Holzhausen, JM; Reich, EK; Wysocki, CR; Zimmerman, LH, 2022) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 4.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "To explore the effect of metoprolol tartrate tablets and recombinant human natriuretic peptide B (NPPB) on sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and patients with heart failure (AMI-HF)." | 4.02 | Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure. ( Lin, Y; Liu, C; Yao, L; Zhang, L, 2021) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 4.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "To assess gender-, age-, and the dose-related influence of metoprolol on cardiac function, motor function, quality-of-life (QoL), and mental status in Chinese chronic heart failure (CHF) patients." | 3.96 | Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study. ( Cheng, X; Feng, Z; Liu, Q; Meng, Y; Zhu, M, 2020) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 3.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| "The objective of this study was to examine the effects of metoprolol versus diltiazem in the acute management of atrial fibrillation (AF) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF)." | 3.91 | Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. ( Ackerbauer, KA; DeMott, JM; Hirschy, R; O'Donnell, EP; Peksa, GD, 2019) |
| "The evidence-based beta-blockers carvedilol, bisoprolol, and metoprolol succinate reduce mortality and hospitalizations among patients with heart failure with reduced ejection fraction (HFrEF)." | 3.91 | Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. ( Brown, TM; Chen, L; Durant, RW; Kilgore, ML; Levitan, EB; Loop, MS; Safford, MM; van Dyke, MK, 2019) |
| "The effects of carvedilol and metoprolol succinate on appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy in patients with heart failure with reduced ejection fraction (HFrEF) are not fully understood." | 3.91 | A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators. ( Alqam, B; Ayan, M; Cross, M; Gheith, Z; Habash, F; Paydak, H; Vallurupalli, S, 2019) |
| "Aim - optimization of the treatment of obesity and chronic heart failure (CHF) patients by identifying key factors for the progression of cardiac decompensation and the principles of using metoprolol succinate, taking into account pharmacogenetic aspects in the complex treatment of this comorbidity." | 3.91 | METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE. ( Gasanov, I; Rudyk, Y, 2019) |
| "Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure." | 3.85 | Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure. ( Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017) |
| " Finally, animals were treated with metoprolol to evaluate a pharmacologic treatment option to prevent the development of heart failure." | 3.85 | Stroke-induced chronic systolic dysfunction driven by sympathetic overactivity. ( Bieber, M; Frantz, S; Heuschmann, PU; Higuchi, T; Hofmann, U; Kleinschnitz, C; Kraft, P; Ritter, O; Schuh, K; Tanai, E; Werner, RA, 2017) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 3.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2 -adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF)." | 3.81 | Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. ( Calzetta, L; Capuano, A; Donniacuo, M; Gritti, G; Martuscelli, E; Matera, MG; Orlandi, A; Rafaniello, C; Rinaldi, B; Rossi, F; Sodano, L, 2015) |
| "To determine if metoprolol succinate or carvedilol is more effective in delaying the time to first cardiovascular disease hospital admission in systolic heart failure patients." | 3.81 | Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study. ( Baker, E; Brennan, MT; Church, KM; Henalt, R; Joseph, J; Smith, GL, 2015) |
| "The effects of metoprolol or/and BNP were studied on cardiac remodelling, excitation-contraction coupling and arrhythmias in an experimental mouse model of ischaemic heart failure following postmyocardial infarction." | 3.80 | Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? ( Aimond, F; Babuty, D; Cassan, C; Fauconnier, J; Gac, A; Karam, S; Lacampagne, A; Le Guennec, JY; Richard, S; Roberge, S; Roussel, J; Thireau, J, 2014) |
| "The β-blockers carvedilol and metoprolol succinate both reduce mortality in patients with heart failure (HF), but the comparative clinical effectiveness of these drugs is unknown." | 3.80 | Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. ( Hviid, A; Melbye, M; Pasternak, B; Svanström, H, 2014) |
| "Clenbuterol (Cl), a β2 agonist, is associated with enhanced myocardial recovery during left ventricular assist device (LVAD) support, and exerts beneficial remodelling effects during mechanical unloading (MU) in rodent heart failure (HF)." | 3.80 | Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading. ( Gandhi, A; Ibrahim, M; Kukadia, P; Navaratnarajah, M; Shah, A; Siedlecka, U; Soppa, G; Terracciano, CM; van Doorn, C; Yacoub, MH, 2014) |
| "Right and left ventricular trabeculae from freshly explanted hearts of 5 non-β-blocker-treated and 15 metoprolol-treated patients with terminal heart failure were paced to contract at 1 Hz." | 3.79 | PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. ( Berk, E; Chen, L; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Hussain, RI; Kaumann, AJ; Krobert, KA; Levy, FO; Molenaar, P; Ravens, U, 2013) |
| "In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks." | 3.79 | Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. ( Babick, A; Dhalla, NS; Elimban, V; Zieroth, S, 2013) |
| "Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown." | 3.79 | Influence of ivabradine on reverse remodelling during mechanical unloading. ( Dias, P; Gandhi, A; Ibrahim, M; Navaratnarajah, M; Sarathchandra, P; Shah, A; Siedlecka, U; Terracciano, CM; van Doorn, C; Yacoub, MH, 2013) |
| " This dosage regimen could be modified according to the judgement of the investigator." | 3.79 | MERIT-HF--description of the trial. ( Wikstrand, J, 2000) |
| "To investigate whether heart rate reduction via I(f)-channel blockade and β-receptor blockade prevents left ventricular (LV) dysfunction, we studied ivabradine and metoprolol in angiotensin II-induced heart failure." | 3.78 | Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. ( Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C, 2012) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 3.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| " We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients." | 3.77 | Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. ( Afzal, S; Andersen, JT; Broedbaek, K; Børglum, AD; Hjelvang, BR; Køber, L; Nyegaard, M; Petersen, M; Poulsen, HE; Stender, S; Torp-Pedersen, C, 2011) |
| "In COMET (Carvedilol or Metoprolol European Trial), carvedilol reduced mortality compared with metoprolol in patients with chronic heart failure." | 3.76 | Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy. ( Boman, K; Cleland, JG; Jansson, JH; Nilsson, T; Poole-Wilson, P; Swedberg, K, 2010) |
| "To investigate the effect of metoprolol on the expression of G protein-coupled receptor kinases 2 (GRK2) in lymphocyte of advanced elderly patients with chronic heart failure." | 3.76 | [Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure]. ( Gao, WQ; Han, CG; Liu, YX; Wang, Q; Yang, TS; Zhao, YX; Zhu, P, 2010) |
| "Obvious elevation of PP is associated with a better response to metoprolol succinate sustained-release tablets in elderly hypertensive patients with chronic heart failure, and 3 months of treatment with the tablets can significantly improve the cardiac function and lower the levels of VEGF, hs-CRP and BNP in these patients." | 3.76 | [Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure]. ( Lin, ZP; Zhang, ZW, 2010) |
| "The use of beta-blocking drugs for dilated cardiomyopathy (DCM), however, is currently investigational." | 3.76 | Treatment of cardiac myopathies with beta blockers. What do we know, where do we go from here? ( Anderson, JL, 1988) |
| "The aims of this study were to examine the relationships between CYP2D6 genotype and metoprolol dose, S- and R-metoprolol concentrations and clinical effects in patients with systolic heart failure." | 3.75 | CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. ( Begg, EJ; Gardiner, SJ; Jensen, BP; Lainchbury, JG; Roberts, RL; Sharp, CF; Troughton, RW, 2009) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 3.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "This retrospective cohort study using administrative claims data included veterans 65 years and older receiving bisoprolol, carvedilol, or metoprolol succinate for which prescribing physicians indicated treatment was for heart failure." | 3.75 | The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. ( Barratt, JD; Gilbert, AL; Killer, G; Peck, R; Pratt, N; Ramsay, E; Roughead, EE; Ryan, P, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 3.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Twenty-two patients with heart failure were investigated at rest and during dobutamine stress echocardiography (DSE), before and after 6 months of metoprolol treatment." | 3.74 | The function of left ventricular basal segments is most important for long-term recovery. ( Andersson, B; Scharin Täng, M; Waagstein, F, 2007) |
| " Here, we investigate whether long-term treatment with carvedilol or metoprolol may functionally alter myofibrillar function in end-stage human heart failure." | 3.74 | Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. ( Bloch, W; Boelck, B; Brixius, K; Grafweg, S; Hoyer, F; Lu, R; Mehlhorn, U; Pott, C; Schwinger, RH, 2007) |
| " Carvedilol is more effective than Metoprolol for improving the hemodynamics and in attenuating ventricular remodeling after heart failure." | 3.74 | Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. ( Chen, GW; Jiang, ZF; Lin, Y; Wang, LX; Wu, TG; Zhao, Q, 2007) |
| "To investigate the effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with heart failure." | 3.74 | [Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure]. ( Han, LH; Jiang, B; Jiang, TB; Jiang, WP; Li, BY; Li, HX; Liu, ZH; Song, JP; Yang, XJ; Zou, C, 2007) |
| " We aimed to verify whether the beta-blocker, metoprolol, and the pure heart-rate-reducing agent, ivabradine, have the same effects on haemodynamic function, ventricular remodeling, and Ca2+ handling in post-myocardial infarction (MI) heart failure in rat." | 3.74 | Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. ( Mackiewicz, U; Maczewski, M, 2008) |
| " Here, we show that blockade of beta-adrenoceptors directly in the brain (chronic intracerebroventricular administration of metoprolol) attenuates the progression of left ventricular remodeling in a rat model of myocardial infarction-induced heart failure." | 3.74 | Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. ( Bondar, SI; Gourine, A; Gourine, AV; Spyer, KM, 2008) |
| "To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death." | 3.74 | Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. ( Anand, IS; Ensrud, KE; Nelson, DB; Rector, TS, 2008) |
| "Using data from a large United States health-insurance claims database, we conducted a retrospective study to compare the risks of death and hospitalization and the cost of inpatient care in heart failure patients receiving carvedilol vs." | 3.73 | Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. ( Delea, TE; Edelsberg, JS; Hagiwara, M; Oster, G; Stanford, R, 2005) |
| "The role of phosphorylation of the ryanodine receptor at serine-2808 (RyRS2808) in congestive heart failure (CHF) is controversial, and effects of RyRS2808 phosphorylation on contraction are unclear." | 3.73 | Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. ( Chen, SR; Davidoff, AW; Mei, J; Obayashi, M; Stuyvers, BD; ter Keurs, HE; Xiao, B, 2006) |
| "We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)." | 3.73 | Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005) |
| "To understand the basis of the effectiveness of carvedilol in heart failure by determining its specific properties at human heart beta1- and beta2-adrenoceptors." | 3.73 | Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. ( Christ, T; Kaumann, A; Molenaar, P; Ravens, U, 2006) |
| "The MERIT-HF trial demonstrated improved survival and fewer hospitalizations for worsening heart failure with extended-release (ER) metoprolol succinate in patients with heart failure." | 3.73 | Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. ( Caro, JJ; Deedwania, PC; Gottlieb, S; Hauch, O; Hillson, E; Hjalmarson, A; Kim, J; Migliaccio-Walle, K; Nova, W; O'Brien, JA; Wedel, H; Wikstrand, J, 2005) |
| "The COMET study suggested the better effect of carvedilol to metoprolol in treating heart failure." | 3.73 | Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. ( Fukagawa, Y; Harada, N; Kametani, R; Kawamura, S; Matsuzaki, M; Miura, T; Shibuya, M; Tan, H; Wang, R, 2006) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 3.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "In contrast to other beta-blockers, bucindolol has failed to reduce mortality in patients with chronic heart failure." | 3.72 | Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. ( Böhm, M; Dabew, E; Engelhardt, S; Lohse, MJ; Lorenz, K; Maack, C; Schäfers, HJ; Vlaskin, L, 2003) |
| "Metoprolol succinate was given to 60 patients with class I-III heart failure and ejection fraction <45% after myocardial infarction." | 3.72 | [Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. ( Churganova, LIu; Gavril'eva, SA; Ivanov, GG; Poltavskaia, MG; Sheianov, MV; Shumilova, KM; Syrkin, AL, 2003) |
| "The aim of this MERIT-HF sub-study was to ascertain whether this Glycine389 variant favourably influences outcome in heart failure similar to that observed with beta-blockers." | 3.72 | An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. ( Ball, SG; Balmforth, AJ; Cuthbert, R; de Boer, RA; Greenwood, D; Hall, AS; Maqbool, A; van Veldhuisen, DJ; White, HL, 2003) |
| "Carvedilol and metoprolol are beta(1)-adrenoceptor antagonists that decrease mortality in heart failure." | 3.72 | Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure? ( Doggrell, SA, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate." | 3.72 | In heart failure, all beta-blockers are not necessarily equal. ( Francis, GS; Militello, M; Tang, WH, 2003) |
| "The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF), the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) have all demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization in patients with heart failure." | 3.72 | How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). ( Deedwania, P; Fagerberg, B; Ghali, J; Goldstein, S; Gottlieb, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2003) |
| "Body weight and plasma norepinephrine, leptin, and insulin levels were measured in 27 subjects with CHF before and after 6 months of beta-adrenergic receptor blockade with carvedilol or long-acting metoprolol." | 3.72 | Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure." | 3.71 | Effects of metoprolol in chagasic patients with severe congestive heart failure. ( Angel, F; Arata de Bellabarba, G; Dávila, DF; Donis, JH, 2002) |
| "The purpose of this study was to estimate the cost-effectiveness of beta-blocker therapy with either metoprolol or carvedilol in addition to conventional therapy for patients with heart failure (HF) in Canada." | 3.71 | Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. ( Briggs, AH; Demers, C; Levy, AR; O'Brien, BJ, 2001) |
| "This study analyzed the effect of the beta(1)-selective beta-blocker metoprolol succinate controlled release/extended release (CR/XL) once daily on mortality, hospitalizations and tolerability in patients with severe heart failure." | 3.71 | Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. ( Fagerberg, B; Goldstein, S; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2001) |
| "We reviewed our experience with the use of metoprolol in four younger children with cardiomyopathy who were referred for consideration for heart transplantation because of severe congestive heart failure." | 3.70 | Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. ( Shaddy, RE, 1998) |
| "We examined dogs with coronary microembolism-induced heart failure treated for 12 weeks with metoprolol (25 mg twice daily)." | 3.70 | Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. ( Kerner, J; Panchal, AR; Sabbah, HN; Stanley, WC, 1998) |
| "This study was designed to examine the effects of denopamine, a selective beta1-adrenergic agonist, in a murine model of congestive heart failure (CHF) due to viral myocarditis." | 3.70 | Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. ( Matsumori, A; Nishio, R; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1998) |
| "Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation." | 3.70 | Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. ( Castaigne, A; Delahaye, N; Dubois-Randé, JL; Fumey, R; Merlet, P; Pouillart, F; Syrota, A, 1999) |
| "Metoprolol improves ventricular function in some children with dilated cardiomyopathy and congestive heart failure." | 3.70 | Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. ( Gidding, SS; Gilbert, EM; Lemes, V; Orsmond, GS; Pahl, E; Shaddy, RE; Tani, LY, 1999) |
| "To investigate the effects of beta-blocker (metoprolol) or angiotensin-converting enzyme inhibitor (captopril) treatment on neurohormonal function in a randomized prospective study on patients with heart failure due to dilated cardiomyopathy." | 3.70 | The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. ( Dahlström, U; Jansson, K; Karlberg, BE; Karlberg, KE; Karlsson, E; Nylander, E; Nyquist, O, 1999) |
| "Long-term metoprolol therapy improves cardiac performance and decreases mortality in patients with chronic congestive heart failure (CHF)." | 3.70 | Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. ( DiBona, GF; Sawin, LL, 1999) |
| "This analysis was carried out to clarify the capacity of metoprolol to prevent cardiac events in Japanese post-myocardial infarction patients during a follow-up period of 16." | 3.70 | Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group. ( Hayashi, T; Inoki, T; Ishikawa, K; Kanamasa, K; Katayama, K; Kimura, A; Kitayama, K; Miyataka, M; Takenaka, T; Yabushita, H, 2000) |
| " Recently completed mortality studies with beta-blockers (BB) in chronic heart failure CIBIS II and MERIT HF confirmed the conclusions of pilot studies with carvedilol that in stabilized chronic heart failure BB reduces the mortality rate as well as the need of hospital admission on account of deteriorating heart failure." | 3.70 | [Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice]. ( Spinar, J; Vítovec, J, 2000) |
| "To evaluate the effect of combined use of Chinese herbal medicine, Captopril and Metoprolol in treating mild-middle degree congestive heart failure." | 3.70 | [Clinical study on treatment of mild-middle degree congestive heart failure with integrated traditional Chinese and Western medicine]. ( He, H; Xu, Y; Zhao, W, 2000) |
| "The alpha-agonist drug phenylephrine has been generally considered to be contraindicated in patients with heart failure for the reason that increased afterload produced by the vasoconstriction should decrease ventricular function; the beta-adrenergic blocking drugs generally have been considered to be contraindicated in heart failure because of the dependence of the failing heart on beta-sympathetic agonism; the angiotensin converting enzyme inhibitors have been indicted recently as causing undesirable cardiovascular depression in patients for coronary artery bypass surgery." | 3.69 | New directions in the treatment of heart failure: some paradoxical observations. ( Merin, RG, 1995) |
| "Sequential haemodynamic evaluation of heart failure patients at baseline and after three months of continuous treatment with the beta 1 selective antagonist metoprolol." | 3.69 | Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses. ( Buchholz-Varley, C; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, O, 1997) |
| "The hemodynamic and myocardial metabolic effects of enoximone (phosphodiesterase III inhibitor), alone or in combination with metoprolol (beta-adrenergic blocker), were studied in patients with congestive heart failure." | 3.68 | Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. ( Branzi, A; Caldarera, I; Galie, N; Grattoni, C; Magnani, B; Magnani, G; Melandri, G; Rapezzi, C, 1993) |
| " beta-receptor density and ejection fraction in congestive heart failure (CHF) before and after conventional therapy with small dose of beta-blocker (metoprolol) or captopril were compared." | 3.68 | [Changes in lymphocyte beta-receptor density in patients with heart failure before and after metoprolol or captopril administration]. ( Ma, C; Qin, S, 1992) |
| "To define the effects of 2 months of metoprolol therapy on cardiac function, aerobic performance and sympathetic nervous system activity, metoprolol (75 to 100 mg/day) was administered to 10 patients with chronic congestive heart failure (CHF)." | 3.68 | Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. ( Abrass, IB; Nemanich, JW; Stratton, JR; Veith, RC, 1990) |
| " A positive correlation was found between serum enzyme activity and most of the clinical variables studied, such as incidence of congestive heart failure, treatment with furosemide, incidence of hypotension, cardiogenic shock, pericarditis, post myocardial infarction syndrome, AV block III, and the duration of hospitalization." | 3.67 | Relationship between the enzymatically estimated infarct size and clinical findings in acute myocardial infarction. ( Herlitz, J; Hjalmarson, A; Waldenström, J, 1984) |
| "To evaluate the short- and long-term effects of beta-adrenergic blockade (metoprolol) as well as the reaction to withdrawal and readministration of metoprolol in severe heart failure, 33 patients (25 men and eight women; mean age, 47." | 3.67 | Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. ( Bergh, CH; Caidahl, K; Hjalmarson, A; Waagstein, F; Wallentin, I, 1989) |
| "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs." | 3.66 | Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases. ( Anderson, ST; Federman, J; Harper, RW; Laufer, E; Pitt, A; Wayne, VS, 1982) |
| " Based on the Chinese and International guidelines and the Chinese clinical practice, we are conducting this study (NCT03413410) to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose in Chinese acute coronary syndrome (ACS) patients during hospitalisation." | 2.90 | Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study. ( Chen, Y; Dong, W; Li, D; Liu, Y; Mu, Y; Wang, J; Zhou, H; Zhou, S, 2019) |
| "Treatment with carvedilol was associated with a significantly decreased risk of hospitalization for HF or death when compared with metoprolol (hazard ratio [HR]: 0." | 2.78 | Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). ( Alexis, J; Jons, C; McNitt, S; Moss, AJ; Ruwald, AC; Ruwald, MH; Zareba, W, 2013) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "metoprolol were 10." | 2.74 | Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. ( Cleland, JG; Kenyon, KW; Komajda, M; Levy, WC; Linker, DT; Metra, M; Mozaffarian, D; Poole-Wilson, PA; Remme, WJ; Torp-Pedersen, C, 2009) |
| "4% for those with a reduced dosage (n." | 2.73 | Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. ( Cleland, JG; Dei Cas, L; Di Lenarda, A; Komajda, M; Metra, M; Poole-Wilson, PA; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 2.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "This study was performed to estimate the mean pharmacokinetic parameters of routinely administered metoprolol in middle-aged and elderly Japanese patients." | 2.71 | Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. ( Hashimoto, Y; Inoue, H; Mizumaki, K; Nozawa, T; Taguchi, M; Tahara, K; Takesono, C, 2004) |
| "Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation." | 2.71 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. ( Charlesworth, A; Cleland, J; Hanrath, P; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "Carvedilol treatment caused a significant reduction in CANESP while metoprolol had a neutral effect (-95+/-27 vs." | 2.71 | Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. ( Al-Hesayen, A; Azevedo, ER; Floras, JS; Hollingshead, S; Lopaschuk, GD; Parker, JD, 2005) |
| "The study comprised 59 patients with congestive heart failure, New York Heart Association class II or III, and left ventricular ejection fraction <35%." | 2.70 | Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. ( de Groot, AC; de Milliano, PA; Lie, KI; Tijssen, JG; van Eck-Smit, BL; Van Zwieten, PA, 2002) |
| "Metoprolol is a beta(1)-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockades of alpha(1)-adrenoceptors." | 2.70 | Differing beta-blocking effects of carvedilol and metoprolol. ( Fruhwald, FM; Klein, W; Koshucharova, G; Maier, R; Stoschitzky, K; Watzinger, N; Zweiker, R, 2001) |
| "Enoximone was given at a dose of < or = 1 mg/kg body weight three times a day." | 2.69 | Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. ( Abraham, WT; Bristow, MR; Ferguson, DA; Gilbert, EM; Lowes, BD; Robertson, AD; Shakar, SF; Zisman, LS, 1998) |
| "Forty-five patients with congestive heart failure were studied with Holter recordings." | 2.69 | Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes. ( Andersson, B; Di Lenarda, A; Hjalmarson, A; Rundqvist, B; Sinagra, G; Tygesen, H; Waagstein, F; Wennerblom, B, 1999) |
| "This study indicates that treatment with metoprolol succinate for a 6-month period is safe and well tolerated and is associated with an increase in left ventricular ejection fraction and a decrease in ventricular ectopic beats." | 2.69 | Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. ( Anderson, JL; Friday, G; Gheorghiade, M; Goldstein, S; Gottlieb, S; Hall, C; Haskell, L; Jessup, M; Karlsberg, RP; Kennedy, HL, 1999) |
| " The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day." | 2.69 | MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. ( Böhm, M; Darius, H; Genth-Zotz, S; Hanrath, P; Hartmann, D; Meyer, J; Sigmund, M; Treese, N; Waagstein, F; Zotz, RJ, 2000) |
| "Both metoprolol and captopril were well tolerated and had favourable effects on LV performance." | 2.69 | The value of repeated echocardiographic evaluation in patients with idiopathic dilated cardiomyopathy during treatment with metoprolol or captopril. ( Dahlström, U; Jansson, K; Karlberg, KE; Karlsson, E; Nylander, E; Nyquist, O, 2000) |
| "The bucindolol group had an increase in systolic elastance, whereas the metoprolol group had a parallel left shift in this relation." | 2.68 | Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. ( Eichhorn, EJ; Hatfield, B; Heesch, CM; Marcoux, L, 1995) |
| "7 years; range 14-66 years) with DCM, advanced functional (NYHA III-IV) and severe left ventricular dysfunction (LVEF < or = 25%) underwent a test dosage with metoprolol (5 mg b." | 2.68 | [Safety and tolerability of beta-blockers in severe cardiac decompensation from dilated cardiomyopathy]. ( Camerini, F; Di Lenarda, A; Lardieri, G; Perkan, A; Pinamonti, B; Rakar, S; Secoli, G; Sinagra, G; Zecchin, M, 1995) |
| "There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme." | 2.66 | Beta-blockers for congestive heart failure in children. ( Al Dakhoul, S; Alabed, S; Bdaiwi, Y; Sabouni, A, 2020) |
| "Metoprolol-treated patients had an improvement in mean exercise capacity by 3 mets (p less than ." | 2.66 | Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. ( Engelmeier, RS; Gunnar, RM; O'Connell, JB; Rad, N; Scanlon, PJ; Walsh, R, 1985) |
| "The incidences of congestive heart failure, hypotension, AV blocks and ventricular arrhythmias were not significantly more common in the control group (8 vs." | 2.65 | Established beta-adrenergic receptor blocking therapy and acute myocardial infarction. A clinical study of risks and benefits. ( Berglund, U; Dahlström, U; Karlsson, E, 1980) |
| "All patients clinically had idiopathic dilated cardiomyopathy; however, at coronary angiography, four had occult coronary disease." | 2.65 | Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. ( Anderson, ST; Currie, PJ; Federman, J; Harper, RW; Kelly, MJ; Lim, YL; McKenzie, A; Pitt, A, 1984) |
| "There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme." | 2.53 | Beta-blockers for congestive heart failure in children. ( Al Dakhoul, S; Alabed, S; Bdaiwi, Y; Frobel-Mercier, AK; Sabouni, A, 2016) |
| "Metoprolol was significantly superior to carvedilol (P = 0." | 2.48 | β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients. ( Cheng, XJ; He, YM; Li, X; Qian, YX; Xu, HF; Yang, XJ; Zhao, X, 2012) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 2.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| "Metoprolol is a selective beta(1)-adrenergic antagonist extensively used in major fields of cardiology since 1975." | 2.42 | [Metoprolol CR/XL: advanced formulation of a classical beta-blocker]. ( Gudkov, KM; Kobalava, ZhD, 2003) |
| "Heart failure is associated with increased sympathetic nervous stimulation that results in down-regulation of myocardial beta-1 receptors." | 2.42 | Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. ( Ahmed, A, 2003) |
| " We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure." | 2.42 | Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? ( Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003) |
| " Pharmacokinetic and pharmacodynamic analyses, however, indicate that the dosing regimen of metoprolol selected for use in the COMET trial produces a magnitude and time course of beta(1)-blockade during a 24-hour period that is similar to the dose of carvedilol targeted for use in the trial." | 2.42 | Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. ( Packer, M, 2003) |
| " These include the choice of dose and dosage regimen of immediate-release metoprolol tartrate, a dosage form that has never been shown to reduce mortality in patients with heart failure." | 2.42 | Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. ( Bauman, JL; Talbert, RL, 2004) |
| " Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population." | 2.42 | The effects of beta blockers on morbidity and mortality in heart failure. ( Jafri, SM, 2004) |
| "Carvedilol is an inherently long-acting beta-blocker while the duration of beta blockade for metoprolol is dependent on the salt and formulation, which is used." | 2.42 | Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. ( Talbert, RL, 2004) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Conversely, in individuals with chronic congestive heart failure, the sustained, heightened activation of adrenergic nervous system, as manifested by increases in circulating catecholamines, results in down- regulation and desensitization of myocardial beta-ARs, and potentially, significant myocardial damage." | 2.41 | Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. ( Gilbert, EM; Port, JD, 2000) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| " Numerous questions concerning the exact indications of these drugs, the nature and dosage of the beta-blocker to be used, the possible combinations with other therapies and the responses to be expected remain to be answered." | 2.38 | [Beta-blockers in the treatment of heart failure]. ( Grosgogeat, Y; Komajda, M; Lechat, P; Salloum, J, 1990) |
| "Many studies of congestive heart failure are done without explicit diagnostic criteria." | 2.37 | Diagnostic heterogeneity in clinical trials for congestive heart failure. ( Alderman, MH; Marantz, PR; Tobin, JN, 1988) |
| "Carvedilol vs metoprolol was also associated with a 16% reduction in the risk of fast VA." | 1.91 | Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients. ( Aktaş, MK; Chen, AY; Diamond, A; Goldenberg, I; Kutyifa, V; McNitt, S; Polonsky, B; Sampath, R; Steinberg, JS; Younis, A; Zareba, W, 2023) |
| "Carvedilol was prescribed in 7 331 patients treated for HF (9." | 1.62 | Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic. ( Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M, 2021) |
| "Metoprolol treatment did not significantly decrease the mRNA expression of myocardial SERCA2a in the unloaded heart after 2 weeks." | 1.62 | Effects of carvedilol and metoprolol on the myocardium during mechanical unloading in a rat heterotopic heart transplantation model. ( Kil, HR; Kim, G; Lee, SS; Quan, C, 2021) |
| "Metoprolol treatment did not delay the onset of heart failure symptoms, improve mitochondrial function, or regress RV hypertrophy." | 1.51 | Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment. ( Hickey, AJ; Jones, TLM; Norman, R; Power, AS; Ward, ML, 2019) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 1.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| "Heart attack (myocardial infarction) is a highly prevalent entity worldwide." | 1.40 | Health and cost benefits associated with the use of metoprolol in heart attack patients. ( Fernández-Jiménez, R; Ibanez, B, 2014) |
| "Metoprolol treatment and ghrelin treatment in KO mice prevented excessive sympathetic activation, decreased plasma epinephrine and norepinephrine levels, and improved heart function and survival rate after MI." | 1.39 | Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice. ( Kangawa, K; Kishimoto, I; Mao, Y; Miyazato, M; Otani, K; Tokudome, T, 2013) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| "Enalapril was continued for 42 days." | 1.38 | Therapeutic challenges and management of heart failure during pregnancy (part I). ( Bilińska, ZT; Czajkowski, K; Dangel, J; Demkow, M; Dzielińska, Z; Konka, M; Kryczka, K; Przybylski, A; Różański, J; Szczudlik, J, 2012) |
| "Treatment with metoprolol decreased systolic blood pressure at 21 months only but improved survival, decreased ventricular weight, prevented chamber dilation, reduced inflammation, decreased fibrosis, attenuated action potential prolongation, improved systolic and diastolic function, decreased stiffness and improved endothelium-independent vascular responses." | 1.37 | Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. ( Brown, L; Chan, V; Fenning, A; Hoey, A, 2011) |
| "Metabolic, hemodynamic, and electrophysiological parameters were studied in all the patients on hospital stay days I and S." | 1.36 | [Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus]. ( Dolgikh, VT; Kondrat'ev, AI; Stotskiĭ, AO, 2010) |
| "Metoprolol was given orally (2." | 1.36 | Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Laval, S; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| " In the first 60 to 90 days after hospital discharge, little up-titration in beta-blocker dosing occurs." | 1.35 | Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, CW; Young, JB, 2008) |
| "Insulin resistance is prevalent in heart failure (HF) patients, and beta2 adrenergic receptors (beta2-AR) are involved in glucose homeostasis." | 1.35 | The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. ( Detry, MA; Johnson, MR; Moran, JJ; Sweitzer, NK; Vardeny, O, 2008) |
| "There were included 56 patients with congestive heart failure, 38 with ischemic heart disease and 18 with idiopathic dilated cardiomyopathy, 40 males and 16 females, aged between 25 and 65 years, who were compared with 19 healthy individuals, 12 males and 7 females, of the same age." | 1.35 | The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure. ( Bodisz, G; Ilea, M; Mălai, A; Pop, D; Zdrenghea, D; Zdrenghea, M, 2009) |
| "Recurrent life-threatening episodes of ventricular tachycardia persisted despite maximal antiarrhythmic theraphy with amiodarone, metoprolol and mexiletine." | 1.33 | Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone. ( Anastasiou-Nana, MI; Kanakakis, J; Rokas, S; Tsagalou, EP, 2005) |
| " Therefore we analyzed 24-h ECG Holter recordings from a study which compared the long-term clinical efficacy of metoprolol tartrate to carvedilol in chronic heart failure patients using the same dosing regimen as in COMET." | 1.33 | Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? ( Chan, SK; Fung, JW; Leung, LY; Sanderson, JE; Yip, GW; Yu, CM, 2005) |
| "Seven transgenic lines developed dilated cardiomyopathy and premature death from congestive heart failure." | 1.33 | Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. ( Abel, ED; Bisping, E; Buerger, A; Dorfman, AL; Izumo, S; Jay, PY; Pu, WT; Rozhitskaya, O; Sherwood, MC, 2006) |
| " Pharmacokinetic studies have also been performed in heart failure patients and have demonstrated that ER metoprolol succinate is associated with a more pronounced and even beta1-blockade over a 24-h period than the IR formulation." | 1.32 | Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. ( Andersson, B; Kendall, MJ; Klibaner, M; Stanbrook, H; Wikstrand, J, 2003) |
| "Metoprolol treatment is associated with a decreased duration of PWM and PWD and this may reflect a reduction in the probability of atrial fibrillation in heart failure patients." | 1.32 | Long-term effects of beta blocker therapy on P-wave duration and dispersion in congestive heart failure patients: a new effect? ( Akkus, MN; Camsari, A; Cin, VG; Döven, O; Pekdemir, H; Yenihan, S, 2003) |
| "The treatment with metoprolol 1 mg/kg/h was initiated in the third week post-infarct for a period of 6 weeks." | 1.32 | Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. ( Bollano, E; Omerovic, E; Soussi, B; Waagstein, F, 2003) |
| "Metoprolol was 35-fold beta(1)-selective and lacked guanine nucleotide modulatable binding." | 1.31 | Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. ( Böhm, M; Cremers, B; Flesch, M; Höper, A; Maack, C; Südkamp, M, 2000) |
| " We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope." | 1.31 | Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. ( Hauptman, PJ; Prirzker, MR; Woods, D, 2002) |
| " Chronic administration of metoprolol, a beta-blocking agent, induced further increase in left ventricular volume and mass without changing left ventricular function and myosin isozyme pattern." | 1.28 | Cardiac adaptation and its limitation in an experimental model of congestive heart failure. ( Iizuka, M; Momomura, S; Ohtani, Y; Serizawa, T; Sugimoto, T; Sugiura, S; Yamashita, H, 1992) |
| "Chronic treatment of heart failure patients with beta-adrenoceptor antagonists leads to an up-regulation of cardiac beta-adrenoceptors, but in a subtype-selective fashion: beta 1-selective antagonists increase only cardiac beta 1-adrenoceptors, whereas non-selective antagonists increase both beta 1- and beta 2-adrenoceptors." | 1.28 | Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. ( Borst, HG; Brodde, OE; Maier, W; Michel, MC; Zerkowski, HR, 1989) |
| "Indirect signs of congestive heart failure tended to be less severe in patients given metoprolol within 12 hours of the onset of symptoms than in those given placebo." | 1.27 | Göteborg Metoprolol Trial: clinical observations. ( Hartford, M; Herlitz, J; Hjalmarson, A; Pennert, K; Waagstein, F; Waldenström, A; Wedel, H; Wilhelmsson, C, 1984) |
| "More metoprolol-treated than placebo-treated patients withdrew because of cardiovascular adverse experience mainly during the very early phase." | 1.27 | Göteborg Metoprolol Trial: tolerance. ( Herlitz, J; Hjalmarson, A; Pennert, K; Vedin, A; Wedel, H; Wilhelmsen, L; Wilhelmsson, C, 1984) |
| "The pharmacologic treatment of dilated cardiomyopathy encompasses measures such as temporary administration of amino acids and calories for those who may be undernourished and avoidance of drugs such as alcohol, nicotine, amphetamines and high doses of tricyclic antidepressants." | 1.27 | Pharmacologic treatment of dilated cardiomyopathy with special reference to the role of beta-blockers. ( Waagstein, F, 1985) |
| "Baseline arrhythmia assessment revealed recurrent ventricular tachycardia in all patients." | 1.27 | Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. ( Allen, BJ; Bessen, M; Brodsky, MA; Henry, WL; Luckett, CR; Siddiqi, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (5.26) | 18.7374 |
| 1990's | 83 (15.06) | 18.2507 |
| 2000's | 290 (52.63) | 29.6817 |
| 2010's | 117 (21.23) | 24.3611 |
| 2020's | 32 (5.81) | 2.80 |
| Authors | Studies |
|---|---|
| Almengló, C | 1 |
| Couselo-Seijas, M | 1 |
| Agra, RM | 1 |
| Varela-Román, A | 1 |
| García-Acuña, JM | 1 |
| González-Peteiro, M | 1 |
| González-Juanatey, JR | 1 |
| Eiras, S | 1 |
| Álvarez, E | 1 |
| Schwartz, B | 1 |
| Pierce, C | 1 |
| Madelaire, C | 1 |
| Schou, M | 1 |
| Kristensen, SL | 1 |
| Gislason, GH | 2 |
| Køber, L | 4 |
| Torp-Pedersen, C | 22 |
| Andersson, C | 1 |
| Oduah, MA | 1 |
| Perera, ND | 1 |
| Brenes-Salazar, JA | 1 |
| Liu, C | 1 |
| Yao, L | 1 |
| Zhang, L | 4 |
| Lin, Y | 2 |
| Hasbrouck, M | 1 |
| Nguyen, TT | 1 |
| Ding, Y | 1 |
| Wei, Z | 1 |
| Li, J | 3 |
| Zhu, L | 1 |
| Li, M | 2 |
| Zheng, C | 1 |
| Kawada, T | 2 |
| Uemura, K | 1 |
| Inagaki, M | 1 |
| Saku, K | 1 |
| Sugimachi, M | 2 |
| Dunlay, SM | 1 |
| Killian, JM | 1 |
| Roger, VL | 1 |
| Schulte, PJ | 1 |
| Blecker, SB | 1 |
| Savitz, ST | 1 |
| Redfield, MM | 1 |
| Esler, M | 1 |
| Kjeldsen, SE | 1 |
| Pathak, A | 1 |
| Grassi, G | 1 |
| Kreutz, R | 1 |
| Mancia, G | 1 |
| Zhu, F | 1 |
| Wang, Q | 2 |
| Wang, Z | 1 |
| Zhang, X | 2 |
| Zhang, B | 1 |
| Wang, H | 1 |
| Lu, Y | 2 |
| Wang, F | 1 |
| Ni, H | 1 |
| Sun, Y | 1 |
| Shi, H | 2 |
| Compagner, CT | 1 |
| Wysocki, CR | 1 |
| Reich, EK | 1 |
| Zimmerman, LH | 1 |
| Holzhausen, JM | 1 |
| Niforatos, JD | 1 |
| Ehmann, MR | 1 |
| Balhara, KS | 1 |
| Hinson, JS | 1 |
| Ramcharran, L | 1 |
| Lobner, K | 1 |
| Weygandt, PL | 1 |
| Kapustova, K | 1 |
| Phan, B | 1 |
| Allison-Aipa, T | 1 |
| Choi, M | 1 |
| Chen, C | 1 |
| Zhang, W | 1 |
| Jiao, D | 1 |
| Shen, J | 1 |
| Zhu, G | 1 |
| Diamond, A | 1 |
| Goldenberg, I | 2 |
| Younis, A | 1 |
| Sampath, R | 1 |
| Kutyifa, V | 2 |
| Chen, AY | 1 |
| McNitt, S | 3 |
| Polonsky, B | 1 |
| Steinberg, JS | 1 |
| Zareba, W | 3 |
| Aktaş, MK | 1 |
| Rahm, AK | 1 |
| Hackbarth, J | 1 |
| Müller, ME | 1 |
| Pfeiffer, J | 1 |
| Gampp, H | 1 |
| Petersenn, F | 1 |
| Rivinius, R | 1 |
| Frey, N | 1 |
| Lugenbiel, P | 1 |
| Thomas, D | 1 |
| Sessa, M | 3 |
| Mascolo, A | 2 |
| Rasmussen, DB | 2 |
| Kragholm, K | 2 |
| Jensen, MT | 2 |
| Sportiello, L | 1 |
| Rafaniello, C | 3 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 2 |
| Rossi, F | 4 |
| Capuano, A | 4 |
| Georgakopoulos, P | 1 |
| Kyriakidis, M | 1 |
| Perpinia, A | 1 |
| Karavidas, A | 1 |
| Zimeras, S | 1 |
| Mamalis, N | 1 |
| Kouvela, M | 1 |
| Charpidou, A | 1 |
| Plümacher, KS | 1 |
| Paul, T | 1 |
| Sigler, M | 1 |
| Li, D | 1 |
| Dong, W | 2 |
| Liu, Y | 1 |
| Wang, J | 5 |
| Mu, Y | 1 |
| Zhou, H | 4 |
| Zhou, S | 1 |
| Chen, Y | 1 |
| Wu, L | 3 |
| Zhang, Q | 4 |
| Shu, Q | 3 |
| Zhang, R | 4 |
| Meng, Y | 6 |
| Razzoli, M | 1 |
| Lindsay, A | 1 |
| Law, ML | 1 |
| Chamberlain, CM | 1 |
| Southern, WM | 1 |
| Berg, M | 1 |
| Osborn, J | 1 |
| Engeland, WC | 1 |
| Metzger, JM | 1 |
| Ervasti, JM | 1 |
| Bartolomucci, A | 1 |
| Wade, C | 1 |
| Wells, JM | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Eijgenraam, TR | 1 |
| Boukens, BJ | 1 |
| Boogerd, CJ | 1 |
| Schouten, EM | 1 |
| van de Kolk, CWA | 1 |
| Stege, NM | 1 |
| Te Rijdt, WP | 1 |
| Hoorntje, ET | 1 |
| van der Zwaag, PA | 1 |
| van Rooij, E | 1 |
| van Tintelen, JP | 1 |
| van den Berg, MP | 2 |
| van der Meer, P | 2 |
| van der Velden, J | 1 |
| Silljé, HHW | 1 |
| de Boer, RA | 5 |
| Alabed, S | 2 |
| Sabouni, A | 2 |
| Al Dakhoul, S | 2 |
| Bdaiwi, Y | 2 |
| Cheng, X | 3 |
| Zhu, M | 1 |
| Liu, Q | 2 |
| Feng, Z | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 2 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Paulus, R | 1 |
| Schmidt, B | 1 |
| Taborsky, M | 1 |
| Aiglova, R | 1 |
| Lazarova, M | 1 |
| Pavlu, L | 1 |
| Danek, J | 1 |
| Precek, J | 1 |
| Schee, A | 1 |
| Gloger, V | 1 |
| Vicha, M | 1 |
| Skala, T | 1 |
| Kim, G | 1 |
| Kil, HR | 1 |
| Quan, C | 1 |
| Lee, SS | 1 |
| Dave, CV | 1 |
| Strom, BL | 1 |
| Kobylarz, FA | 1 |
| Horton, DB | 1 |
| Gerhard, T | 1 |
| Tseng, CL | 1 |
| Dejanovic, I | 1 |
| Nyandege, A | 1 |
| Setoguchi, S | 1 |
| Yang, F | 1 |
| Yu, J | 3 |
| Han, W | 1 |
| Qiao, C | 1 |
| Wang, Y | 1 |
| Yin, Z | 1 |
| Wang, L | 3 |
| Zhang, Y | 1 |
| Shan, T | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 2 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Priti, K | 1 |
| Ranwa, BL | 1 |
| Gokhroo, RK | 1 |
| Kishore, K | 1 |
| Bisht, DS | 1 |
| Gupta, S | 1 |
| Fröhlich, H | 2 |
| Torres, L | 1 |
| Täger, T | 2 |
| Schellberg, D | 2 |
| Corletto, A | 1 |
| Kazmi, S | 1 |
| Goode, K | 2 |
| Grundtvig, M | 2 |
| Hole, T | 3 |
| Katus, HA | 2 |
| Cleland, JGF | 1 |
| Atar, D | 2 |
| Clark, AL | 3 |
| Agewall, S | 2 |
| Frankenstein, L | 2 |
| Carroll, C | 1 |
| Hassanin, A | 1 |
| Huang, J | 5 |
| Liu, X | 2 |
| Takayanagi, R | 1 |
| Fujito, K | 1 |
| Kimura, K | 1 |
| Yamada, Y | 1 |
| Yan, S | 1 |
| Xia, Z | 1 |
| Zhu, B | 1 |
| Hu, J | 1 |
| Liao, KM | 1 |
| Lin, TY | 2 |
| Huang, YB | 2 |
| Kuo, CC | 1 |
| Chen, CY | 2 |
| Bieber, M | 1 |
| Werner, RA | 1 |
| Tanai, E | 1 |
| Hofmann, U | 1 |
| Higuchi, T | 1 |
| Schuh, K | 1 |
| Heuschmann, PU | 1 |
| Frantz, S | 1 |
| Ritter, O | 1 |
| Kraft, P | 1 |
| Kleinschnitz, C | 1 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 1 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Ruwald, AC | 3 |
| Vinther, M | 1 |
| Johansen, JB | 1 |
| Nielsen, JC | 1 |
| Philbert, BT | 1 |
| Riahi, S | 1 |
| Jøns, C | 1 |
| Hirschy, R | 2 |
| Ackerbauer, KA | 2 |
| Peksa, GD | 2 |
| O'Donnell, EP | 2 |
| DeMott, JM | 2 |
| Ajam, T | 2 |
| Ajam, S | 2 |
| Devaraj, S | 2 |
| Mohammed, K | 1 |
| Sawada, S | 1 |
| Kamalesh, M | 2 |
| Piccini, JP | 2 |
| Connolly, SJ | 2 |
| Abraham, WT | 4 |
| Healey, JS | 2 |
| Steinberg, BA | 1 |
| Al-Khalidi, HR | 1 |
| Dignacco, P | 1 |
| van Veldhuisen, DJ | 9 |
| Sauer, WH | 2 |
| White, M | 6 |
| Wilton, SB | 2 |
| Anand, IS | 3 |
| Dufton, C | 2 |
| Marshall, DA | 1 |
| Aleong, RG | 1 |
| Davis, GW | 1 |
| Clark, RL | 1 |
| Emery, LL | 2 |
| Bristow, MR | 7 |
| Ingram, A | 1 |
| Valente, M | 1 |
| Mert, GÖ | 1 |
| Dural, M | 1 |
| Mert, KU | 1 |
| Fudim, M | 1 |
| Loop, MS | 1 |
| van Dyke, MK | 1 |
| Chen, L | 2 |
| Safford, MM | 1 |
| Kilgore, ML | 1 |
| Brown, TM | 1 |
| Durant, RW | 1 |
| Levitan, EB | 1 |
| Erolu, E | 1 |
| Akalın, F | 1 |
| Saylan Çevik, B | 1 |
| Yücelten, D | 1 |
| Ayan, M | 1 |
| Habash, F | 1 |
| Alqam, B | 1 |
| Gheith, Z | 1 |
| Cross, M | 1 |
| Vallurupalli, S | 1 |
| Paydak, H | 1 |
| Park, JJ | 1 |
| Park, HA | 1 |
| Cho, HJ | 1 |
| Lee, HY | 1 |
| Kim, KH | 1 |
| Yoo, BS | 1 |
| Kang, SM | 1 |
| Baek, SH | 1 |
| Jeon, ES | 1 |
| Kim, JJ | 1 |
| Cho, MC | 1 |
| Chae, SC | 1 |
| Oh, BH | 1 |
| Choi, DJ | 1 |
| Gasanov, I | 1 |
| Rudyk, Y | 1 |
| Yamamoto, H | 1 |
| Shimizu, S | 1 |
| Hayama, Y | 1 |
| Shishido, T | 1 |
| Iwanaga, Y | 1 |
| Fukuda, K | 1 |
| Miyazaki, S | 1 |
| Power, AS | 1 |
| Norman, R | 1 |
| Jones, TLM | 1 |
| Hickey, AJ | 1 |
| Ward, ML | 1 |
| Carroll, IA | 1 |
| Aleong, R | 1 |
| Rienstra, M | 1 |
| Krueger, SK | 1 |
| Ayala-Paredes, F | 1 |
| Khaykin, Y | 1 |
| Merkely, B | 1 |
| Miloradović, V | 1 |
| Wranicz, JK | 1 |
| Ilkhanoff, L | 1 |
| Ziegler, PD | 1 |
| Davis, G | 1 |
| Marshall, D | 1 |
| Kao, DP | 1 |
| Molenaar, P | 2 |
| Christ, T | 2 |
| Hussain, RI | 1 |
| Engel, A | 1 |
| Berk, E | 1 |
| Gillette, KT | 1 |
| Galindo-Tovar, A | 1 |
| Krobert, KA | 1 |
| Ravens, U | 2 |
| Levy, FO | 1 |
| Kaumann, AJ | 1 |
| Eschenhagen, T | 2 |
| Ruwald, MH | 4 |
| Jons, C | 2 |
| Alexis, J | 1 |
| Moss, AJ | 4 |
| Mao, Y | 1 |
| Tokudome, T | 1 |
| Otani, K | 1 |
| Kishimoto, I | 1 |
| Miyazato, M | 1 |
| Kangawa, K | 1 |
| Babick, A | 1 |
| Elimban, V | 1 |
| Zieroth, S | 1 |
| Dhalla, NS | 1 |
| Fonarow, G | 1 |
| Díez-Manglano, J | 1 |
| Ghali, JK | 7 |
| De Pauw, M | 1 |
| Van Heuverswyn, F | 1 |
| Duytschaever, M | 1 |
| De Buyzere, M | 1 |
| Raitt, MH | 1 |
| Abu-Zeitone, A | 1 |
| de Peuter, OR | 1 |
| Verberne, HJ | 1 |
| Kok, WE | 1 |
| van den Bogaard, B | 1 |
| Schaap, MC | 1 |
| Nieuwland, R | 1 |
| Meijers, JC | 1 |
| Somsen, GA | 1 |
| Bakx, A | 1 |
| Kamphuisen, PW | 1 |
| Ibanez, B | 2 |
| Macaya, C | 1 |
| Sánchez-Brunete, V | 1 |
| Pizarro, G | 1 |
| Fernández-Friera, L | 1 |
| Mateos, A | 1 |
| Fernández-Ortiz, A | 1 |
| García-Ruiz, JM | 1 |
| García-Álvarez, A | 1 |
| Iñiguez, A | 1 |
| Jiménez-Borreguero, J | 1 |
| López-Romero, P | 1 |
| Fernández-Jiménez, R | 2 |
| Goicolea, J | 1 |
| Ruiz-Mateos, B | 1 |
| Bastante, T | 1 |
| Arias, M | 1 |
| Iglesias-Vázquez, JA | 1 |
| Rodriguez, MD | 1 |
| Escalera, N | 1 |
| Acebal, C | 1 |
| Cabrera, JA | 1 |
| Valenciano, J | 1 |
| Pérez de Prado, A | 1 |
| Fernández-Campos, MJ | 1 |
| Casado, I | 1 |
| García-Rubira, JC | 1 |
| García-Prieto, J | 1 |
| Sanz-Rosa, D | 1 |
| Cuellas, C | 1 |
| Hernández-Antolín, R | 1 |
| Albarrán, A | 1 |
| Fernández-Vázquez, F | 1 |
| de la Torre-Hernández, JM | 1 |
| Pocock, S | 1 |
| Sanz, G | 1 |
| Fuster, V | 1 |
| Schiller, AM | 2 |
| Haack, KK | 2 |
| Pellegrino, PR | 2 |
| Curry, PL | 3 |
| Zucker, IH | 3 |
| Batty, JA | 1 |
| Hall, AS | 3 |
| White, HL | 3 |
| Wikstrand, J | 21 |
| van der Harst, P | 1 |
| Waagstein, F | 26 |
| Hjalmarson, Å | 23 |
| Kjekshus, J | 13 |
| Balmforth, AJ | 2 |
| Whayne, TF | 1 |
| Thireau, J | 2 |
| Karam, S | 2 |
| Roberge, S | 2 |
| Roussel, J | 1 |
| Aimond, F | 2 |
| Cassan, C | 2 |
| Gac, A | 1 |
| Babuty, D | 2 |
| Le Guennec, JY | 1 |
| Lacampagne, A | 2 |
| Fauconnier, J | 2 |
| Richard, S | 2 |
| Rinaldi, B | 2 |
| Gritti, G | 2 |
| Donniacuo, M | 3 |
| Scotto Di Vettimo, A | 1 |
| Sodano, L | 2 |
| Matera, MG | 2 |
| Zhang, F | 1 |
| Zhan, Q | 1 |
| Dong, X | 1 |
| Jiang, B | 2 |
| Sun, L | 1 |
| Gao, S | 1 |
| He, Z | 1 |
| Tao, X | 1 |
| Maggioni, AP | 3 |
| Pasternak, B | 3 |
| Svanström, H | 3 |
| Melbye, M | 1 |
| Hviid, A | 3 |
| Navaratnarajah, M | 2 |
| Siedlecka, U | 2 |
| Ibrahim, M | 2 |
| van Doorn, C | 2 |
| Soppa, G | 1 |
| Gandhi, A | 2 |
| Shah, A | 2 |
| Kukadia, P | 1 |
| Yacoub, MH | 2 |
| Terracciano, CM | 2 |
| Cho, MJ | 1 |
| Lim, RK | 1 |
| Jung Kwak, M | 1 |
| Park, KH | 1 |
| Kim, HY | 1 |
| Kim, YM | 1 |
| Lee, HD | 1 |
| Briasoulis, A | 1 |
| Palla, M | 1 |
| Afonso, L | 1 |
| Balderia, PG | 1 |
| Wongrakpanich, S | 1 |
| Patel, M | 1 |
| Stanek, M | 1 |
| Martuscelli, E | 1 |
| Orlandi, A | 1 |
| Calzetta, L | 1 |
| Santulli, G | 1 |
| Mattsson, A | 1 |
| Zhao, J | 1 |
| Cebola, R | 1 |
| Kelloniemi, A | 1 |
| Aro, J | 1 |
| Näpänkangas, J | 1 |
| Koivisto, E | 1 |
| Mustonen, E | 1 |
| Ruskoaho, H | 1 |
| Rysä, J | 1 |
| Church, KM | 1 |
| Henalt, R | 1 |
| Baker, E | 1 |
| Smith, GL | 1 |
| Brennan, MT | 1 |
| Joseph, J | 1 |
| Tang, CH | 1 |
| Wang, CC | 1 |
| Chen, TH | 1 |
| Hong, CY | 1 |
| Sue, YM | 1 |
| Frobel-Mercier, AK | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Gulati, G | 1 |
| Heck, SL | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Schulz-Menger, J | 1 |
| Fagerland, MW | 1 |
| Gravdehaug, B | 1 |
| von Knobelsdorff-Brenkenhoff, F | 1 |
| Bratland, Å | 1 |
| Storås, TH | 1 |
| Hagve, TA | 1 |
| Røsjø, H | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Omland, T | 1 |
| Fi, Z | 1 |
| Szentes, V | 1 |
| Liu, J | 2 |
| Perreault, S | 1 |
| de Denus, S | 1 |
| White-Guay, B | 1 |
| Bouvier, M | 1 |
| Dorais, M | 1 |
| Dubé, MP | 1 |
| Rouleau, JL | 3 |
| Tardif, JC | 2 |
| Jenna, S | 1 |
| Haibe-Kains, B | 1 |
| Leduc, R | 1 |
| Deblois, D | 1 |
| Luzum, JA | 1 |
| Sweet, KM | 1 |
| Binkley, PF | 2 |
| Schmidlen, TJ | 1 |
| Jarvis, JP | 1 |
| Christman, MF | 1 |
| Sadee, W | 1 |
| Kitzmiller, JP | 1 |
| Tregubov, VG | 2 |
| Kanorskiy, SG | 1 |
| Pokrovskiy, VM | 1 |
| Hanada, K | 1 |
| Asari, K | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Mita, M | 1 |
| Ogata, H | 1 |
| Braun, M | 1 |
| Edelmann, F | 1 |
| Knapp, M | 1 |
| Schön, S | 1 |
| Schwencke, C | 1 |
| Simonis, G | 1 |
| Borst, M | 1 |
| Weinbrenner, C | 1 |
| Strasser, RH | 1 |
| Bartholomeu, JB | 1 |
| Vanzelli, AS | 2 |
| Rolim, NP | 1 |
| Ferreira, JC | 1 |
| Bechara, LR | 1 |
| Tanaka, LY | 1 |
| Rosa, KT | 1 |
| Alves, MM | 1 |
| Medeiros, A | 2 |
| Mattos, KC | 1 |
| Coelho, MA | 1 |
| Irigoyen, MC | 1 |
| Krieger, EM | 1 |
| Krieger, JE | 1 |
| Negrão, CE | 1 |
| Ramires, PR | 1 |
| Guatimosim, S | 1 |
| Brum, PC | 2 |
| Sehnert, AJ | 1 |
| Daniels, SE | 1 |
| Elashoff, M | 1 |
| Wingrove, JA | 1 |
| Burrow, CR | 1 |
| Horne, B | 1 |
| Muhlestein, JB | 1 |
| Donahue, M | 1 |
| Liggett, SB | 1 |
| Anderson, JL | 3 |
| Kraus, WE | 1 |
| Rastogi, S | 3 |
| Sharov, VG | 4 |
| Mishra, S | 3 |
| Gupta, RC | 4 |
| Blackburn, B | 1 |
| Belardinelli, L | 1 |
| Stanley, WC | 4 |
| Sabbah, HN | 6 |
| Zacà, V | 1 |
| Wang, M | 1 |
| Goldstein, S | 18 |
| Fonarow, GC | 1 |
| Albert, NM | 1 |
| Stough, WG | 1 |
| Gheorghiade, M | 4 |
| Greenberg, BH | 1 |
| O'Connor, CM | 4 |
| Sun, JL | 1 |
| Yancy, CW | 1 |
| Young, JB | 4 |
| Vardeny, O | 1 |
| Detry, MA | 1 |
| Moran, JJ | 1 |
| Johnson, MR | 1 |
| Sweitzer, NK | 1 |
| Kobayashi, M | 2 |
| Machida, N | 2 |
| Tanaka, R | 1 |
| Yamane, Y | 2 |
| Rengo, G | 1 |
| Lymperopoulos, A | 1 |
| Zincarelli, C | 1 |
| Soltys, S | 1 |
| Rabinowitz, JE | 1 |
| Koch, WJ | 2 |
| Ulu, N | 1 |
| Henning, RH | 1 |
| Goris, M | 1 |
| Schoemaker, RG | 1 |
| van Gilst, WH | 2 |
| Levy, WC | 1 |
| Mozaffarian, D | 1 |
| Linker, DT | 1 |
| Kenyon, KW | 1 |
| Cleland, JG | 22 |
| Komajda, M | 14 |
| Remme, WJ | 12 |
| Metra, M | 20 |
| Poole-Wilson, PA | 13 |
| Szmit, S | 1 |
| Nurzyński, P | 1 |
| Szaluś, N | 1 |
| Opolski, G | 2 |
| Szczylik, C | 1 |
| Nagatomo, Y | 3 |
| Yoshikawa, T | 6 |
| Kohno, T | 5 |
| Yoshizawa, A | 5 |
| Baba, A | 2 |
| Anzai, T | 5 |
| Meguro, T | 3 |
| Satoh, T | 5 |
| Ogawa, S | 6 |
| Sharp, CF | 1 |
| Gardiner, SJ | 1 |
| Jensen, BP | 1 |
| Roberts, RL | 1 |
| Troughton, RW | 2 |
| Lainchbury, JG | 1 |
| Begg, EJ | 1 |
| Sal'nikov, EV | 1 |
| Chen, X | 1 |
| Macdonnell, SM | 1 |
| Kranias, EG | 1 |
| Lorenz, JN | 1 |
| Leitges, M | 1 |
| Houser, SR | 1 |
| Molkentin, JD | 1 |
| Ghader, FR | 1 |
| Abaskhanian, ZA | 1 |
| Zebrack, JS | 1 |
| Munger, M | 1 |
| Macgregor, J | 1 |
| Lombardi, WL | 1 |
| Stoddard, GP | 1 |
| Gilbert, EM | 4 |
| Adams, KF | 7 |
| Giles, TD | 2 |
| Lü, HS | 1 |
| He, BB | 1 |
| Huang, GH | 1 |
| Boman, K | 2 |
| Jansson, JH | 1 |
| Nilsson, T | 1 |
| Swedberg, K | 24 |
| Poole-Wilson, P | 5 |
| Roughead, EE | 1 |
| Barratt, JD | 1 |
| Ramsay, E | 1 |
| Pratt, N | 1 |
| Ryan, P | 1 |
| Peck, R | 1 |
| Killer, G | 1 |
| Gilbert, AL | 1 |
| Wagner, CC | 1 |
| Locher, P | 1 |
| Elke, B | 1 |
| Corti, N | 1 |
| Zdrenghea, D | 1 |
| Pop, D | 1 |
| Ilea, M | 1 |
| Bodisz, G | 1 |
| Mălai, A | 1 |
| Zdrenghea, M | 1 |
| Zhou, J | 1 |
| Zhang, J | 2 |
| Fu, M | 1 |
| Ge, J | 1 |
| Kondrat'ev, AI | 1 |
| Dolgikh, VT | 1 |
| Stotskiĭ, AO | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Krum, H | 4 |
| Hayward, CS | 1 |
| Gao, WQ | 1 |
| Han, CG | 1 |
| Zhao, YX | 1 |
| Zhu, P | 1 |
| Yang, TS | 1 |
| Liu, YX | 1 |
| Ito, H | 1 |
| Baudhuin, LM | 1 |
| Miller, WL | 1 |
| Train, L | 1 |
| Bryant, S | 1 |
| Hartman, KA | 1 |
| Phelps, M | 1 |
| Larock, M | 1 |
| Jaffe, AS | 1 |
| Bauer, R | 1 |
| Blain, A | 1 |
| Greally, E | 1 |
| Bushby, K | 1 |
| Lochmüller, H | 1 |
| Laval, S | 1 |
| Straub, V | 1 |
| MacGowan, GA | 1 |
| Sirvente, Rde A | 1 |
| Salemi, VM | 1 |
| Mady, C | 1 |
| Zhang, ZW | 1 |
| Lin, ZP | 1 |
| Tian, X | 1 |
| Hou, Y | 1 |
| Xu, W | 1 |
| Dong, Y | 1 |
| Liang, J | 1 |
| Li, XD | 1 |
| Wang, JC | 1 |
| Ye, L | 1 |
| Zhao, Y | 1 |
| Zhou, NN | 1 |
| Zhu, X | 1 |
| McMurray, JJ | 2 |
| Petersen, M | 1 |
| Andersen, JT | 1 |
| Hjelvang, BR | 1 |
| Broedbaek, K | 1 |
| Afzal, S | 1 |
| Nyegaard, M | 1 |
| Børglum, AD | 1 |
| Stender, S | 1 |
| Poulsen, HE | 1 |
| George, I | 2 |
| Xu, K | 1 |
| Wang, N | 1 |
| Kubo, T | 4 |
| Azevedo, ER | 5 |
| Newton, GE | 5 |
| Picton, P | 2 |
| Parker, JD | 6 |
| Floras, JS | 5 |
| Li, VH | 1 |
| Mallick, A | 1 |
| Concannon, C | 1 |
| Li, VY | 1 |
| Ozova, EM | 1 |
| Kiiakbaev, GK | 1 |
| Kobalava, ZhD | 2 |
| Moiseev, VS | 1 |
| Chan, V | 1 |
| Fenning, A | 1 |
| Hoey, A | 1 |
| Brown, L | 1 |
| Kar, S | 1 |
| Gao, L | 2 |
| Belatti, DA | 1 |
| Falskov, B | 1 |
| Hermann, TS | 1 |
| Raunsø, J | 1 |
| Christiansen, B | 2 |
| Rask-Madsen, C | 1 |
| Major-Pedersen, A | 1 |
| Dominguez, H | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Talameh, JA | 1 |
| McLeod, HL | 1 |
| Patterson, JH | 3 |
| He, YM | 1 |
| Yang, XJ | 2 |
| Zhao, X | 1 |
| Cheng, XJ | 1 |
| Xu, HF | 1 |
| Qian, YX | 1 |
| Li, X | 1 |
| Lim, E | 1 |
| Dokos, S | 1 |
| Salamonsen, RF | 1 |
| Rosenfeldt, FL | 1 |
| Ayre, PJ | 1 |
| Lovell, NH | 1 |
| Zhang, SJ | 1 |
| Liu, ZH | 3 |
| Zou, C | 2 |
| Becher, PM | 1 |
| Lindner, D | 1 |
| Miteva, K | 1 |
| Savvatis, K | 1 |
| Zietsch, C | 1 |
| Schmack, B | 1 |
| Van Linthout, S | 1 |
| Westermann, D | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Ma, Y | 1 |
| Chilton, RJ | 1 |
| Lindsey, ML | 1 |
| Kryczka, K | 1 |
| Dzielińska, Z | 1 |
| Przybylski, A | 1 |
| Szczudlik, J | 1 |
| Dangel, J | 1 |
| Konka, M | 1 |
| Czajkowski, K | 1 |
| Różański, J | 1 |
| Bilińska, ZT | 1 |
| Demkow, M | 1 |
| Blaich, A | 1 |
| Pahlavan, S | 1 |
| Tian, Q | 1 |
| Oberhofer, M | 1 |
| Poomvanicha, M | 1 |
| Lenhardt, P | 1 |
| Domes, K | 1 |
| Wegener, JW | 1 |
| Moosmang, S | 1 |
| Ruppenthal, S | 1 |
| Scholz, A | 1 |
| Lipp, P | 1 |
| Hofmann, F | 1 |
| Cazorla, O | 1 |
| Du, Y | 1 |
| Yan, L | 1 |
| Du, H | 1 |
| Ding, F | 1 |
| Quan, L | 1 |
| Song, K | 1 |
| Liu, H | 1 |
| Kanorskiĭ, SG | 1 |
| Pokrovskiĭ, VM | 1 |
| Quan, H | 1 |
| Shih, WJ | 1 |
| Ouyang, SP | 1 |
| Chen, J | 1 |
| Zhao, PL | 1 |
| Hirsh, BJ | 1 |
| Mignatti, A | 1 |
| Garan, AR | 1 |
| Uriel, N | 1 |
| Colombo, P | 1 |
| Sims, DB | 1 |
| Jorde, UP | 3 |
| Teeter, WA | 1 |
| Thibodeau, JT | 1 |
| Rao, K | 1 |
| Brickner, ME | 1 |
| Toto, KH | 1 |
| Nelson, LL | 1 |
| Mishkin, JD | 1 |
| Ayers, CR | 1 |
| Miller, JG | 1 |
| Mammen, PP | 1 |
| Patel, PC | 1 |
| Markham, DW | 1 |
| Drazner, MH | 1 |
| Dias, P | 1 |
| Sarathchandra, P | 1 |
| Shore, S | 1 |
| Aggarwal, V | 1 |
| Zolty, R | 2 |
| Alekseeva, IuM | 1 |
| Potievskaia, VI | 1 |
| Sakovich, EA | 1 |
| Sitnikov, AV | 1 |
| Soiustova, EL | 1 |
| Fin'ko, VA | 1 |
| Ardashev, AV | 1 |
| Fagerberg, B | 9 |
| Wedel, H | 13 |
| Bobadilla, RV | 1 |
| Fung, JW | 3 |
| Chan, SK | 5 |
| Yeung, LY | 4 |
| Sanderson, JE | 8 |
| de Milliano, PA | 2 |
| de Groot, AC | 1 |
| Tijssen, JG | 2 |
| van Eck-Smit, BL | 2 |
| Van Zwieten, PA | 1 |
| Lie, KI | 3 |
| Sinagra, G | 5 |
| Perkan, A | 2 |
| Cherubini, A | 1 |
| Salvatore, L | 1 |
| Di Lenarda, A | 16 |
| Dávila, DF | 1 |
| Angel, F | 1 |
| Arata de Bellabarba, G | 1 |
| Donis, JH | 1 |
| Anguita Sánchez, M | 1 |
| Nodari, S | 4 |
| D'Aloia, A | 1 |
| Muneretto, C | 1 |
| Robertson, AD | 2 |
| Dei Cas, L | 6 |
| Anastasiou-Nana, MI | 2 |
| Margari, ZJ | 1 |
| Terrovitis, JV | 1 |
| Rapti, AC | 1 |
| Alexopoulos, GP | 1 |
| Nanas, JN | 1 |
| Groenning, BA | 2 |
| Nilsson, JC | 2 |
| Hildebrandt, PR | 2 |
| Kjaer, A | 1 |
| Fritz-Hansen, T | 2 |
| Larsson, HB | 2 |
| Sondergaard, L | 2 |
| Piccirillo, G | 1 |
| Quaglione, R | 1 |
| Nocco, M | 1 |
| Naso, C | 1 |
| Moisè, A | 1 |
| Lionetti, M | 1 |
| Di Carlo, S | 1 |
| Marigliano, V | 1 |
| Bruns, LA | 1 |
| Canter, CE | 1 |
| Rollins, G | 1 |
| Gattis, WA | 3 |
| Leimberger, JD | 1 |
| Felker, GM | 1 |
| Vittorio, TJ | 2 |
| Lang, CC | 1 |
| Katz, SD | 3 |
| Packer, M | 3 |
| Mancini, DM | 1 |
| Andersson, B | 11 |
| Kendall, MJ | 1 |
| Stanbrook, H | 2 |
| Klibaner, M | 3 |
| Loppnow, H | 1 |
| Werdan, K | 1 |
| Werner, C | 1 |
| Parrinello, G | 1 |
| Giubbini, R | 2 |
| Manca, C | 1 |
| Tangeman, HJ | 1 |
| Bollano, E | 2 |
| Täng, MS | 3 |
| Inoko, M | 1 |
| Nohara, R | 1 |
| Camsari, A | 1 |
| Pekdemir, H | 1 |
| Akkus, MN | 1 |
| Yenihan, S | 1 |
| Döven, O | 1 |
| Cin, VG | 1 |
| Bouzamondo, A | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 3 |
| Etheridge, SP | 1 |
| Shaddy, RE | 4 |
| Sallach, JA | 1 |
| Maack, C | 3 |
| Böhm, M | 5 |
| Vlaskin, L | 1 |
| Dabew, E | 1 |
| Lorenz, K | 1 |
| Schäfers, HJ | 1 |
| Lohse, MJ | 1 |
| Engelhardt, S | 1 |
| Dargie, HJ | 1 |
| Hanrath, P | 7 |
| Lubsen, J | 1 |
| Lutiger, B | 4 |
| Scherhag, A | 8 |
| Skene, A | 2 |
| Rajput, FS | 1 |
| Gnanasekeram, H | 1 |
| Satwani, S | 1 |
| Davenport, JD | 1 |
| Gracely, EJ | 1 |
| Gopalan, R | 1 |
| Narula, J | 1 |
| Song, JP | 2 |
| Shen, B | 1 |
| Jiang, WP | 2 |
| Syrkin, AL | 2 |
| Poltavskaia, MG | 2 |
| Shumilova, KM | 1 |
| Ivanov, GG | 1 |
| Churganova, LIu | 1 |
| Sheianov, MV | 1 |
| Gavril'eva, SA | 1 |
| Huneycutt, B | 1 |
| Hryniewicz, K | 2 |
| Androne, AS | 2 |
| Hudaihed, A | 2 |
| Yu, CM | 3 |
| Yip, G | 2 |
| Chan, S | 3 |
| Yandle, TG | 2 |
| Richards, AM | 2 |
| Nicholls, MG | 2 |
| Deedwania, P | 6 |
| Gottlieb, S | 8 |
| Maqbool, A | 1 |
| Greenwood, D | 1 |
| Cuthbert, R | 1 |
| Ball, SG | 1 |
| Coletta, AP | 2 |
| Seymour, AM | 1 |
| Blanchet, M | 2 |
| Ducharme, A | 2 |
| Racine, N | 2 |
| Juneau, M | 2 |
| Marquis, J | 2 |
| Larivée, L | 1 |
| Nigam, A | 1 |
| Fortier, A | 1 |
| Boucher, JM | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| McKelvie, RS | 4 |
| Afzal, R | 1 |
| Held, P | 1 |
| Yusuf, S | 3 |
| Heinzl, S | 1 |
| Jánosi, A | 2 |
| Herlitz, J | 13 |
| Czuriga, I | 2 |
| Akbulut, M | 1 |
| Ozbay, Y | 1 |
| Ilkay, E | 1 |
| Karaca, I | 1 |
| Arslan, N | 1 |
| Gudkov, KM | 1 |
| Bolger, AP | 1 |
| Al-Nasser, F | 1 |
| Liebson, PR | 1 |
| Johnsson, G | 1 |
| Aberg, J | 2 |
| Ahmed, A | 2 |
| Omerovic, E | 1 |
| Soussi, B | 1 |
| Doggrell, SA | 1 |
| Tang, WH | 3 |
| Militello, M | 1 |
| Francis, GS | 2 |
| Gupta, R | 2 |
| Voors, AA | 2 |
| Paul, S | 1 |
| Trupp, RJ | 1 |
| Lechat, PP | 1 |
| Ghali, J | 1 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Massie, BM | 1 |
| Feldman, AM | 1 |
| Cohn, JN | 1 |
| Shepherd, AM | 1 |
| von Haehling, S | 1 |
| Tabrizchi, R | 1 |
| Kosorok, MR | 1 |
| Yuanjun, S | 1 |
| DeMets, DL | 2 |
| Frøland, G | 1 |
| Gullestad, L | 7 |
| Offstad, J | 1 |
| Skjaerpe, T | 1 |
| Ertl, G | 1 |
| Nitschmann, S | 1 |
| Meyer, TE | 1 |
| Giesler, G | 1 |
| Lenihan, DJ | 1 |
| Durand, JB | 1 |
| Udelson, JE | 3 |
| Erhardt, L | 5 |
| Charlesworth, A | 7 |
| Greenberg, B | 1 |
| Abdulla, J | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Smith, KM | 1 |
| Deedwania, PC | 5 |
| Wikstrand, JC | 3 |
| Sabbadini, G | 1 |
| Bauman, JL | 1 |
| Talbert, RL | 2 |
| Nakamura, I | 3 |
| Moritani, K | 1 |
| Suzuki, M | 2 |
| Iwanaga, S | 1 |
| Mitamura, H | 1 |
| Dell'Italia, LJ | 1 |
| Torp-Pedersen, CT | 1 |
| Taguchi, M | 1 |
| Nozawa, T | 1 |
| Mizumaki, K | 1 |
| Inoue, H | 1 |
| Tahara, K | 1 |
| Takesono, C | 1 |
| Hashimoto, Y | 1 |
| Jafri, SM | 1 |
| Anh, D | 1 |
| Marine, JE | 1 |
| Nordling, MK | 1 |
| Dunselman, P | 1 |
| Gottlieb, SS | 6 |
| McBride, BF | 1 |
| White, CM | 2 |
| Mitsuishi, M | 1 |
| Egstrup, K | 1 |
| Elkayam, U | 1 |
| Rashkow, A | 1 |
| Bermann, G | 1 |
| Hildebrandt, P | 1 |
| Spinar, J | 2 |
| Vitovec, J | 4 |
| Delea, TE | 1 |
| Stanford, R | 1 |
| Hagiwara, M | 1 |
| Edelsberg, JS | 1 |
| Oster, G | 1 |
| Sauls, JL | 1 |
| Rone, T | 1 |
| Terra, SG | 2 |
| Pauly, DF | 2 |
| Lee, CR | 1 |
| Schofield, RS | 2 |
| Belgado, BS | 1 |
| Hamilton, KK | 1 |
| Aranda, JM | 1 |
| Hill, JA | 1 |
| Yarandi, HN | 1 |
| Walker, JR | 1 |
| Phillips, MS | 1 |
| Gelfand, CA | 1 |
| Johnson, JA | 2 |
| Tu, W | 1 |
| Morris, AB | 1 |
| Wu, J | 1 |
| Young, J | 1 |
| Brater, DC | 1 |
| Murray, MD | 1 |
| Tsagalou, EP | 1 |
| Kanakakis, J | 1 |
| Rokas, S | 1 |
| Olsson, LG | 2 |
| Cleland, J | 1 |
| Murakami, T | 1 |
| Cinquegrana, G | 1 |
| D'Aniello, L | 1 |
| Landi, M | 1 |
| Spinelli, L | 1 |
| Grande, G | 1 |
| De Prisco, F | 1 |
| Petretta, M | 1 |
| Díez Manglano, J | 1 |
| van der Steege, G | 1 |
| Ekman, I | 2 |
| Parameswaran, AC | 1 |
| Al-Hesayen, A | 2 |
| Hollingshead, S | 1 |
| Lopaschuk, GD | 1 |
| Wolk, R | 1 |
| Johnson, BD | 1 |
| Somers, VK | 1 |
| Allison, TG | 1 |
| Squires, RW | 1 |
| Gau, GT | 1 |
| Olson, LJ | 1 |
| Reiffel, JA | 1 |
| Kowey, PR | 1 |
| Sonntag, F | 1 |
| Schöffski, O | 1 |
| Hass, B | 1 |
| Wuerzner, G | 2 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Nussberger, J | 1 |
| Burnier, M | 2 |
| Baruch, L | 1 |
| Kunamneni, P | 1 |
| Lukas, MA | 5 |
| Leung, LY | 1 |
| Yip, GW | 1 |
| McMurray, J | 1 |
| Cohen-Solal, A | 1 |
| Dietz, R | 2 |
| Eichhorn, E | 1 |
| Hobbs, FD | 1 |
| Maggioni, A | 1 |
| Piña, IL | 2 |
| Soler-Soler, J | 2 |
| Atchison, DJ | 1 |
| Obayashi, M | 1 |
| Xiao, B | 1 |
| Stuyvers, BD | 1 |
| Davidoff, AW | 1 |
| Mei, J | 1 |
| Chen, SR | 1 |
| ter Keurs, HE | 1 |
| Huang, WY | 1 |
| Sun, M | 2 |
| Zhou, HY | 1 |
| Pei, ZF | 1 |
| Yang, TL | 1 |
| Andersson, G | 1 |
| Doğan, SM | 1 |
| Aydin, M | 1 |
| Gürsürer, M | 1 |
| Dursun, A | 1 |
| Cam, F | 1 |
| Onuk, T | 1 |
| Madak, H | 1 |
| Sun, YL | 1 |
| Hu, SJ | 1 |
| Wang, LH | 1 |
| Hu, Y | 1 |
| Zhou, JY | 1 |
| Kaumann, A | 1 |
| Williams, RE | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| O'Brien, JA | 1 |
| Nova, W | 1 |
| Kim, J | 1 |
| Hauch, O | 1 |
| Hillson, E | 1 |
| Weber, MA | 1 |
| Schröder, H | 1 |
| Davis, ME | 1 |
| Frampton, CM | 1 |
| Kametani, R | 1 |
| Miura, T | 1 |
| Harada, N | 1 |
| Shibuya, M | 1 |
| Wang, R | 1 |
| Tan, H | 1 |
| Fukagawa, Y | 1 |
| Kawamura, S | 1 |
| Matsuzaki, M | 1 |
| Urrutia, A | 1 |
| Lupón, J | 1 |
| Altimir, S | 1 |
| González, B | 1 |
| Herreros, J | 1 |
| Díez, C | 1 |
| Coll, R | 1 |
| Valle, V | 1 |
| Rey-Joly, C | 1 |
| Aass, H | 1 |
| El Allaf, D | 2 |
| Dunselman, PH | 2 |
| Halinen, M | 2 |
| Ohlsson, L | 1 |
| Filipiak, KJ | 1 |
| Aquilante, CL | 1 |
| Hatton, PS | 1 |
| Buerger, A | 1 |
| Rozhitskaya, O | 1 |
| Sherwood, MC | 1 |
| Dorfman, AL | 1 |
| Bisping, E | 1 |
| Abel, ED | 1 |
| Pu, WT | 1 |
| Izumo, S | 1 |
| Jay, PY | 1 |
| Berlowitz, DR | 1 |
| Miller, DR | 1 |
| Oliveria, SA | 1 |
| Cunningham, F | 1 |
| Gomez-Caminero, A | 1 |
| Rothendler, JA | 1 |
| Miao, GB | 1 |
| Liu, JC | 1 |
| Liu, MB | 2 |
| Wu, JL | 2 |
| Zhang, G | 1 |
| Chang, J | 1 |
| Hou, YP | 1 |
| Fan, Q | 1 |
| Yin, BL | 1 |
| Arslan, S | 1 |
| Erol, MK | 1 |
| Bozkurt, E | 1 |
| Acikel, M | 1 |
| Gundogdu, F | 1 |
| Atesal, S | 1 |
| Senocak, H | 1 |
| Doughty, RN | 2 |
| White, HD | 1 |
| Spark, P | 5 |
| Scharin Täng, M | 1 |
| Cheng, Y | 1 |
| Yi, GH | 1 |
| Reiken, S | 2 |
| Gu, A | 1 |
| Tao, YK | 1 |
| Muraskin, J | 1 |
| Qin, S | 2 |
| He, KL | 1 |
| Hay, I | 1 |
| Yu, K | 1 |
| Oz, MC | 1 |
| Burkhoff, D | 3 |
| Holmes, J | 1 |
| De Freitas, O | 1 |
| Lenz, O | 1 |
| Fornoni, A | 1 |
| Materson, BJ | 1 |
| Moullet, C | 3 |
| Loh, H | 1 |
| Windram, J | 1 |
| Brixius, K | 1 |
| Lu, R | 1 |
| Boelck, B | 1 |
| Grafweg, S | 1 |
| Hoyer, F | 1 |
| Pott, C | 1 |
| Mehlhorn, U | 1 |
| Bloch, W | 1 |
| Schwinger, RH | 1 |
| Zhao, Q | 1 |
| Wu, TG | 1 |
| Jiang, ZF | 1 |
| Chen, GW | 1 |
| Wang, LX | 1 |
| Handa, S | 1 |
| Imai, M | 1 |
| Mika, Y | 1 |
| Rousso, B | 1 |
| Ben-Haim, S | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Kawano, S | 1 |
| Kveiborg, B | 1 |
| Major-Petersen, A | 1 |
| Remme, W | 1 |
| Andreev, DA | 1 |
| Svet, AV | 1 |
| Sarkisova, EA | 1 |
| Kalashnikov, VIu | 1 |
| Spark, PA | 1 |
| Go, AS | 1 |
| Yang, J | 1 |
| Gurwitz, JH | 1 |
| Hsu, J | 1 |
| Lane, K | 1 |
| Platt, R | 1 |
| Tomcsányi, J | 1 |
| Wettstein, A | 1 |
| Toldy-Schedel, E | 1 |
| Somlói, M | 1 |
| Jiang, TB | 1 |
| Li, HX | 1 |
| Han, LH | 1 |
| Li, BY | 1 |
| Huang, CC | 1 |
| Chen, PC | 1 |
| Huang, CW | 1 |
| Luo, M | 1 |
| Bi, Y | 1 |
| Xu, YX | 1 |
| Pleger, ST | 1 |
| Most, P | 1 |
| Abdellah, AT | 1 |
| Cullington, D | 1 |
| Rigby, AS | 1 |
| Kasper, ME | 1 |
| Khandwalla, RM | 1 |
| Hirsh, DS | 1 |
| Tseng, CH | 1 |
| Ahuja, K | 1 |
| Kataoka, M | 1 |
| Maczewski, M | 1 |
| Mackiewicz, U | 1 |
| Gourine, A | 1 |
| Bondar, SI | 1 |
| Spyer, KM | 1 |
| Gourine, AV | 1 |
| Rector, TS | 1 |
| Nelson, DB | 1 |
| Ensrud, KE | 1 |
| Sidorenko, BA | 1 |
| Bugrimova, MA | 1 |
| Iosava, IK | 1 |
| Pataraia, SA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Dahlström, U | 3 |
| Berglund, U | 1 |
| Karlsson, E | 3 |
| Moses, JW | 1 |
| Borer, JS | 1 |
| Hahn, B | 1 |
| Strauer, BE | 1 |
| Weber, KT | 1 |
| Likoff, MJ | 1 |
| McCarthy, D | 1 |
| Wayne, VS | 1 |
| Harper, RW | 2 |
| Laufer, E | 1 |
| Federman, J | 2 |
| Anderson, ST | 2 |
| Pitt, A | 2 |
| Currie, PJ | 1 |
| Kelly, MJ | 1 |
| McKenzie, A | 1 |
| Lim, YL | 1 |
| Waldenström, J | 3 |
| Ikram, H | 1 |
| Fitzpatrick, MA | 1 |
| Holmberg, S | 4 |
| Vedin, A | 4 |
| Waldenström, A | 3 |
| Wilhelmsen, L | 3 |
| Wilhelmsson, C | 3 |
| Pennert, K | 4 |
| Hartford, M | 1 |
| Elmfeldt, D | 1 |
| Málek, I | 1 |
| Nyberg, G | 1 |
| Rydén, L | 1 |
| Swedeberg, K | 1 |
| Wallentin, I | 2 |
| Persson, H | 2 |
| Rythe'n-Alder, E | 1 |
| Melcher, A | 1 |
| Merin, RG | 1 |
| Santostasi, G | 1 |
| Marinato, PG | 1 |
| Miraglia, G | 1 |
| Egloff, C | 1 |
| Maragno, I | 1 |
| Yamamoto, K | 1 |
| Asada, S | 1 |
| Yabunouchi, T | 1 |
| Morozumi, R | 1 |
| Kusuoka, H | 1 |
| Nishimura, T | 1 |
| Olsen, SL | 1 |
| Taylor, DO | 1 |
| Bullock, EA | 1 |
| Tani, LY | 2 |
| Renlund, DG | 1 |
| Heesch, CM | 2 |
| Marcoux, L | 2 |
| Hatfield, B | 1 |
| Eichhorn, EJ | 2 |
| Maisel, AS | 1 |
| Caidahl, K | 2 |
| Hatfield, BA | 1 |
| Crijns, HJ | 1 |
| Haber, HL | 1 |
| Simek, CL | 1 |
| Gimple, LW | 1 |
| Bergin, JD | 1 |
| Subbiah, K | 1 |
| Jayaweera, AR | 1 |
| Powers, ER | 1 |
| Feldman, MD | 1 |
| Fisher, ML | 3 |
| Plotnick, GD | 1 |
| Greenberg, NL | 1 |
| Patten, RD | 1 |
| Bennett, SK | 2 |
| Hamilton, BP | 1 |
| Kanda, T | 1 |
| Inoue, M | 1 |
| Suzuki, T | 1 |
| Murata, K | 1 |
| Berger, PB | 1 |
| Ruocco, NA | 1 |
| Ryan, TJ | 1 |
| Frederick, MM | 1 |
| Podrid, PJ | 1 |
| Lomsky, M | 2 |
| Galie, N | 1 |
| Branzi, A | 2 |
| Magnani, G | 1 |
| Melandri, G | 1 |
| Caldarera, I | 1 |
| Rapezzi, C | 3 |
| Grattoni, C | 1 |
| Magnani, B | 1 |
| Chan, WW | 1 |
| Hung, YT | 1 |
| Shum, IO | 1 |
| Raymond, K | 3 |
| Woo, KS | 4 |
| Kukin, ML | 5 |
| Kalman, J | 5 |
| Mannino, M | 2 |
| Freudenberger, R | 2 |
| Buchholz, C | 1 |
| Ocampo, O | 4 |
| Zecchin, M | 1 |
| Lardieri, G | 1 |
| Rakar, S | 1 |
| Secoli, G | 1 |
| Pinamonti, B | 1 |
| Camerini, F | 2 |
| Okamoto, M | 1 |
| Miyazaki, H | 1 |
| Tsuzuki, M | 1 |
| Ino, T | 1 |
| Ezaki, K | 1 |
| Hirano, M | 1 |
| Sigmund, M | 2 |
| Jakob, H | 1 |
| Becker, H | 1 |
| Schumacher, C | 1 |
| Schmitz, W | 1 |
| Scholz, H | 1 |
| Steinfath, M | 1 |
| Rodgers, A | 1 |
| Sharpe, N | 2 |
| MacMahon, S | 1 |
| Deutsch, HJ | 1 |
| Hartmann, D | 2 |
| Rosée, KL | 1 |
| Stäblein, A | 2 |
| Lindqvist, J | 1 |
| Buchholz-Varley, C | 4 |
| Kukin, M | 1 |
| Fowler, MB | 1 |
| Mannino, MM | 3 |
| Ritchie, RH | 1 |
| Wuttke, RD | 1 |
| Hii, JT | 1 |
| Jarrett, RG | 1 |
| Carey, AL | 1 |
| Horowitz, JD | 1 |
| Boccanelli, A | 1 |
| Gavazzi, A | 1 |
| Gronda, E | 1 |
| Opasich, C | 1 |
| Scherillo, M | 1 |
| Tavazzi, L | 1 |
| Chan, WM | 1 |
| Chan, KW | 2 |
| Shakar, SF | 1 |
| Lowes, BD | 1 |
| Zisman, LS | 1 |
| Ferguson, DA | 1 |
| De Marco, T | 1 |
| Chatterjee, K | 1 |
| Schreiner, MS | 1 |
| Rüchardt, A | 1 |
| Eisenlohr, H | 1 |
| Lydtin, H | 1 |
| Panchal, AR | 1 |
| Kerner, J | 1 |
| From, AH | 1 |
| Nishio, R | 1 |
| Matsumori, A | 1 |
| Shioi, T | 1 |
| Wang, W | 1 |
| Yamada, T | 1 |
| Ono, K | 1 |
| Sasayama, S | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Tomlinson, B | 1 |
| Kay, R | 1 |
| Bernardi, L | 1 |
| Merlet, P | 1 |
| Pouillart, F | 1 |
| Dubois-Randé, JL | 1 |
| Delahaye, N | 1 |
| Fumey, R | 1 |
| Castaigne, A | 1 |
| Syrota, A | 1 |
| Crilley, JG | 1 |
| Dark, JH | 1 |
| Hall, JA | 1 |
| Tygesen, H | 1 |
| Rundqvist, B | 1 |
| Wennerblom, B | 1 |
| Gidding, SS | 1 |
| Pahl, E | 1 |
| Orsmond, GS | 1 |
| Lemes, V | 1 |
| Tendera, M | 1 |
| Strömblad, SO | 1 |
| Jansson, K | 2 |
| Karlberg, BE | 1 |
| Nylander, E | 2 |
| Nyquist, O | 2 |
| Karlberg, KE | 2 |
| DiBona, GF | 1 |
| Sawin, LL | 1 |
| Carson, PE | 1 |
| Freudenberger, RS | 2 |
| Steinmetz, M | 1 |
| Ocampo, ON | 1 |
| Ferguson, JJ | 1 |
| Kulbertus, H | 1 |
| vom Dahl, J | 1 |
| Schotten, U | 1 |
| Sasse, A | 1 |
| Liedholm, H | 1 |
| Linné, AB | 1 |
| Merlo, J | 1 |
| Kennedy, HL | 1 |
| Hall, C | 2 |
| Jessup, M | 2 |
| Karlsberg, RP | 1 |
| Friday, G | 1 |
| Haskell, L | 1 |
| Witkowska, M | 1 |
| Song, J | 1 |
| Xu, H | 1 |
| Aldershvile, J | 1 |
| Neuhaus, KL | 1 |
| Thorgeirsson, G | 2 |
| Kuch, J | 1 |
| Rickenbacher, P | 1 |
| Ball, S | 1 |
| Califf, RM | 2 |
| Hoppel, CL | 1 |
| Miller, JL | 1 |
| Garlichs, C | 1 |
| Daniel, WG | 1 |
| Ishikawa, K | 1 |
| Miyataka, M | 1 |
| Kanamasa, K | 1 |
| Hayashi, T | 1 |
| Takenaka, T | 1 |
| Inoki, T | 1 |
| Katayama, K | 1 |
| Kimura, A | 1 |
| Yabushita, H | 1 |
| Kitayama, K | 1 |
| Hara, Y | 1 |
| Hamada, M | 1 |
| Shigematsu, Y | 1 |
| Kodama, K | 1 |
| Kuwahara, T | 1 |
| Hashida, H | 1 |
| Ikeda, S | 1 |
| Ohtsuka, T | 1 |
| Hiasa, G | 1 |
| Hiwada, K | 1 |
| Reddy, P | 1 |
| Dunn, AB | 1 |
| Genth-Zotz, S | 1 |
| Zotz, RJ | 1 |
| Treese, N | 1 |
| Meyer, J | 1 |
| Darius, H | 1 |
| Cremers, B | 1 |
| Flesch, M | 1 |
| Höper, A | 1 |
| Südkamp, M | 1 |
| Rifkin, W | 1 |
| Walerstein, S | 1 |
| Wiener, DH | 1 |
| Boldi, E | 2 |
| Modena, MG | 1 |
| Dickerson, LM | 1 |
| Carek, PJ | 1 |
| Mylona, P | 1 |
| Zannad, F | 1 |
| McNulty, SE | 1 |
| McKenna, WJ | 1 |
| Denbow, CE | 1 |
| Port, JD | 1 |
| Frantz, RP | 1 |
| Whorlow, SL | 1 |
| Prakash, A | 1 |
| Markham, A | 1 |
| Podzolkov, VI | 1 |
| Samoĭlenko, VV | 1 |
| Osadchiĭ, KK | 1 |
| Strizhakov, LA | 1 |
| Todor, A | 1 |
| Singh, V | 1 |
| Movahed, A | 1 |
| Chavey, WE | 1 |
| Hart, SM | 1 |
| Arumanayagam, M | 1 |
| Tong, S | 1 |
| Rodríguez, A | 1 |
| Motta, J | 1 |
| Pichel, D | 1 |
| Nuñez, P | 1 |
| Arrocha, A | 1 |
| Calzada, N | 1 |
| Ueland, T | 1 |
| Brunsvig, A | 1 |
| Simonsen, S | 1 |
| Frøland, SS | 1 |
| Aukrust, P | 1 |
| Aronow, WS | 1 |
| Gregory, D | 1 |
| Konstam, MA | 2 |
| Antonopoulos, GV | 1 |
| Berlin, JA | 1 |
| Chittams, J | 1 |
| Stoschitzky, K | 2 |
| Koshucharova, G | 1 |
| Zweiker, R | 1 |
| Maier, R | 1 |
| Watzinger, N | 1 |
| Fruhwald, FM | 1 |
| Klein, W | 1 |
| Lee, S | 1 |
| Spencer, A | 1 |
| Coutinho, J | 1 |
| O'Shea, JC | 1 |
| Manhenke, C | 1 |
| Aarsland, T | 1 |
| Skårdal, R | 1 |
| Fagertun, H | 1 |
| Demets, D | 1 |
| Levy, AR | 1 |
| Briggs, AH | 1 |
| Demers, C | 2 |
| O'Brien, BJ | 1 |
| Negassa, A | 1 |
| Edes, I | 1 |
| Elter, T | 1 |
| Nickenig, G | 1 |
| LaRosee, K | 1 |
| Crivaro, M | 1 |
| Wuttke, H | 1 |
| Tsuyuki, RT | 1 |
| Arnold, JM | 1 |
| Barretto, AC | 1 |
| Carvalho, AC | 1 |
| Isaac, DL | 1 |
| Kitching, AD | 1 |
| Piegas, LS | 1 |
| Teo, KK | 1 |
| Mak, S | 1 |
| Schofield, A | 1 |
| Allan, R | 1 |
| Kelly, S | 1 |
| Sleiman, OI | 1 |
| Murin, J | 1 |
| Ghanem, WM | 1 |
| Gaburjakova, M | 1 |
| Gaburjakova, J | 1 |
| He Kl, KL | 1 |
| Prieto, A | 1 |
| Becker, E | 1 |
| Yi Gh, GH | 1 |
| Marks, AR | 1 |
| Sveälv, BG | 1 |
| Mobini, R | 1 |
| Lindelöw, B | 1 |
| He, H | 1 |
| Zhao, W | 1 |
| Xu, Y | 1 |
| Andréasson, K | 1 |
| Kahan, T | 1 |
| Eriksson, SV | 1 |
| Tidgren, B | 1 |
| Hjemdahl, P | 1 |
| Denny, M | 1 |
| Fenster, P | 1 |
| Heywood, T | 1 |
| Masszi, G | 1 |
| Rasmussen, S | 1 |
| Wachtell, K | 1 |
| Richardt, G | 1 |
| Richardt, D | 1 |
| Adler, S | 1 |
| Kraatz, E | 1 |
| Nötzold, A | 1 |
| Kurz, T | 1 |
| Hauptman, PJ | 1 |
| Woods, D | 1 |
| Prirzker, MR | 1 |
| J Remme, W | 1 |
| Levin, MC | 1 |
| Marullo, S | 1 |
| Muntaner, O | 1 |
| Magnusson, Y | 1 |
| Smith, MF | 1 |
| Bacharach, SL | 1 |
| Dilsizian, V | 1 |
| Li, G | 1 |
| Xie, X | 1 |
| Huang, Y | 1 |
| Ma, C | 1 |
| Lopatin, IuM | 1 |
| Ghani, P | 1 |
| Sinitsin, VE | 1 |
| Mareev, VIu | 1 |
| Momomura, S | 1 |
| Yamashita, H | 1 |
| Sugiura, S | 1 |
| Ohtani, Y | 1 |
| Serizawa, T | 1 |
| Iizuka, M | 1 |
| Sugimoto, T | 1 |
| Blomström-Lundqvist, C | 1 |
| Hedner, T | 1 |
| Paolisso, G | 1 |
| Gambardella, A | 1 |
| Marrazzo, G | 1 |
| Verza, M | 1 |
| Teasuro, P | 1 |
| Varricchio, M | 1 |
| D'Onofrio, F | 1 |
| Salloum, J | 1 |
| Grosgogeat, Y | 1 |
| Nemanich, JW | 1 |
| Veith, RC | 1 |
| Abrass, IB | 1 |
| Stratton, JR | 1 |
| Bergh, CH | 1 |
| Brodde, OE | 1 |
| Zerkowski, HR | 1 |
| Borst, HG | 1 |
| Maier, W | 1 |
| Michel, MC | 1 |
| Moncloa, F | 1 |
| Sromovsky, JA | 1 |
| Walker, JF | 1 |
| Davies, RO | 1 |
| Ruffolo, RR | 1 |
| Kopia, GA | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Bessen, M | 1 |
| Luckett, CR | 1 |
| Siddiqi, R | 1 |
| Henry, WL | 1 |
| Benfield, P | 1 |
| Clissold, SP | 1 |
| Brogden, RN | 1 |
| Marantz, PR | 1 |
| Alderman, MH | 1 |
| Tobin, JN | 1 |
| Engelmeier, RS | 1 |
| O'Connell, JB | 1 |
| Walsh, R | 1 |
| Rad, N | 1 |
| Scanlon, PJ | 1 |
| Gunnar, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome[NCT03413410] | 1,000 participants (Anticipated) | Interventional | 2018-02-01 | Recruiting | |||
| GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure[NCT01970501] | Phase 2 | 267 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)[NCT01389843] | 5,625 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy[NCT00180271] | 1,820 participants (Actual) | Interventional | 2004-12-31 | Completed | |||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial[NCT04912518] | 250 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | |||
| ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial[NCT03004703] | Phase 2 | 200 participants (Actual) | Interventional | 2017-03-16 | Completed | ||
| "Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The MEEffect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial[NCT01311700] | Phase 4 | 221 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction[NCT03516903] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-04-17 | Terminated (stopped due to Due to the COVID-19 pandemic. With a second wave just beginning, and considering that we are testing an immunosuppressant in patients with high risk for COVID-19 complications, we would not be able to re-start recruitment safely in the near future.) | ||
| Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome[NCT05536271] | Phase 2 | 127 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Potential Drug Interactions With Bisoprolol in Egyptian Patients With Acute Coronary Syndrome[NCT05536284] | Phase 2 | 128 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
| Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.[NCT03392740] | Phase 4 | 200 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| [NCT00497003] | Phase 4 | 50 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure[NCT01971944] | 50 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment[NCT03387605] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-03-15 | Recruiting | ||
| Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients[NCT01502787] | Phase 4 | 46 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| Racial Differences in the Natriuretic Peptide Response to Exercise and Beta-blockers[NCT03070184] | Phase 2 | 80 participants (Actual) | Interventional | 2017-04-30 | Active, not recruiting | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Italian Registry on Cardiac Contractility Modulation Therapy[NCT04327323] | 200 participants (Anticipated) | Observational [Patient Registry] | 2019-09-01 | Recruiting | |||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction[NCT00052026] | Phase 3 | 161 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| [NCT00000505] | Phase 3 | 0 participants | Interventional | 1983-04-30 | Completed | ||
| Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310] | 50 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System[NCT00433043] | Phase 4 | 2 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Insufficient enrollment) | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Effects of a Physical Therapist-driven Individualized Hybrid Model of the Exercise Component of Cardiac Rehabilitation on Patient Outcomes: a Prospective Cohort Study[NCT06030115] | 100 participants (Actual) | Observational | 2019-07-01 | Completed | |||
| Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation[NCT01719367] | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.[NCT02770443] | 22 participants (Actual) | Interventional | 2016-02-19 | Terminated (stopped due to Study closed to recruitment early as endpoints were reached on several participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with adequate ventricular rate control following the start of medication during the 24-week Follow-up Period (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Bucindolol Hydrochloride | 84 |
| Metoprolol Succinate | 116 |
Time-to-event is calculated as the date of the event minus the date of initiation of efficacy follow-up, with 1 added in order to include both the start date and end date of the interval. Cox's proportional hazards model will be used to calculate estimated hazard ratios and 95% confidence intervals. The calculations will be performed with the SAS PHREG procedure, with the stratification variables specified in the STRATA statement and the treatment group comparator and any covariates being examined specified in the MODEL statement. For the primary endpoint, the appropriateness of assuming proportional hazards will be explored by the graphing of log (-log(survival function)) over follow-up for each treatment group. (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | days (Mean) |
|---|---|
| Bucindolol Hydrochloride | 35.9 |
| Metoprolol Succinate | 33.2 |
Number of days on study medication before participant experienced symptomatic or asymptomatic atrial fibrillation, atrial flutter, or all-cause mortality during the 24 week follow up period. (NCT01970501)
Timeframe: end of treatment week 24
| Intervention | days (Mean) |
|---|---|
| Bucindolol Hydrochloride | 37.86 |
| Metoprolol Succinate | 31.06 |
Total number of hospitalization days per patient (all-cause) following the start of study medication during the Total Study Period (24 weeks). Hospitalization was defined by a hospital admission (note that same day admit and discharge equates to 0 days duration), ER visits were not counted as events. (NCT01970501)
Timeframe: 24 weeks
| Intervention | days (Median) |
|---|---|
| Bucindolol Hydrochloride | 2 |
| Metoprolol Succinate | 2 |
"MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:~administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician's office, etc.), or~administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay." (NCT00180271)
Timeframe: Outcome measured at average follow-up duration of 2.4 years.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Patients who are Event Free | Patients with Death or Heart Failure Event | Patients with Heart Failure Event Alone | Patients with Death at Any Time | |
| Cardiac Resynchronization Therapy + Defibrillator | 901 | 188 | 152 | 74 |
| Implantable Cardioverter Defibrillator Alone | 543 | 188 | 170 | 53 |
(NCT01502787)
Timeframe: 12 weeks after initiation of metoprolol
| Intervention | mmHg (Mean) |
|---|---|
| Metoprolol | 114 |
| Nebivolol | 113 |
(NCT01502787)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Initial Treatment With Metoprolol | 101 |
| Initial Treatment With Nebivolol | 103 |
(NCT01502787)
Timeframe: 12 weeks after each specified medication
| Intervention | ml/min (Mean) |
|---|---|
| First Intervention Metoprolol: 12 Weeks | 96 |
| Second Intervention Nebivolol: 24 Weeks | 105 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 5minutes of exercise
| Intervention | beats per minute (Mean) |
|---|---|
| Atenolol: Ancestral Alleles | -10 |
| Atenolol: Variant Carriers | -13 |
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 10 amd 15 minutes of exercise
| Intervention | beats per minute (Mean) | |
|---|---|---|
| After 10 minutes | After 15 minutes | |
| Atenolol: Ancestral Alleles | -11 | -25.5 |
| Atenolol: Variant Carriers | -19.7 | -35.2 |
99 reviews available for metoprolol and Cardiac Failure
| Article | Year |
|---|---|
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Comorbidity | 2022 |
Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Diltiazem; Heart Failure; Humans | 2023 |
Practical recommendations for the use of beta-blockers in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Heart Failure; Humans; Metoprolol; Myocardial Isc | 2020 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2020 |
Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Cytochrome P-450 CYP2D6; Genetic Variation; Hea | 2020 |
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Global Health; Heart Failure; H | 2015 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2016 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 2002 |
Use of beta-blockers for heart failure in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Diabetes C | 2002 |
[Frequent drug interactions in old age].
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Cytochrome P-450 Enzyme System; D | 2009 |
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Gene Deletion; Genetic Variat | 2012 |
β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; China; Hea | 2012 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor | 2002 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Chronic Di | 2002 |
Extended-release metoprolol succinate in chronic heart failure.
Topics: Delayed-Action Preparations; Drug Interactions; Heart Failure; Humans; Metoprolol; Randomized Contro | 2003 |
[Use of beta-blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2003 |
Tolerability of beta-blockers in heart failure: reassurance needed, reassurance provided.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Metoprolol | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Use of beta-blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; F | 2003 |
Choosing metoprolol or carvedilol in heart failure (a pre-COMET commentary).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failu | 2003 |
[Metoprolol CR/XL: advanced formulation of a classical beta-blocker].
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Contraindications; Heart Failure; Humans; Hyperte | 2003 |
Beta-blockers for chronic heart failure: surviving longer but feeling better?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; | 2003 |
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Topics: Adrenergic beta-Antagonists; Aging; Carbazoles; Carvedilol; Down-Regulation; Heart Failure; Hemodyna | 2003 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinical Trials as | 2003 |
A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
Should beta-blockers form the cornerstone for the treatment of congestive heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Dose | 2003 |
The update on the rationale, use and selection of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Ventricular remodeling in heart failure and the effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Clinical Trials as Topic; Heart Failure; | 2004 |
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Top | 2004 |
Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Use of beta-blockers in older adults with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiovascu | 2004 |
The effects of beta blockers on morbidity and mortality in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2004 |
Beta blockers as anti-arrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Carvedilol; H | 2004 |
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2005 |
Emerging trends in the management of heart failure: Beta blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Heart Failur | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Beta-blockers in heart failure: is more better?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor | 2006 |
[Beta-adrenolytics in heart failure--are they all really equal?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2005 |
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; D | 2006 |
Are there clinically important differences between beta-blockers in heart failure?
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Dosage Forms; Dose-Response Rel | 2005 |
[COMET: metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2007 |
[Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2007 |
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Prop | 2007 |
[Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups].
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Dose-Response Relationship, Drug; Heart Fa | 2008 |
Beta-adrenergic antagonists in the treatment of patients with heart disease.
Topics: Acebutolol; Adrenergic beta-Agonists; Alprenolol; Animals; Arrhythmias, Cardiac; Bronchial Spasm; Ca | 1981 |
[Adrenergic betablockers and heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiomyopathy, Dilated; Heart Failure; Humans; Metoprolol; | 1995 |
Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Follow-Up Studies; Heart | 1997 |
Clinical studies on beta blockers and heart failure preceding the MERIT-HF Trial. Metoprolol CR/XL Randomized Intervention Trial in Heart Failure.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Metoprolol; Randomized Controlled Trials as Topi | 1997 |
[Beta blockers in heart failure. Experiences and recommendations for clinical use. ANMCO-Area Heart Failure].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Controlled Clinical Trials as | 1998 |
Beta-blockers for heart failure: is slowing of heart rate essential?
Topics: Adrenergic beta-Antagonists; Heart Failure; Heart Rate; Humans; Metoprolol; Randomized Controlled Tr | 1999 |
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exe | 1999 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
The merit of beta(1)-blockade in heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Heart F | 1999 |
Beta-adrenoceptor blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
The effect of beta-blockers on health-related quality of life in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Health St | 2000 |
The impact of beta-blockade on mortality rates in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
Beta-adrenergic blockade in the treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Beta-blockers and spironolactone in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Mineralocort | 2000 |
Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Heart F | 2000 |
Metoprolol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Chemistry, Pharmaceutical; Disease Progression; Heart Failure; Hemodyna | 2000 |
[Use of metoprolol CR/ZOK in the cardiological practice].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials | 2000 |
Beta blockers and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
The importance of beta blockers in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Drug Administrat | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
MERIT-HF--description of the trial.
Topics: Adrenergic beta-Antagonists; Cause of Death; Delayed-Action Preparations; Heart Failure; Humans; Met | 2000 |
MERIT-HF mortality and morbidity data.
Topics: Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Delayed-Action Preparations; Heart Failure; Hos | 2000 |
Economic impact of beta blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2001 |
Metoprolol CR/XL in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Metoprolol | 2001 |
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2001 |
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans | 2001 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Statistical issues relating to international differences in clinical trials.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Metoprolol; Multicente | 2001 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
Beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
[Beta-blockers in the treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Heart Failure; Humans; Metoprolol; Propranol | 1990 |
Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Enalapril; Female | 1985 |
Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Dogs; | 1986 |
Treatment of cardiac myopathies with beta blockers. What do we know, where do we go from here?
Topics: Adrenergic beta-Antagonists; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic | 1988 |
Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.
Topics: Adult; Age Factors; Aged; Arrhythmias, Cardiac; Cardiomegaly; Coronary Disease; Drug Interactions; D | 1986 |
Diagnostic heterogeneity in clinical trials for congestive heart failure.
Topics: Amrinone; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Hydralazine; Metoprolol; Researc | 1988 |
New concepts in the treatment of elderly hypertensive patients.
Topics: Aged; Aging; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Heart Ventricles; Hum | 1988 |
164 trials available for metoprolol and Cardiac Failure
| Article | Year |
|---|---|
Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Blood Coagulation; Calcitonin Gene-Related Peptide; Delayed-Acti | 2022 |
The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Doxorubicin; Echocardiograp | 2019 |
Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Blood Pressure; China; Dose-Respons | 2019 |
Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine".
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Atrioventricular Block; Benzazepines | 2017 |
Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Chronic Disease; Exercise Tolerance; Female; Hear | 2018 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2018 |
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Genotype; Heart | 2019 |
Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Carbazoles; Cardiac Resynchron | 2013 |
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carb | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri
Topics: Adrenergic beta-Antagonists; Biomarkers; Cardiotonic Agents; Combined Modality Therapy; Creatine Kin | 2013 |
An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Chronic Disease; Cytochrome P-450 CYP2D6; DNA; Do | 2014 |
Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; C | 2015 |
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Anthracyclines; Antineoplastic Agents | 2016 |
A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Output; China; Chronic Disease; Female; Heart Failure; Heart R | 2017 |
The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiomyopathy, Dilated; Double-Blind Method; | 2009 |
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Confidence Intervals; Follow-Up Studies; Heart | 2009 |
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Autoantibodies; Carbazoles; Car | 2009 |
Influence of metoprolol on systolic and diastolic function in children with heart failure.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Diastole; Double-Blind Method; Echocardiograph | 2009 |
Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2009 |
[Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Drug Therap | 2009 |
Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antihypertensive Agents; Endpoint Determin | 2010 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Effects of cAMP and β-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cell Separation; Cyclic AMP; Femal | 2011 |
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia].
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Autoantibodies; Carbazoles; Carvedilol; Female; Heart | 2010 |
β-blockade restores muscle sympathetic rhythmicity in human heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Ca | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvasta | 2011 |
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Substitution; Endothelium, Vascular; Female; H | 2011 |
[Advantages of quinapril therapy in patients with arterial hypertension and functional class III chronic heart failure with preserved left ventricular ejection fraction].
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure; Drug Monitoring; Female; Heart Fai | 2012 |
Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Biomarkers; Bisoprolol; Carbazoles; Carved | 2012 |
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow | 2002 |
Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2002 |
Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Double-Blind Method; Down-Regulation; Fema | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biological Factors; Biomarkers; Blood P | 2002 |
Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Heart Failure; Hu | 2002 |
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Double-Blind Method; | 2003 |
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting En | 2003 |
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Chronic Disease; Cross-Over | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Double-Blind Method; Female; Fo | 2003 |
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazo | 2003 |
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 2003 |
Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure).
Topics: Adrenergic beta-Antagonists; Black or African American; Black People; Female; Heart Failure; Humans; | 2003 |
Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
Topics: Adrenergic beta-Antagonists; Aged; Blood Gas Analysis; Carbazoles; Carvedilol; Case-Control Studies; | 2003 |
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Double-Bl | 2003 |
Effects of spironolactone and metoprolol on QT dispersion in heart failure.
Topics: Aged; Echocardiography; Electrocardiography; Electrophysiology; Female; Heart Failure; Humans; Male; | 2003 |
Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Echocardiography; Female; Heart Failure; Humans; Male; Metoprolol | 2004 |
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Body Mass Index; Carbazoles; Carvedilol; Comorbidity | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Dose-Response Relations | 2004 |
[A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Female; Follow-Up St | 2004 |
Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 | 2004 |
Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Delayed-Action Preparations; | 2004 |
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Chronic Disease; Delayed-Action Prepara | 2005 |
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Delayed-Action Preparations; Diabetes Complications; Diabe | 2005 |
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Topics: Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Drug Administration Schedule; Drug Resistance; | 2005 |
Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure.
Topics: Aged; Algorithms; Cardiovascular Agents; Dosage Forms; Emergency Service, Hospital; Female; Health S | 2005 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Fema | 2005 |
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe | 2005 |
The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Cohort Studies; Cytosine; Female; Follow-Up Studi | 2005 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men.
Topics: Adrenergic beta-Antagonists; Adult; Heart Failure; Humans; Kidney Tubules; Lower Body Negative Press | 2005 |
How should COMET influence heart failure practice?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Meth | 2004 |
Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Morbidity; M | 2004 |
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Dose-Response | 2005 |
[Effects of beta-blockers on transmitral, pulmonary venous flows, and spontaneous echo-contrast grades in heart failure].
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Echocardiography; Female; Heart Failure; Humans; M | 2005 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Fun | 2005 |
Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Natriuretic Factor; Cyclic GMP; Heart Failure; Humans; Mal | 2006 |
Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; He | 2006 |
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Autonomic Nervous System; Blood Pressure; Chronic Disease; Cross- | 2006 |
Plasma concentration of Fas/Fas ligand and left ventricular function in response to metoprolol in conjunction with standard treatment.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Biomarkers; Cardiotonic Agents; Di | 2007 |
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Function, Left; Carbazoles; Carvedilol; Echocardiography, | 2007 |
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Chi-Square Distribution; D | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Carbazo | 2007 |
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; | 2007 |
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; H | 2007 |
Switching beta-blocker therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Chronic Disease; Heart Failure; Humans; Metoprolol | 2008 |
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Chi-Square Distribution; | 2007 |
Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2008 |
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carbon Dioxide; Carvedilol; Dose-Resp | 2008 |
Established beta-adrenergic receptor blocking therapy and acute myocardial infarction. A clinical study of risks and benefits.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Femal | 1980 |
The influence of beta-adrenoceptor blockade on left ventricular function.
Topics: Adrenergic beta-Antagonists; Cardiac Output; Heart; Heart Failure; Humans; Hypertension; Metoprolol; | 1982 |
Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomyopathy, Dila | 1984 |
Beta blockade for dilated cardiomyopathy: the evidence against therapeutic benefit.
Topics: Cardiomegaly; Clinical Trials as Topic; Dilatation, Pathologic; Heart Failure; Humans; Metoprolol; P | 1983 |
Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Furosemide; Heart Failure; Humans; Metop | 1984 |
Göteborg Metoprolol Trial: design, patient characteristics and conduct.
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electroca | 1984 |
Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Exercise Test; Fem | 1995 |
Influence of beta-blockade with metoprolol on symptoms and functional capacity of patients with idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chronic Disease; Exercise Test; Exercise Tolerance; Female; He | 1994 |
Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Male; | 1995 |
Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function.
Topics: Adult; Aged; Cell Division; Concanavalin A; Heart Failure; Humans; Immune System; Lymphocyte Subsets | 1994 |
Recovery from left ventricular asynergy in ischemic cardiomyopathy following long-term beta blockade treatment.
Topics: Aged; Echocardiography; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Myocardial Contraction | 1994 |
Predictors of pressure and stroke volume response to afterload reduction with nitroprusside in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Topics: Blood Pressure; Cardiac Catheterization; Cardiomyopathy, Dilated; Heart Failure; Humans; Metoprolol; | 1994 |
Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy?
Topics: Adrenergic beta-Antagonists; Depression, Chemical; Female; Heart Failure; Hemodynamics; Humans; Male | 1993 |
Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial.
Topics: Coronary Disease; Double-Blind Method; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; | 1994 |
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial In
Topics: Female; Heart Failure; Humans; Hypotension; Incidence; Male; Metoprolol; Middle Aged; Myocardial Inf | 1993 |
Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
Topics: Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Celiprolol; Double-Blind Method; Female; Hea | 1995 |
Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Chronic Disease; Doxazosin; | 1996 |
[Safety and tolerability of beta-blockers in severe cardiac decompensation from dilated cardiomyopathy].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Cardiomyopathy, Dilated; Female; Heart Failure | 1995 |
Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Down-Regulation; Female; GTP-Binding Proteins; Heart Failu | 1996 |
Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Drug Synergis | 1997 |
Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Heart Failure; Humans; Injections, Intravenous; Ma | 1997 |
Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Bli | 1997 |
Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomyopathy, Dilated; Female; Heart Failure; Hemodynami | 1997 |
Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Celiprolol; Chi-Square Distribution; Double | 1998 |
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cardiotonic Agents; Drug Therapy, Combination; En | 1998 |
3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Double-Blind | 1998 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
Effect of beta-blockade on baroreceptor and autonomic function in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Autonomic Nervous System; Blood Pressure; C | 1999 |
Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Electrocardiography, Ambulatory; Female; Follo | 1999 |
Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiac Output; Double-Blind Method; Female; Follow-Up Stu | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Death, Sudden; | 1999 |
Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Calcium Channel Blockers; Drug Therapy, Combination; | 1999 |
[Clinical study of the month. The MERIT-HF study].
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Di | 1999 |
The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Delayed-Action Preparations; Female; Heart Failure; Humans | 1999 |
Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; | 1999 |
Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction.
Topics: Double-Blind Method; Electrocardiography, Ambulatory; Female; Heart Failure; Humans; Male; Metoprolo | 1999 |
Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Dose-Response Relationship, Drug; Dr | 2000 |
[Changes of plasma endothelin-1 in patients with congestive heart failure and the influence of metoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Endothelin-1; Female; Heart Failure; Humans; Male; Metopro | 1998 |
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure | 2000 |
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure | 2000 |
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure | 2000 |
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure | 2000 |
MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiac Volume; Cardiomyopathy, Dilated; Double-Blind Meth | 2000 |
Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female | 2000 |
The value of repeated echocardiographic evaluation in patients with idiopathic dilated cardiomyopathy during treatment with metoprolol or captopril.
Topics: Adult; Captopril; Cardiomyopathy, Dilated; Double-Blind Method; Echocardiography, Doppler; Female; F | 2000 |
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Doub | 1999 |
Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes.
Topics: Adrenergic beta-Antagonists; Aged; Epoprostenol; Female; Heart Failure; Humans; Male; Metoprolol; Mi | 1999 |
Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Double-Blind Method; Drug Monitoring; Female; Heart Failure; Humans; Ma | 2000 |
Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Heart Fail | 2000 |
Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Antioxidants; Carbazoles; Carvedilol | 2001 |
MERIT-HF--description of the trial.
Topics: Adrenergic beta-Antagonists; Cause of Death; Delayed-Action Preparations; Heart Failure; Humans; Met | 2000 |
MERIT-HF mortality and morbidity data.
Topics: Adrenergic beta-Antagonists; Death, Sudden, Cardiac; Delayed-Action Preparations; Heart Failure; Hos | 2000 |
Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Cytokines; Double-Blind Method; Female; Heart Failure; Humans; In | 2001 |
Effect of beta blockers on mortality and morbidity in persons treated for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Bli | 2001 |
Differing beta-blocking effects of carvedilol and metoprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Cr | 2001 |
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial.
Topics: Aged; Chronic Disease; Confidence Intervals; Delayed-Action Preparations; Double-Blind Method; Drug | 2001 |
Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Heart Failure; Humans; International Cooperation; | 2001 |
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2001 |
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cross-Over Studies; Female; He | 2001 |
Acute precipitants of congestive heart failure exacerbations.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dise | 2001 |
Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; | 2001 |
Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2001 |
Longitudinal myocardial contraction improves early during titration with metoprolol CR/XL in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Catecholamines; Chronic Disease; Delayed-Action Preparations; Diastole; | 2002 |
Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Circadian Rhythm; Dose-Response Relationship, Dru | 2001 |
Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Facto | 2002 |
Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Heart Fail | 2002 |
Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Delayed-Action Preparat | 2002 |
Cardiac 123 I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Female; Follow-Up Studies; Heart Failure; | 2002 |
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Europe; Female; Heart Fail | 2002 |
[Potential possibilities of using adrenergic beta blockers in chronic heart failure].
Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Metopro | 1992 |
Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Double-Blind Method; Fatty Acids, Nonesterified; Female; Gluco | 1992 |
Treatment of cardiac myopathies with beta blockers. What do we know, where do we go from here?
Topics: Adrenergic beta-Antagonists; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic | 1988 |
[Beta-blockade therapy in heart failure. Rational bases of the interpretation of clinical data and clinical evidence in search of rational interpretation].
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Clinical Trials as Topic; Heart Failure; Human | 1988 |
New concepts in the treatment of elderly hypertensive patients.
Topics: Aged; Aging; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Heart Ventricles; Hum | 1988 |
Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Bradycardia; Cardiomyopathy, Dilated; Clinical Trials as Topic; Exercise Test; Female; Heart | 1985 |
295 other studies available for metoprolol and Cardiac Failure
| Article | Year |
|---|---|
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Topics: Acute Coronary Syndrome; ADAM17 Protein; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angio | 2021 |
Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.
Topics: Aged; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Metoprolo | 2021 |
52-Year-Old Woman With Palpitations, Abdominal Distension, and Severe Abdominal Pain.
Topics: Abdominal Pain; Antithyroid Agents; Ascites; Atrial Fibrillation; Diagnosis, Differential; Echocardi | 2021 |
Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarke | 2021 |
Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department.
Topics: Adolescent; Atrial Fibrillation; Diltiazem; Emergency Service, Hospital; Heart Failure; Heart Rate; | 2022 |
Early donepezil monotherapy or combination with metoprolol significantly prevents subsequent chronic heart failure in rats with reperfused myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Donepezil; Heart Failure; Metoprolol; Myocardial Infarction; R | 2022 |
Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2022 |
Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart.
Topics: A Kinase Anchor Proteins; Animals; Fibrosis; Heart; Heart Failure; Metoprolol; Quality of Life; Rats | 2022 |
Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine.
Topics: Aged; Cardiovascular Diseases; China; Coronary Disease; Glucose; Heart Failure; Humans; Metoprolol; | 2022 |
Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Diltiazem; Female; Heart Failure; H | 2022 |
Acute rate control with metoprolol versus diltiazem in atrial fibrillation with heart failure with reduced ejection fraction.
Topics: Adult; Atrial Fibrillation; Cohort Studies; Diltiazem; Heart Failure; Heart Rate; Humans; Hypotensio | 2023 |
Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure.
Topics: Amlodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Metoprolol | 2023 |
Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carvedilol; Defibrillators, Implantable; Heart Fai | 2023 |
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K
Topics: Bisoprolol; Carvedilol; Heart; Heart Failure; Humans; Metoprolol; Protein Isoforms | 2023 |
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Expectoration of bronchial casts in association with Ramipril treatment.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Bronchi; Fe | 2019 |
Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients.
Topics: Adult; Aged; Anxiety; Asian People; China; Chronic Disease; Depression; Female; Heart Failure; Heart | 2019 |
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Disease Models, Animal; Dystrophin; Gait Di | 2020 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.
Topics: Animals; Calcium-Binding Proteins; Cardiomyopathies; Eplerenone; Heart Failure; Metoprolol; Mice; Mu | 2020 |
Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study.
Topics: Administration, Oral; Aged; Asian People; Chronic Disease; Female; Heart Failure; Humans; Male; Meto | 2020 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
90-year-old man • dyspnea • lower extremity edema • limitations in daily activities • Dx?
Topics: Activities of Daily Living; Aged, 80 and over; Diagnosis, Differential; Diuretics; Dyspnea; Edema; F | 2020 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Fa | 2021 |
Effects of carvedilol and metoprolol on the myocardium during mechanical unloading in a rat heterotopic heart transplantation model.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Heart Failure; Heart Transplantation; Metoprolol; | 2021 |
Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes.
Topics: Aged; Carvedilol; Diabetes Mellitus; Heart Failure; Humans; Hyperglycemia; Male; Medicare; Metoprolo | 2021 |
Efficacy observation and analysis of metoprolol combined with dopamine in patients with severe pneumonia complicated with heart failure.
Topics: Adrenergic beta-Antagonists; Dopamine; Heart Failure; Humans; Metoprolol; Pneumonia | 2022 |
Evaluation of ultrasonic indexes and exercise endurance application of diuretic mixture combined with metoprolol in the treatment of senile chronic heart failure.
Topics: Adrenergic beta-Antagonists; Chronic Disease; Diuretics; Heart Failure; Humans; Metoprolol; Ultrason | 2022 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atorvastatin; Atrial Fibrillatio | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
A rare form of extremely wide QRS complex due to reversed homologous electrical ventricular separation of acute heart failure.
Topics: Acute Disease; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzaze | 2018 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Stroke-induced chronic systolic dysfunction driven by sympathetic overactivity.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Brain Ischemia; Echocardiography; Epinephrine; Hear | 2017 |
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; | 2018 |
Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction.
Topics: Acute Disease; Administration, Intravenous; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dilti | 2019 |
Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up S | 2018 |
Comparison of acute management of atrial fibrillation in heart failure with unequal sized groups.
Topics: Atrial Fibrillation; Diltiazem; Heart Failure; Humans; Metoprolol; Stroke Volume | 2018 |
The authors respond "Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction".
Topics: Atrial Fibrillation; Diltiazem; Heart Failure; Humans; Metoprolol; Stroke Volume | 2018 |
Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male; Meto | 2018 |
Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Carvedilol; Cohort Studies; Drug Prescript | 2019 |
Arrhythmogenic right ventricular dysplasia, cutaneous manifestations and desmoplakin mutation: Carvajal syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmogenic Rig | 2018 |
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arkansas; Carvedilol; Cause of Death; Death, Su | 2019 |
Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Anxiety; Chronic Disease; Depression; Female; Heart; Hea | 2019 |
Improvement in quality of life of Chinese chronic heart failure patients with neuropsychiatric complications over 12-months post-treatment with metoprolol.
Topics: Aged; Anti-Arrhythmia Agents; Anxiety; China; Chronic Disease; Depression; Female; Heart Failure; Hu | 2019 |
β-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2019 |
METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE.
Topics: Adrenergic beta-Antagonists; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Met | 2019 |
Acute effects of intravenous carvedilol versus metoprolol on baroreflex-mediated sympathetic circulatory regulation in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Baroreflex | 2019 |
Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment.
Topics: Adenosine Triphosphatases; Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Animals; Di | 2019 |
PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antago | 2013 |
PDE4 in the human heart - major player or little helper?
Topics: Adrenergic beta-1 Receptor Antagonists; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Failure; | 2013 |
Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice.
Topics: Animals; Blood Pressure; Ghrelin; Heart; Heart Failure; Heart Rate; Male; Metoprolol; Mice; Mice, In | 2013 |
Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.
Topics: Adenosine Triphosphatases; Animals; Calcium; Calcium-Binding Proteins; Cardiac Output; Dopamine; Epi | 2013 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
[Economic analysis of the treatment of heart failure with beta-blockers].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Top | 2013 |
Here we go again.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Female; Heart Failure; H | 2013 |
Reply: To PMID 23500269.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Female; Heart Failure; H | 2013 |
Chronotropic incompetence: real life observations of a theoretical concept.
Topics: Adrenergic beta-1 Receptor Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; | 2013 |
Inappropriate implantable defibrillator shocks: an adverse outcome that can be prevented.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; Defibrillators, Implantable; Female; Hear | 2013 |
Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Autonomic Nervous System; Baroreflex; Heart; Heart | 2013 |
Reply: Carvedilol versus metoprolol, but which metoprolol? Effect on inappropriate cardioverter-defibrillator therapy.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Female; Heart Failure; H | 2014 |
Carvedilol versus metoprolol, but which metoprolol? Effect on inappropriate cardioverter-defibrillator therapy.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Female; Heart Failure; H | 2014 |
Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Re | 2014 |
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Bro | 2014 |
Shengxian decoction in chronic heart failure treatment and synergistic property of Platycodonis Radix: a metabolomic approach and its application.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drugs, Chinese Herbal; Gene Expression Regulation; | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |
Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Denmark; Female; Follow-Up Studies | 2014 |
Health and cost benefits associated with the use of metoprolol in heart attack patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Heart Fa | 2014 |
Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Calcium; Clenb | 2014 |
Healing the orphaned heart: heart failure in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Aged; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Female; Glucosephosphate Dehydrogenase | 2015 |
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Blood Pressure | 2015 |
β-Blockers in diabetic patients with heart failure--reply.
Topics: Adrenergic beta-Antagonists; Carbazoles; Female; Heart Failure; Humans; Male; Metoprolol; Propanolam | 2015 |
β-Blockers in diabetic patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Female; Heart Failure; Humans; Male; Metoprolol; Propanolam | 2015 |
Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Cohort Studies; Denmark | 2015 |
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene | 2015 |
Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; He | 2015 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Databases, Fa | 2017 |
Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 2017 |
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cytochrome P-45 | 2017 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; | 2016 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Disease Progression; Female; Genotype; Ha | 2008 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardio | 2008 |
Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Disease Models, Animal; Dogs; Drug Therapy, Combinat | 2009 |
Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Drug Administration Schedule; F | 2008 |
The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2008 |
Effects of beta-blocker on left ventricular remodeling in rats with volume overload cardiac failure.
Topics: Adrenergic beta-Antagonists; Animals; Echocardiography, Transesophageal; Heart Bypass, Right; Heart | 2008 |
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di | 2009 |
Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure.
Topics: Animals; Benzazepines; Heart Failure; Heart Rate; Ivabradine; Male; Metoprolol; Myocardial Infarctio | 2009 |
Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Di | 2009 |
CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Alleles; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Gen | 2009 |
Heart rate variability in rats with experimental chronic heart failure and long-term exposure to beta-adrenoblockers.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Bisoprolol; Ethanolamines; Heart Failur | 2009 |
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Signaling; Cardiomegaly; Disease Models, Animal; Fibro | 2009 |
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Meto | 2010 |
The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Australia; Bisoprolol; Carbazoles; Carvedilol; | 2009 |
The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Case-Control Studies; Female; Heart Failure; H | 2009 |
[Efficacy of ivabradine in combination therapy for complicated acute coronary syndrome in patients with type 2 diabetes mellitus].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Benzazepines; Diabetes Mellitus, Type 2 | 2010 |
[Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure].
Topics: Aged, 80 and over; Chronic Disease; G-Protein-Coupled Receptor Kinase 2; Heart Failure; Humans; Lymp | 2010 |
Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; Carvedilol; Drug Evaluation; Female; Glome | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Carbazoles; Carvedilol; Chronic Disease; Comorbidity; Cy | 2010 |
Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models | 2010 |
Association of physical training with beta-blockers in heart failure in mice.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin | 2010 |
[Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Pressure; C-Reactive Protein; Chronic Di | 2010 |
Heart failure: acute ischemic events in HF--should we include sudden death?
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Benzopyrans; Death, Sudden, Cardiac | 2011 |
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Genotype; Heart Failure; Humans; Male; Meto | 2011 |
β-adrenergic receptor blockade reduces endoplasmic reticulum stress and normalizes calcium handling in a coronary embolization model of heart failure in canines.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Apoptosis; Blotting, Western; Calcium; C | 2011 |
Wide complex tachycardia causing congestive heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Catheter Ablation; Cyclohexane Monoterpenes | 2011 |
Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Aging; Animals; Blood Pressure; Disease Models, Animal; Dose | 2011 |
Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Chronic Disease; Consci | 2011 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Numerical optimization studies of cardiovascular-rotary blood pump interaction.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Blood Volume; | 2012 |
Effect of metoprolol on sarcoplasmic reticulum Ca2+ leak in a rabbit model of heart failure.
Topics: Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP-Dependent Protein K | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nuc | 2012 |
Heart rate reduction: an old and novel candidate heart failure therapy.
Topics: Animals; Benzazepines; Heart Failure; Ivabradine; Male; Metoprolol; Tachycardia; Ventricular Dysfunc | 2012 |
Therapeutic challenges and management of heart failure during pregnancy (part I).
Topics: Adult; Digitalis; Drug Therapy, Combination; Enalapril; Female; Furosemide; Heart Failure; Humans; M | 2012 |
Mutation of the calmodulin binding motif IQ of the L-type Ca(v)1.2 Ca2+ channel to EQ induces dilated cardiomyopathy and death.
Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Bindin | 2012 |
Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Electrocardiography; Heart Failure; Male; Metoprolol; Mice; | 2012 |
β1 -adrenergic receptor autoantibodies from heart failure patients enhanced TNF-α secretion in RAW264.7 macrophages in a largely PKA-dependent fashion.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antibody Specificity; Autoantibodies; Biomarkers; B | 2012 |
Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials.
Topics: Bayes Theorem; Biostatistics; Clinical Trials as Topic; Data Interpretation, Statistical; Delayed-Ac | 2013 |
The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cohort Studies; Defibrillators, Implanta | 2012 |
Influence of ivabradine on reverse remodelling during mechanical unloading.
Topics: Animals; Atrophy; Benzazepines; Calcium; Calcium Channels, L-Type; Excitation Contraction Coupling; | 2013 |
Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Cohort Studies; Delayed-Actio | 2012 |
[The rare case of Bland-White-Garland syndrome in adult patient].
Topics: Adult; Benzazepines; Cardiovascular Agents; Cardiovascular Surgical Procedures; Coronary Angiography | 2012 |
Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Brain Stem; Chronic Disease; Con | 2013 |
Current research on carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2002 |
Effects of metoprolol in chagasic patients with severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Chagas Cardiomyopathy; Female; Heart Failure; Hum | 2002 |
Effectiveness of amiodarone therapy in patients with severe congestive heart failure and intolerance to metoprolol.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Case-Control Studies; Drug Tolerance; Female; Follo | 2002 |
Beta-blockers work as well in women as in men.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Clinical Trials as Topic; Female; Heart Failur | 2002 |
Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Heart Failure; Humans; Metoprolol | 2003 |
The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Ant | 2002 |
Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-Up Stud | 2003 |
Long-term effects of beta blocker therapy on P-wave duration and dispersion in congestive heart failure patients: a new effect?
Topics: Adrenergic beta-Antagonists; Electrocardiography, Ambulatory; Female; Heart Conduction System; Heart | 2003 |
QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child Welfare; Child, Presch | 2003 |
Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; | 2003 |
Beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
[The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Female; | 2003 |
[Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Female; Heart | 2003 |
Immediate- vs extended-release metoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Metoprolol | 2003 |
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Arginine; Blood Pressure; Female; Genotype; Glycine; Heart Failur | 2003 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Defibrillators, Imp | 2003 |
Decreased heart rate recovery after exercise in patients with congestive heart failure: effect of beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Diastole; Exercise | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Heart Failure; Humans; Metoprolol; Ra | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carve | 2003 |
[Comet or snoop?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
[The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Metopro | 2003 |
Top heart failure drugs compared.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Met | 2003 |
[For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Doubl | 2003 |
[Comparative study in heart failure. Which beta blocker saves more life time?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
AVID and COMET.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Heart Conduction System; | 2003 |
[A fairer comparison between carvedilol and metoprolol is still to be done].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2003 |
A COMET lost.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Controlled Clinical Trials as Topic; Dose-Respo | 2003 |
Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Echocardiography | 2003 |
Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male | 2004 |
In heart failure, all beta-blockers are not necessarily equal.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2003 |
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ambulatory Care Facilities; Carbazoles; Carvedilol; | 2004 |
[Beta-blocking drugs indicated in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Diseases; Heart Failure; | 2003 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
[Beta blocker in heart failure. Dosage too low].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response Relatio | 2003 |
Beta-blocker efficacy according to heart rate and rhythm in patients with heart failure. Commentary on the Cardiac Insufficiency Bisoprolol Study II analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Conduction System; Heart Failure; Heart Rate; Humans; | 2003 |
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Black People; Diabetic Angiopathies; Heart Failure; Humans; Hypertensio | 2003 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
A comment on COMET: how to interpret a positive trial?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Europe; Heart | 2003 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2003 |
Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Biomarkers; Blood Pressure; Body Weight; Cachexia; Carbazoles; Carvedil | 2003 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
Design and analysis of group sequential clinical trials with multiple primary endpoints.
Topics: Adrenergic beta-Antagonists; Biometry; Clinical Trials, Phase III as Topic; Endpoint Determination; | 2004 |
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Chronic Disease; Double-Blind M | 2004 |
The carvedilol or metoprolol European trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Female; Heart Failure; Humans; Male; Metoprolol; Propanolam | 2004 |
Commentary on the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Carvedilol and metoprolol European trial: do the results merit challenge?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Human | 2004 |
Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Carbazoles; | 2004 |
Beta-blockers and heart failure.
Topics: Adrenergic beta-Antagonists; Cardiac Output, Low; Heart Failure; Humans; Metoprolol; Quality of Life | 2000 |
Estimating mortality reduction by comparing survival curves.
Topics: Carbazoles; Cardiovascular Agents; Carvedilol; Computer Simulation; Evidence-Based Medicine; Heart F | 2004 |
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp | 2004 |
Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2005 |
Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Defibrillator | 2005 |
Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Contraindications; Female; Follow-Up Studies; Heart Failure; Hosp | 2005 |
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; He | 2005 |
[Numerous indications in cardiology. Beta receptor blockers can never be overlooked].
Topics: Adrenergic beta-Antagonists; Controlled Clinical Trials as Topic; Heart Diseases; Heart Failure; Hum | 2005 |
Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; Female; Foll | 2005 |
[Does the use of metoprolol-succinate in patients with chronic heart failure lead to a higher efficacy in treatment without causing additional costs?].
Topics: Adrenergic beta-Antagonists; Cost Savings; Drug Costs; Germany; Heart Failure; Humans; Metoprolol; N | 2005 |
Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Electrocardiography, Ambulatory; Heart Failure; | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover.
Topics: Adrenergic beta-Antagonists; Baroreflex; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Humans; | 2005 |
Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Diastole; Echocardiography; Heart Fa | 2006 |
[Effect of the polymorphism of the angiotensin-converting enzyme gene on the drug treatment in patients with chronic heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benz | 2004 |
Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Varian | 2006 |
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz | 2005 |
Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
Topics: Adrenergic beta-Antagonists; Calcium Channels, L-Type; Carbazoles; Carvedilol; Dose-Response Relatio | 2006 |
Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Delayed-Action P | 2005 |
[Antihypertensive therapy with left cardiac insufficiency].
Topics: Acebutolol; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2006 |
[Use of betablockers in elderly patients with congestive heart failure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprol | 2006 |
Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Delayed-Action Preparations; Heart Failure; Hum | 2006 |
Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Biomarker | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol | 2006 |
Autoantibody against beta1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment.
Topics: Adrenergic beta-Antagonists; Autoantibodies; Drug Administration Schedule; Exercise Test; Female; He | 2006 |
The function of left ventricular basal segments is most important for long-term recovery.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Echocardiography; Female; Heart Failure; Humans; | 2007 |
Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Coronary Stenosis; Dogs; Echocardiograp | 2007 |
Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium.
Topics: Adrenergic beta-Antagonists; Calcium; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Metoprol | 2007 |
Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Gene | 2007 |
Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Defibrillators, Implantable; Disease Models, Animal; Dogs; Ele | 2007 |
Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aluminum; Atenolol; California; Carbazo | 2007 |
[Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure].
Topics: Animals; Aortic Valve Insufficiency; Calcium; Calcium-Binding Proteins; Disease Models, Animal; Hear | 2007 |
Aristolochic Acid induces heart failure in zebrafish embryos that is mediated by inflammation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aristolochic Acids; Cyclooxygenase 2; Cyclooxygen | 2007 |
Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Female; Genotype; Heart Failure; Humans | 2007 |
Recent findings into the potential of gene therapy to reverse heart failure.
Topics: Antihypertensive Agents; Genetic Therapy; Heart Failure; Humans; Metoprolol; S100 Proteins | 2007 |
Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy.
Topics: Adrenergic beta-Antagonists; American Heart Association; Arrhythmias, Cardiac; Atrial Fibrillation; | 2008 |
Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Disease Models, Animal; Heart Failure; | 2008 |
Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Brain; Disease Models, | 2008 |
Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Delaye | 2008 |
Low-dose beta blockade in the treatment of chronic cardiac failure.
Topics: Adrenergic beta-Antagonists; Adult; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Propranolo | 1982 |
Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Coronary Disease; Drug Interactions; Drug Therapy, C | 1982 |
Relationship between the enzymatically estimated infarct size and clinical findings in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Creatine Kinase; Follow-Up Studies; Furose | 1984 |
Correlation between electrocardiographically and enzymatically estimated infarct size and its relation to clinical course in inferior myocardial infarction.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Double-Blind Method; Electrocardiogr | 1984 |
Relationship between electrocardiographically estimated infarct size and clinical findings in anterior myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Heart Failure; Humans; Hypotension; Length o | 1984 |
Göteborg Metoprolol Trial: clinical observations.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Furosemide; Heart Failure; Heart Rate | 1984 |
Göteborg Metoprolol Trial: tolerance.
Topics: Administration, Oral; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; | 1984 |
Göteborg Metoprolol Trial: mortality and causes of death.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Female; Heart Failure; Hea | 1984 |
Beta-blockers in dilated cardiomyopathies: they work.
Topics: Administration, Oral; Adult; Aged; Digoxin; Dilatation, Pathologic; Drug Therapy, Combination; Femal | 1983 |
New directions in the treatment of heart failure: some paradoxical observations.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 1995 |
[Serial assessment of MIBG scintigraphy in a case of DCM with heart failure improved by beta-blocker therapy].
Topics: 3-Iodobenzylguanidine; Cardiomyopathy, Dilated; Follow-Up Studies; Heart; Heart Failure; Humans; Iod | 1995 |
Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients.
Topics: Adolescent; Child; Doxorubicin; Heart Failure; Humans; Male; Metoprolol; Remission Induction; Time F | 1995 |
Reversion of tachycardiomyopathy after beta-blocker.
Topics: Adult; Atrial Fibrillation; Cardiomyopathy, Dilated; Exercise Test; Heart Failure; Heart Rate; Human | 1993 |
Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice.
Topics: Animals; Captopril; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Metoprolol; | 1993 |
[A study on congestive heart failure with ventricular arrhythmia and the catecholamine beta receptor system].
Topics: Adult; Female; Heart Failure; Humans; Lymphocytes; Male; Metoprolol; Middle Aged; Receptors, Adrener | 1993 |
The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol.
Topics: Adolescent; Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathies; Diastole; Dose-Response Relat | 1993 |
Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Coronary Circulation; Drug Synergism; Drug Therapy, Com | 1993 |
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
Topics: Aclarubicin; Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Cardiomyopathy, Hypert | 1995 |
Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Epinephrine; Heart Conduction System; Heart Failure; Hemodynamics; Huma | 1996 |
Effects of beta blockers on symptoms and functional capacity in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Tolerance; Heart Failure; Hospitalizat | 1997 |
Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Female; Heart Failure; Heart Rate; H | 1997 |
The force-interval relationship of the left ventricle: a quantitative description in patients with ischemic heart disease.
Topics: Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Male; Metoprolol; Midd | 1995 |
Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade?
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Enoximone; Heart Failure; Humans; Metoprolol | 1998 |
Safety and effectiveness data: will children gain access?
Topics: Adrenergic beta-Antagonists; Child; Female; Heart Failure; Humans; Metoprolol; Pregnancy; Safety; Tr | 1998 |
Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Echocardiography; Female; Follow-U | 1998 |
[Myocardial involvement in carrier states for Duchenne muscular dystrophy. A rare cause of supraventricular arrhythmia].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fi | 1998 |
Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Dogs | 1998 |
Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm?
Topics: Adrenergic beta-Antagonists; Animals; Fatty Acids; Heart Failure; Humans; Metoprolol; Myocardium; Ox | 1998 |
Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Cardiovirus Infe | 1998 |
Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Cardiomyopathy, Dilated; Echocardiography | 1999 |
Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Cardiac Output; Dobutamine; Drug A | 1998 |
Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience.
Topics: Adolescent; Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Child; Child, Preschool; Echocardi | 1999 |
The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriu | 1999 |
Benefit of beta-blockers for heart failure: proven in 1999.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Metoprolol; Randomized Controlled Trials as Topi | 1999 |
Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure.
Topics: Adrenergic beta-Agonists; Animals; Diet, Sodium-Restricted; Heart Failure; Hemodynamics; Isoproteren | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Pharmacological treatment of systolic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Failure; Humans; Metoprolol; Research Design | 1999 |
[The role of beta-adrenergic blocking agents in treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
Beta-blocker therapy for heart failure: the evidence is in, now the work begins.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Metoprolol | 2000 |
Mitochondrial dysfunction in heart failure: potential for therapeutic interventions?
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Energ | 2000 |
Study documents benefits of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Metoprolol; Randomized Controlled Trials as Topi | 2000 |
[New milestones in the therapy of chronic heart failure with beta blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Cardi | 2000 |
Retrospective analysis showing less cardiac events in post-myocardial infarction patients treated with metoprolol. Secondary Prevention Group.
Topics: Adrenergic beta-Antagonists; Aged; Death, Sudden, Cardiac; Drug Evaluation; Female; Heart Failure; H | 2000 |
Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Fac | 2000 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Heart Failure; Humans; | 2000 |
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Guanylyl I | 2000 |
Beta-blockade for patients with heart failure.
Topics: Adrenergic beta-Antagonists; Clinical Protocols; Clinical Trials as Topic; Ethics, Medical; Heart Fa | 2000 |
Beta-blockade for patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Hospitalizatio | 2000 |
Are there differences between vasodilating and nonvasodilating beta-blockers in patients with heart failure? Do patients with ischemic heart disease benefit to the same degree?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; Humans; | 2000 |
Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; M | 2000 |
[Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Heart Failure; Hospitalization; Humans; Me | 2000 |
[Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2000 |
Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Calsequestrin; Caspase | 2000 |
[Cardiac insufficiency and B-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart F | 1998 |
Beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Oxygen Consu | 2001 |
Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cana | 2001 |
Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Female; He | 2001 |
beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Binding, Competitive; Calcium; Cardiac Pacing, Artificial; Cyc | 2001 |
[Clinical study on treatment of mild-middle degree congestive heart failure with integrated traditional Chinese and Western medicine].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Captopril; Coronary Disease; Drug Therapy, Combination; Dr | 2000 |
Beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2002 |
Unique effects of carvedilol on noradrenaline release in the human heart.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; H | 2002 |
Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2002 |
The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation.
Topics: Down-Regulation; Genotype; Glycine; GTP-Binding Proteins; Heart Failure; Humans; Metoprolol; Polymor | 2002 |
Effect of metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiography; Cardiac Output; Cardiomyopathies; Chi-Square | 2002 |
[Significance of the changes of plasma endothelin, norepinephrine and atrial natriuretic peptide in treatment of heart failure with beta-blocker].
Topics: Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Coronary Disease; Endothelins; Female | 1999 |
Effects of work and acute beta-receptor blockade on myocardial noradrenaline release in congestive cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiac Output; Heart Failure; Heart | 1979 |
[Administration of metoprolol in refractory and severe heart failure].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Female; Heart Failure; Heart Rate; Humans; Male; Metoprolol; M | 1992 |
[Changes in lymphocyte beta-receptor density in patients with heart failure before and after metoprolol or captopril administration].
Topics: Adult; Aged; Captopril; Cardiomyopathy, Dilated; Female; Heart Failure; Humans; Lymphocytes; Male; M | 1992 |
Cardiac adaptation and its limitation in an experimental model of congestive heart failure.
Topics: Adaptation, Physiological; Animals; Cardiomegaly; Cricetinae; Heart; Heart Failure; In Vitro Techniq | 1992 |
Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Energy Metabolism; Epinephrine; Exercise; Fema | 1991 |
Beta-adrenergic blockade in congestive heart failure: answering the old questions.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Heart; Heart Failure; Hemodynamics; Humans; Me | 1991 |
Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.
Topics: Aged; Cardiomyopathy, Dilated; Catecholamines; Chronic Disease; Coronary Disease; Epinephrine; Exerc | 1990 |
Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.
Topics: Adolescent; Adult; Aged; Cardiac Catheterization; Cardiomyopathy, Dilated; Drug Evaluation; Echocard | 1989 |
Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors.
Topics: Adolescent; Adult; Cardiomyopathy, Dilated; Child; Child, Preschool; Coronary Disease; Heart Failure | 1989 |
Pharmacologic treatment of dilated cardiomyopathy with special reference to the role of beta-blockers.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Drug Therapy, Combination; Electrocardiography | 1985 |
Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart F | 1988 |